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Abstract: Incorporation of fluorine into molecules can result in enhanced properties of 
functional molecules in a variety of fields. As such, there is great interest to synthesize 
organofluorines.  Despite substantial progress, direct fluorination strategies are often 
unselective.  Often the simplest compounds are a challenge to synthesize. This problem is 
magnified when multiple fluorines are located on one arene.  An alternative approach to 
the synthesis of multifluorinated arenes is to start with a perfluoroarene, in which every 
possible position has been fluorinated, and then functionalize the undesired C–F bonds.  
This approach has been pioneered by Swartz, Milstein, and Aizenberg.  More recently, the 
Weaver group has researched new methodology for the selective removal of fluorine from 
fluorinated arenes.  The key C–F fragmentation relies on the visible light mediated 
photocatalytic electron transfer from a mild tertiary amine reductant.  This has been a 
substantial advancement for the field of C–F functionalization, and has revealed two needs 
preventing further advancement.  Namely, there is a need to increase access to both Ir-
based photocatalysts and highly fluorinated building blocks. Notably, thousands of other 
photocatalytic reactions have emerged utilizing ruthenium and iridium photocatalysts. 
Since these photocatalysts play a vital role in such reactions, we describe an improved 
synthesis to a class of homoleptic iridium (III) based complexes that allow rapid access to 
these compounds in high yields. Using a well-known method, we expanded our 
photocatalyst library by synthesizing a range of hetereoleptic complexes. Additionally, we 
report their photophysical and electrochemical properties. Later, we report a modified 
method, which has been applied to homoleptic complexes to obtain multigram quantities 
of the photocatalyst in high purity, without the use of a column, and with excellent recovery 
of excess ligand in high yield, substantially enhancing access to this class of photocatalyst. 
In an application of these complexes, we developed a photocatalytic reductive coupling of 
aryl bromides with a broad set of alkenes. We next developed a method that provided 
fluorinated amino acid building blocks via nucleophilic aromatic substitution of highly 
fluorinated (hetero)arenes with an oxazolone enolate. Moreover, we demonstrated the utility in 
a one pot synthesis of medicinally relevant 2-aminohydantoins. We further explored the 
reactivity of the enolate generated from the alpha amino esters. We showed that the 
monoanion enolate was a competent nucleophile that could undergo catalytic Michael 
addition of α-amino esters. We also provided insight into the governing principles, which 
resulted in an expansion of the scope.  The study concludes with a late-stage 
functionalization of peptidic γ-secretase inhibitor, DAPT, which highlights the power of 
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1.1 Strategies for the synthesis of fluorinated aromatics 
Fluorinated compounds are extremely important and are highly valued in a variety of fields, 
namely, pharmaceuticals,1 agrochemicals,2 and industrial applications.3 This is due to the ability of 
fluorine to substantially alter the properties of molecules in these various applications.4 Below 
Scheme 1.1 illustrates several examples. Although many applications rely on the use of 
fluoroaromatics, none are naturally occurring,4 thus they must be synthesized.  In contrast to their 
importance, there is a relative dearth of useful methods that rapidly yield multifluorinated arenes.  
Scheme 1.1 Examples of aryl fluoride applications  
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One potential synthetic strategy is the selective installation of fluorine on an arene (Scheme 
1.2, left). This approach is popular,5 but often can be challenging to accomplish multifluorination. 
In most cases, the appropriate functional group must be pre-installed for every fluorination pattern 
desired and as a consequence the reaction steps become lengthy synthetic sequences (Scheme 1.2, 
right).5 These apparent drawbacks make it less than ideal to rapidly synthesizing analogs.  
Scheme 1.2 Strategies in synthesis of fluorinated aromatics 
 
For example, in 20106 Codexis and Merck described a synthesis to Januvia, an antidiabetic 
drug, in high yield with an excellent enantiomeric excess (Scheme 1.3a). However, while not 
performed by Merck, synthesis of the fluorinated carboxylic acid (Scheme 1.3b) became lengthy 
and cumbersome progressing through a series of harsh and potentially dangerous reactions to yield 
the starting material for Merck. 





Despite the limitations, a variety of reactions have been developed to synthesize aryl 
fluorides. Examples include substitution reactions with existing halogenated arenes (Scheme 1.4a), 
cross-coupling reactions with organometallics (Scheme 1.4b), and C–H activations via fluorination 
with the help of preexisting directing groups (Scheme 1.4c). While beyond the scope of this 
discussion, Campbell and Ritter discuss C–F bond forming reactions, but this can be reviewed 
within this article.7 
Scheme 1.4 Installation of fluorine to an aryl substrate 
 
C–F functionalization to prepare highly fluorinated or perfluorinated (hetero)arenes is an 
attractive alternative to the aforementioned approaches to arylfluorides, and is proving to be 
exceptionally fruitful.  The advantage stems from the fact that perfluorinated arenes are relatively 
inexpensive and already possess the difficult to install fluorines in the desired locations. The 
potential advantage of C–F functionalization has been recognized by others, and advancements 
have been made in the field.8  Taken in conjunction with recently developed photocatalytic C–F 
functionalization,8-10 considerable access to these important motifs are now obtainable. 
4 
 
In regards to C–C bond formation this chemistry possesses many challenges,11 with 
unavoidable challenge being that the aryl C–F bond is the shortest and strongest among the 
halogens (Figure 1.1).12 The C–F bond also presents significant obstacles due to its relative 
inertness towards traditional transition metal complexes used to activate aryl halides, and active 
complexes are rare.5  Complexes with metal centers of Ni, Pt, and Pd can be identified as the major 
contributors in C–F activation, and usually undergo a catalytic cycle via a rate determining 
oxidative addition step into the C–F bond.  Later improvements emerged that are assisted by various 
directing groups.9  
Figure 1.1 Selected C–X bond energies and lengths 
 
1.2 ArF building blocks and nucleophilic aromatic substitution (SNAr) 
Another mechanistic topic that is extremely useful is nucleophilic aromatic substitution or 
SNAr (Scheme 1.5). Generally, this class of substitution consists of an electrophilic aromatic ring 
which is attacked by a suitable nucleophile.  Upon nucleophilic attack, a carbanion intermediate 
(Meisenheimer complex) is formed, and finally collapses kicking out the halide leaving group, 






Scheme 1.5 Typical SNAr mechanism 
 
Nucleophilic aromatic substitution has been used to introduce oxygen, nitrogen, carbon, 
and sulfur based nucleophiles.13 The key to a successful SNAr reaction begins with stabilization of 
the anion, which is electronically influenced by the groups attached to the ring. The electron 
withdrawing groups on a perfluoroarene for example increase the rate of the reaction by stabilizing 
the anion both inductively and potentially by resonance, and make the reaction possible. Generally, 
the SNAr reactivity of Caryl–X (where X = F, Cl, Br, I) bonds decrease in the order of fluoride > 
chloride > bromide > iodide, which the opposite is that observed for aliphatic halides in a SN2 
reaction.  This trend is thought to reflect the fact that attack of the arene by the nucleophile is the 
most challenging step, and is accelerated by the small, extremely electronegative fluoride. 
While the SNAr reaction has been extensively explored on many substrates, perfluoroarenes 
are conspicuously absent from most exploration.14-17  One potential explanation, is that until 
recently the remaining C–F bonds of a perfluoroarene would amount to synthetic dead ends, thus, 
little work was done to explore this reaction of great synthetic potency.  Out of the possible 
nucleophiles, we are most interested in coupling partners that will create new C–C bonds 
selectively. Our group developed reaction conditions that facilitate per- and polyfluoroarylation of 
Medrum’s acid18 (Scheme 1.6) to generate a completely new class of synthetically versatile 
fluorinated building blocks. The reaction is controlled by taking advantage of the low 
nucleophilicity of the resulting arylated enolate salts which allows, for the first time, the selective 
monoarylation of Meldrum’s acid to give access to tertiary carbon centers. While alkylation proved 
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challenging, quaternarization of the α-carbon could be accomplished by reversing the order of 
events, i.e. alkylation of Meldrum’s acid, followed by arylation. Given the demand for partially 
fluorinated arenes in various fields, we were satisfied with the results. Later in Chapter IV we will 
review a reaction we developed shortly after this report appeared involving polyfluoroarylation of 
oxazolone, an amino acid surrogate, which gives rise to polyfluorinated amino acid derivatives.  
Scheme 1.6 Polyfluoroarylation of Meldrum’s acid 
 
1.3 Introduction to photocatalysis 
Another mechanistically intriguing mode of reactivity for polyfluorinated arenes is electron 
transfer facilitated functionalization. These types of mechanisms take advantage of the 
energetically accessible LUMO which looks primarily like the π* orbital of the polyfluorinated 
arene. Upon addition of an electron to the π* orbital, an unstable radical anion is formed, which 
undergoes fragmentation to extrude fluoride and generates an aryl radical plus a fluoride. The initial 
electron transfer is accomplished via photocatalysis, and the next section is a brief introduction to 
photocatalysis, a description of the electrochemical properties of the photocatalyst, and discussion 
of how photocatalysis is applied to halogenated arenes to obtain reactive intermediates. 
A primary objective of organic chemistry is to discover or invent new methodologies that 
enable the assembly of molecules of substantial value. Furthermore, any new methodology should 
be aware of safety, and environmental concerns, and should deliver products with haste. Modern 
concepts to develop such methodology consist of discovering catalytic mechanisms that will enable 
a broad range of chemical transformations to take place.19  Lewis acid catalysis,20 organocatalysis,21 
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and transition metal catalysis22 are all examples of such catalytic tools. Among transition metal 
catalysis, photocatalytic strategies have evolved. Photocatalysis involves the use of visible light to 
deliver or strip an electron away, also the catalyst can undergo energy transfer events to promote 
reactivity from common functional groups. For more than 30 years, transition metal complexes 
have been known to mediate these single-electron transfers (SET) and have led to SET-initiated 
polymerization reactions,23 dye-sensitized solar cells,24 and light emitting diodes.25  However, it is 
important to note there are a growing number of examples of visible light absorbing organic dyes 
that facilitate photocatalysis, but are not the subject of this thesis.26  
Early reports of transition metal-based photocatalytic mediated organic transformations 
utilized Ru-based photocatalysts such as tris(2,2′-bipyridine) ruthenium(II) or Ru(bpy)32+, which 
when excited by visible light undergoes a metal to ligand charge transfer (MLCT) and facilitates 
one-electron oxidation or reduction of the complex.27 In 1981, Pac and co-workers28 utilized a 
ruthenium photocatalyst in one of the first reports of small organic molecule activation by these 
type of complexes. In this paper, they reported the reduction of electron deficient alkenes using a 
stoichiometric reductant.  Again in 1990, Fukuzumi29 described reductive dehalogenation of 
phenacyl bromide utilizing this complex.  Over the last few years, the number of reported organic 
transformations that utilize transition metal photocatalysts has increased steadily.  
 Recently in 2008, MacMillian30 reported direct asymmetric alkylation of aldehydes and 
Yoon31 reported [2+2] cycloadditions of enones both utilizing Ru(bpy)3Cl2 modernizing transition 
metal photochemistry.  In 1985, King and coworkers reported the synthesis and characterization of 
neutral fac-tris-phenylpyridinato iridium(III), (Ir(ppy)3), which constitutes the parent 
photocatalyst32 of a complimentary class of photocatalysts.33  
Notably, this complementary group of iridium complexes are tris-cyclometalated d-6, 18-
electron complexes that are known to be remarkably stable in the ground state.  However, upon 
absorption of photons of the appropriate energy-in the blue region of the visible spectrum, the 
complexes undergo excitation (Scheme 1.7). While an excited singlet state is the initial outcome, 
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it rapidly relaxes to a long-lived, triplet state.34 The triplet state has undergone a metal-to-ligand 
charge transfer.  By virtue of charge transfer, it can serve as both a potent oxidant and reductant.  
By knowing the excited state redox potentials of E1/2(Ir+/Ir*) and E1/2(Ir*/Ir-) complexes, one can 
begin to rationally construct novel chemical transformations provided the relevant potentials of 
substrates are known.   
Scheme 1.7 Energy and electron transfer processes in tris-cyclometalated iridium complexes 
1*  
IrL3 represents the higher energy spin allowed excited state and 
3*IrL3 represents the lowest spin forbidden excited state 
 
The neutral tris-homoleptic Ir-complexes have also proved to be of substantial value in 
synthesis and lighting applications.35-36 The complex fac-Ir(ppy)3 has more reducing power then 
Ru(bpy)3Cl2 and a longer excited state lifetime.37  In 2012, Stephenson37 subsequently presented 
Ir(ppy)3 as a proficient complex for the dehalogenation of alkyl, alkenyl, and aryl iodides.  In 2014, 
MacMillan also used various neutral complexes,  demonstrating that differences in properties result 
in differences in reactivity.31 Recently other groups,38 including our own,39-46 have utilized fac-
Ir(ppy)3 and its derivatives, in order to perform a series of other powerful transformations with high 
catalytic efficiencies. Later in Chapter III, work done by Amandeep Arora and myself, will be 
described, in which we demonstrate a photocatalytic reductive coupling of aryl bromides with a 
broad range of alkenes. 
In 2014, our group described a photocatalytic hydrodefluorination (HDF) reaction of 
perfluoroarenes.  The method amounted to a convenient way to perform outer-sphere electron 
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transfers using Ir(ppy)3. Understanding the general mechanism of this reaction, its significance, and 
the key intermediates, we can start to visualize a vast number of transformations that could 
undertake by selecting the right coupling partner.  
The HDF reaction starts with the absorption of photons by the photocatalyst (Scheme 1.8, 
eq 1). The catalyst is promoted to an excited state and rapidly undergoes intersystem crossing to 
give the long-lived triplet state. Again, here the photocatalyst can act as both an oxidant or a 
reductant.  In presence of this photoredox catalyst, an electron donation from diisopropylethyl 
amine (DIPEA, eq 4) while slightly endothermic results in an amine radical cation (eq 6) and a 
reduced photocatalyst. Compared to the reduced photocatalyst, a perfluoroarene such as 
pentafluoropyridine (eq 2) has a slight over potential. We postulated the outer sphere electron 
transfer takes place from the photocatalyst to the arene (eq 3), to form the perfluoroaryl radical 
anion (not shown). From the meta-stable radical anion, fluoride is expelled generating an aryl 
radical (eq 5).   The aryl radical then abstracts an H-atom from the amine (or amine radical cation) 
giving the HDF product (eq 7). We further explored other possible synthetic scenarios and imagined 
how we would control the use of this aryl radical intermediate (eq 8) and supply a new generation 










Scheme 1.8 Photocatalytic HDF reaction and interception of an aryl radical 
 
As the exploration of these photocatalysts continue, the new properties they possess will 
likely expand and give rise to powerful reactions. However, in our own group, we have often found 
the number of commercially available photocatalysts were low.  Arguably, this will limit access to 
a handful of researchers who have these complexes, which will result in slower advances in the 
field.  Thus, a need exists for a reliable method that delivers these powerful complexes to the 
organic community as a whole. 
Despite a rich history of exploration of the properties of these complexes, syntheses for 
many the facial homoleptic variants47 are scattered, and often lack complete chemical, 
photophysical, and electrochemical characterization.  Aware of what was available to the scientific 
community, we believed it would be valuable to develop a simple and robust method to synthesize 
homoleptic photocatalysts. This would allow us to adjust the redox potentials and triplet state 
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energies of the iridium photocatalysts, and potentially give rise to new synthetic transformations 






FACILE SYNTHESIS OF CYCLOMETALATED IRIDIUM (III) COMPLEXES FOR 
PHOTOCATALYSIS 
 
2.1 Introduction of iridium photocatalysts methodology 
A survey of the current literature revealed that there are a number of reported synthetic 
methods that use more expensive Ir(III) salt, Ir(acac)348-50 or alternatively require two steps, first  
forming the chloro-bridged dimer, and then subsequently breaking the dimer by the addition of 
the third ligand.  This is done even in the case of the tris-homoleptic-cyclometalated complexes, 
which is less than ideal since it requires an additional chemical step just to add the third ligand.  
Furthermore, a stoichiometric chloride scavenger like AgOTf is often employed51-52  Konno 
reported a microwave synthesis of tris-cyclometalated iridium complexes, but this required a large 
excess of ligand (50-100 equiv) which limited the scope of the reaction to readily available ligands 
such as 2-phenylpyridine.53 Therefore, working with a post-doc in the group, Dr. Anuradha Singh, 
we set about to develop a general and simple synthesis that would allow us to acquire the facial 
homoleptic iridium complexes in high chemical yield via a simple and selective one step process.  
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2.2 Development of methodology for the synthesis of tris-homoleptic complexes 
In our initial attempt (Table 2.1), a glass pressure vial was charged with IrCl3•nH2O, 2-
phenylpyridine, Na2CO3 and water and heated at 200 °C for 48 h. Unfortunately, this reaction 
resulted in extremely low yield (<8%) of the desired complex, Ir(ppy)3.  However, it was observed 
that the reaction was heterogeneous until temperatures reached nearly 200 °C.  Concerned that 
even higher temperatures may be needed to ensure homogeneity, reproducibility, and faster 
reaction rates the remaining reactions were performed in a Parr reactor for safety purposes, 
allowing us to safely heat H2O to 260 °C.  Routine optimization of this reaction provided 
improvement in yields on increasing the equivalents of base from 1.5 to 6, 2-phenylpyridine from 
3.3 to 12, and the temperature from 200 to 260 °C.  Using optimized conditions (entry 3), the 
reaction yielded 79% of Ir(ppy)3, 3a, in just 24 h. 
Table 2.1 Optimization of Reaction Conditions 
 
Pleased with this result, we next attempted to investigate the scope of the method, which 
required the syntheses of the requisite 2-phenylpyridine ligands 2b-g (Scheme 2.1) which we 
hoped would lead to catalysts with a range of properties.  The ligands were synthesized quite easily 
via Suzuki coupling of 2-chloropyridine (1 equiv) and the requisite boronic acid (1.2 equiv) with 
only minor modifications to the literature procedure.52 Conveniently, the procedure could be 
performed outside the glovebox.  In all cases, the Suzuki coupling reaction led to good yields of 
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the desired phenylpyridine products and in one case (2c) approached quantitative yields.  Ligand 
2h (4-(tert-butyl)-2-(4-fluorophenyl)pyridine) was synthesized via Baran’s procedure.54 
Scheme 2.1 Ligand Synthesis 
 
With ligands (2a-h) in hand, we returned to the cyclometalation reaction (Scheme 2.2).  
However, under the standard reaction conditions, several of the substrates presented problems.  
Upon modification of our initial conditions, yields were improved and substantial quantities were 
obtained.  For instance, when 2-(4-tert-butyl-phenylpyridine) (2e) was subjected to the reaction 
conditions the expected 3e was not formed.  Rather, 3a Ir(ppy)3 along with 2-phenylpyridine, 2a, 
were the primary products recovered which apparently resulted from the de-tert-butylation of 
either (or both) ligand or Ir-complex at 260 °C.  However, by lowering the temperature to 200 °C 
we were able to suppress de-tert-butylation and obtain 3e in high yield.  Moreover, our initial 
attempts to synthesize 3c resulted in a mixture of iridium complexes in which partial hydrolysis 
of fluorine had occurred.  Additionally, we observed a migration of fluorine on the ring of the 
ligand recovered from the reaction mixture.55 To avoid this problem, reaction with 2-(4-
fluorophenyl) pyridine, 2c, ligand was performed in the absence of sodium carbonate and at lower 
temperatures (200 °C for 48 h).  Surprisingly, using these conditions the reaction proceeded 
smoothly to achieve 3c in excellent yield.  This experiment suggested that no base is required to 
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synthesize tris-cyclometalated iridium complexes and, to the best of our knowledge, this is the 
first report that suggests that the base is not necessary for the formation of these complexes.  Thus, 
for the remainder of the fluorinated substrates, the reactions were carried out with no base which 
allowed us to acquire 3b-e, and 3h complexes in moderate to high yields.  Compound 3h was 
synthesized in 84% yield and was very recently used as a catalyst for the decarboxylative arylation 
of α-amino acids and α-etheral acids though its synthesis and properties had never been reported. 
56A more modest yield was observed for 3d but is likely a result of the effectively lowered 
concentration of 2d, since only 6 equivalents were used due to smaller quantities on hand.  Using 
standard conditions, new complex, 3f, was obtained only in trace amounts and addition of base 
did not prove helpful.  In these cases, the major product was the choro-bridged dimer.  However, 
3f was finally successfully obtained by subjecting the chloro-bridging dimer to excess ligand in 
the presence of AgOAc. 
 




aNo Na2CO3 used. 
 
2.3 Nonoyama’s procedure: expansion of the library to hetereoleptic complexes 
While our initial focus was in the syntheses of the homoleptic iridium complexes, cationic 
heteroleptic iridium complexes have also proven to be effective photocatalysts and we sought to 
synthesize a library of cationic complexes as well.  In the cationic complexes, the third 2-
phenylpyridine ligand is replaced with a 2,2’-bipyridine type ligand (i.e. a neutral ligand).  Thus, 
in order to be able to modify the third ligand, the dichloro-bridged iridium dimer was selectively 
synthesized according to Nonoyama’s procedure,57 which was then subsequently treated with the 
third, bipyridyl ligand to afford cationic heteroleptic iridium complexes (Scheme 2.3)58  




Cationic heteroleptic Ir(III) Complexes 4a-h with PF6
- counteranion.  First step yield 
followed by second step. 
The cyclometalated iridium(III) chloro-bridged dimer [Ir(ligand)2Cl]2 was prepared by 
following Nonoyama’s procedure57 in which hydrated iridium(III) chloride was heated with 
substituted phenylpyridine ligand in a 2:1 methoxyethanol/H2O mixture at 120 °C.  Upon cooling, 
the chloro-bridging dimer precipitated and was filtered off. The dimer was carried on to the second 
step without purification.  The catalysts were diversified by use of several bipyridine ligands.  
Finally, anion metathesis was achieved by the addition of aqueous NH4PF6.  In this manner, 
complexes 4xy (Scheme 2.3) were synthesized.  In some cases, complexes were further purified 
by recrystallization.  This is the first report for complexes 3f, 4ab, 4cb and 4fd.  All synthesized 
facial homoleptic and cationic heteroleptic complexes were characterized by 1H, 13C, 19F, 31P 
NMR, LCMS, and new complexes by elemental analysis. 
 
2.4 Discussion on electrochemical properties  
With iridium complexes in hand, we next turned to the investigation of the photophysical 
properties of the facial homoleptic 3a-f and the heteroleptic 4xy complexes.  Absorbance of the 
facial homoleptic (Figure 2.1) and the heteroleptic (Figure 2.2) complexes were measured in 
acetonitrile (10 μM).  As depicted in Figure 2.1 and 2.2 all the complexes show intense UV 
absorption bands below 325 nm-characteristic of spin allowed transition of ligand (π-π⃰)59 and 
weaker, broad and unresolved absorption bands in the visible region from 320-480 nm generally 




Figure 2.1 Absorbance Spectra: Facial Homoleptic Iridium Complexes: (3a-f,h) 10 µM in MeCN. 
 
Figure 2.2 Absorbance spectra of 3a and heteroleptic iridium complexes 
 
From a catalysis standpoint, the emission frequency corresponds to the energy available 
for transfer to substrates, (i.e., the triplet state energy, TSE).  The complexes were excited in the 
region of 370-390 nm which corresponds to the metal-to-ligand charge transfer excitation (Figure 
2.3).60 In general, electron-withdrawing substituents on the phenyl ring such as fluorine lower the 
energy of HOMO resulting in larger HOMO-LUMO gaps and greater emission energies (more 
blue shifted).  Whereas electron-donating substituents such as alkyl groups raise the HOMO 




Figure 2.3 Emission spectra of facial homoleptic iridium complexes  
 
Hay and coworkers62 report time-dependent density functional theory calculations that 
illustrate, to the first approximation, the HOMO in such complexes is based primarily on the metal 
and metallated aryl ring, while the LUMO is largely associated with the pyridyl ring (Scheme 2.4, 
eqn 1).62  Also park illustrated the HOMO-LUMO orbitals of Ir(dFppy)3 studied the electronic 
properties of the complex using the B3LYP functional and the structural analysis of the optimized 
geometries.63  The substituents on the aryl ring tend to affect the HOMO energy to a greater extent 
than the LUMO (Scheme 2.4, eqn 2), while the reverse is true for the pyridyl ring (Scheme 2.4, 
eqn 3).64 These effects depend greatly on the position of the substituent within the two rings:64-65 
Electron withdrawing groups normally stabilize the orbitals by decreasing the HOMO level and/or 
electron donating groups on the pyridyl ring increases the LUMO which both results in a larger 
energy gap i.e. blue shift. Electron donating groups normally destabilize the orbitals by increasing 
the HOMO level and/or electron withdrawing groups on the pyridyl ring decreases the LUMO 





Scheme 2.4A HOMO/LUMO of cyclometalated Ir arylpyridine type of complexes  
Scheme 2.4B The effect of substituents on the energies of orbitals 
 
 
As expected, in complexes that have electron-withdrawing groups (3b-d and 3h) a 10-40 
nm hypsochromic shift is observed whereas bathochromic shift of 5-10 nm is observed in alkyl 
substituted complexes (on the phenyl ring), 3e and 3f, when compared to that of Ir(ppy)3 (3a).  
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Furthermore, as the degree of fluorine substitution increases, more blue shifting is observed (3d 
vs. 3c).  Similar trends are observed in the case of heteroleptic cationic iridium complexes (Figure 
2.5). 
 
Figure 2.4 Emission spectra of 3a and heteroleptic iridium complexes  
Electron withdrawing groups (4ga, gb, gc) resulted in a 42-45 nm blue shift with respect 
to Ir(ppy)3 (3a).  Complex 4db shows a 55 nm bathochromic shift relative to more fluorinated 
complexes 4ga, gb, gc.  Addition of electron donating tert-butyl groups on bipyridyl (4de) resulted 
in a 12 nm hypsochromic shift compared to complex 4db.  In the mono-fluoro series, a similar 
trend was observed (4cb and 4cc).  Complexes 4db, 4cb, 4cc and 4fd depict a 10-42 nm red shift 
and 4ga, 4gb, 4gc, 4dc a 2-45 nm blue shift from Ir(ppy)3 (3a).  Furthermore, among these 
complexes, complex 4fd was found to be the most red shifted (vs. 3a) with poor emission which 
could be due to the methoxy substituents.66  In most complexes, broad emission spectra were 
observed which could be due to a significant degree of charge transfer (CT) whereas structured 
spectra in 4ga and 4gc suggest a small CT contribution.67 
In all complexes emission is from the lowest energy triplet state which is likely formed 
by mixing of the 3MLCT, 3LC and 3LLCT states68-69  The emission maximum (λmax) is the triplet 
state energy, which can be used in photocatalysis for energy transfer processes.70  
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Having investigated the photophysical properties, we next turned to the electrochemical 
properties of the iridium complexes via cyclic voltammetry (CV) which is reported relative to 
ferrocenium/ferrocene redox couple as shown in Table 2.2.  The cyclic voltammograms of 
complexes were collected at a scan rate of 50 mV/s.  As anticipated, complexes having electron 
withdrawing fluorine groups (3b-d vs 3a) show higher ground state Eox1/2 (Ir+/Ir) due to lowering 
of the HOMO energy level.  All cationic complexes show higher ground state Eox1/2 (Ir+/Ir) when 
compared to that of 3a, and among all complexes 4ga and 4gc exhibit the highest ground state 
Eox1/2.  Whereas, lower Eox1/2 potentials were observed when an electron donating t-Bu-substituent 
was located on the ligand (3e, 3f vs. 3a) as this group is expected to raise the HOMO energy level 
making it more easily oxidized.71 
Complexes that have electron withdrawing fluorines on the ligand make them less 
reducing (smaller negative ground state) Ered1/2 (Ir/Ir-) as observed in 3b-d and 3h relative to 3a.  
Complexes that have an electron donating alkyl group (3e vs. 3a) possess a more negative Ered1/2 
(Ir/Ir-) potential-though 3f is slightly less reducing than 3a.  Among the cationic complexes 4fd, 
is the most reducing as it contains electron rich t-Bu- and methoxy substituent on ligands.  
Furthermore, tBu-bipyridine complexes are more reducing (4da vs. 4dc, 4cb vs. 4cc) 
Knowing the excited state redox values is a key element in designing photocatalytic 
reactions, but the excited state redox potentials cannot be directly evaluated.  However, they can 
be calculated from the electrochemically determined ground state Eox1/2 and Ered1/2 potentials and 
the energy gap (Egap).  Egap values were determined from the CV.   
E1/2 (Ir+/Ir*) = Eox1/2 – Egap eV  (eq 1) 
E1/2 (Ir*/Ir-) = Egap eV + Ered1/2  (eq 2) 
We calculated the redox values of the excited state complexes, E1/2 (Ir*/Ir+) and E1/2 
(Ir*/Ir-) using equations 1 and 2 and the potentials are shown in Table 2.2.  The table is arranged 
in descending emission energy values. 
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Table 2.2 Photophysical and electrochemical data for iridium complexes 
 
 
In conclusion, we have reported simple synthetic procedures that allow rapid access to an 
important class of iridium photoredox catalysts.  We have successfully developed a simple and 
general synthesis that provides efficient access to facial tris-cyclometalated iridium complexes 
directly from less expensive IrCl3•nH2O.  In addition, we applied Nonoyama’s method in order to 
synthesize a number of cationic heteroleptic iridium complexes.  Importantly, we have provided 
the chemical, photophysical, and electrochemical characterization necessary to facilitate catalysis.  
This should significantly aid in the design of novel chemical transformations via photocatalysis 
by facilitating access to the catalysts and by providing the relevant photophysical and 
electrochemical properties necessary to rationally design new synthetic methods. 
 
2.5 Experimental section 
All reagents were obtained from commercial suppliers (Sigma-Aldrich, Oakwood Chemicals, Alfa 
Aesar, Strem, and VWR) and used without further purification unless otherwise noted.  NMR 
complex λmax TSE kcal/mol E1/2 ox V E1/2
 
red V E gap eV E1/2 (Ir
+





4gb 473 60.4 1.23 -1.23 2.2 -0.97 0.97
4ga 475 60.2 1.81 -1.25 2.64 -0.83 1.39
4gc 476 60.1 1.77 -1.35 2.77 -1 1.42
3d 476 60.1 0.98 -1.82 2.21 -1.23 0.39
3h 481 59.4 0.926 -1.58 2.2 -1.274 0.62
3c 488 58.6 1 -2.13 2.86 -1.86 0.73
3b 507 56.4 1.11 -2.13 2.76 -1.65 0.63
4dc 516 55.4 1.63 -1.42 2.56 -0.93 1.14
3a 518 55.2 0.78 -2.2 2.75 -1.97 0.55
3e 525 54.5 0.69 -2.27 2.59 -1.9 0.32
3f 528 54.2 0.7 -2.03 2.28 -1.59 0.25
4db 528 54.2 1.66 -1.32 2.46 -0.8 1.14
4cc 540 53 1.49 -1.45 2.52 -1.04 1.07
4cb 556 51.4 1.51 -1.37 2.4 -0.89 1.03
4fd 560 51.2 1.17 -1.5 2.35 -1.12 0.85
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spectra were obtained on 400 MHz Bruker Avance III spectrometer and 400 MHz Unity Inova 
spectrometer.  1H, and 13C, NMR chemical shifts are reported in ppm relative to the residual solvent 
peak while 19F and 31P NMR are set relative to an external standard.  Purifications were carried 
out using a Teledyne Isco Combiflash Rf 200i flash chromatograph with a Redisep Rf normal 
phase silica (24 g, 40 g, or 80 g) column with product detection at 254 and 280 nm and by ELSD 
(evaporative light scattering detector).  Substrate synthesis reactions were monitored by thin layer 
chromatography (TLC) obtained from Sorbent Technology (Silica XHL TLC Plates, w/UV254), 
glass backed, 250 µm, and were visualized with ultraviolet light.  Photophysical properties were 
studied on Varian Cary Eclipse spectrophotometer and LCMS was taken on Shimadzu liquid 
chromatograph mass spectrometer (LCMS-2010 E).  Electrochemical measurements were 
performed with CH instruments using a glassy-carbon electrode as a working electrode with a 
Ag/AgCl reference electrode and a platinum wire as a counter electrode.  All sample solutions 
were prepared in acetonitrile and degassed with nitrogen bubbling for 20 min. prior to 
voltammetric studies.  Tetra-(n-butyl)-ammonium hexafluorophosphate (NBu4PF6, 0.1 M in 
acetonitrile) was used as supporting electrolyte.  The HOMO and LUMO energy is calculated from 
equation eq 3. 
E HOMO/LUMO = - ( E onset oxi/red  vs Fc +4.8) eV (eq 3) 
 
General procedure A for the synthesis of ligands (2b-2g) 
 
To a two-necked, 100-mL round-bottomed flask equipped with a magnetic stir bar were added 2-
chloropyridine (1 equiv), phenylboronic acid (1.2 equiv), triphenylphosphine (0.1 equiv), 2 M 
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potassium carbonate (2.7 equiv) and 1,2 dimethoxyrthane (0.9 M).  The mixture was degassed 
with Ar for 15 min.  Pd(OAc)2 (2.5 mol%) was added to the reaction mixture and degassing was 
continued for 15 more minutes and then the outlet was removed.  The reaction mixture was heated 
to reflux.  The progress of the reaction was monitored by TLC (hexane:EtOAc 90:10).  Upon 
completion (typically 18-24 h), the reaction mixture was cooled to room temperature and extracted 
with DCM (3 x 20 mL).  The combined organic portion was washed with water (3 x 20 mL) and 
brine (1 x 20 mL), dried over anhydrous sodium sulfate and then concentrated in vacuo.  The crude 
material was purified by flash chromatography to obtain pure the ligand.  
2b, The general procedure A was followed using 2-chloropyridine (2.0 g, 17.62 mmol), (4-
(trifluoromethyl)phenyl)boronic acid (4.08 g, 21.15 mmol), 2 M K2CO3 (6.55 g, 47.52 mmol), 
PPh3 (461 mg, 1.760 mmol), Pd(OAc)2 (99 mg, 0.4420 mmol) and 1,2 dimethoxyrthane (20 mL).  
The crude material was purified by flash chromatography using hexane: ethyl acetate (0-5 % 
EtOAc for 40 cv and ramped to 100 % EtOAc for 40-70 cv and then held at 100% EtOAc 70-80 
cv on a 24 g silica column) to afford 2b in 67% yield (2.60 g, 11.65 mmol) as a white solid.  The 
1H NMR matched literature values.55 
2c, General procedure A was followed using 2-chloropyridine (2.0 g, 17.62 mmol), (4-
fluorophenyl) boronic acid (2.96 g, 21.15 mmol), 2 M K2CO3 (6.55 g, 47.52 mmol), PPh3 (461 
mg, 1.760 mmol), Pd(OAc)2 (99 mg, 0.4420 mmol) and 1,2 dimethoxyrthane (20 mL).  The crude 
material was purified by flash chromatography using hexane:ethyl acetate (0-5 % EtOAc for 40 
cv and ramped to 100 % EtOAc for 40-70 cv and then held at 100% EtOAc 70-80 cv on s 24 g 
silica column) to afford 2c in quantitative yield (3.0 g, 17.32 mmol) as a white solid.  The 1H NMR 
matched the literature values.55 
2d, General procedure A was followed using 2-chloropyridine (1.0 g, 8.80 mmol), (2,4-
difluorophenyl) boronic acid (1.67 g, 10.56 mmol), 2 M K2CO3 (3.28 g, 23.76 mmol), PPh3 (231 
mg, 0.8817 mmol), Pd(OAc)2 (49 mg, 0.2188 mmol) and 1,2 dimethoxyrthane (10 mL).  The crude 
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material was purified by flash chromatography using hexane:ethyl acetate (0-5 % EtOAc for 40 
cv and ramped to 100 % EtOAc for 40-70 cv and then held at 100% EtOAc 70-80 cv on a 24 g 
silica column) to afford 2d in 56% yield (0.94 g, 4.92 mmol) as a colorless oily liquid.  The 1H 
NMR matched the literature values.55 
2e, General procedure A was followed using 2-chloropyridine (2.0 g, 17.62 mmol), (4-(tert-butyl) 
phenylboronic acid (3.76 g, 21.15 mmol), 2 M K2CO3 (6.55 g, 47.52 mmol), PPh3 (461 mg, 1.760 
mmol), Pd(OAc)2 (99 mg, 0.4442 mmol) and 1,2 dimethoxyrthane (20 mL).  The crude material 
was purified by flash chromatography using hexane:ethyl acetate (0-5 % EtOAc for 40 cv and 
ramped to 100 % EtOAc for 40-70 cv and then held at 100% EtOAc 70-80 cv on a 24 g silica 
column) to afford 2e in 79% yield (2.93 g, 13.90 mmol) as a colorless oily liquid. The 1H NMR 
matched the literature values.55 
2f, General procedure A was followed using 2-chloropyridine (2.0 g, 17.62 mmol), (3-(tert-
butyl)phenyl) boronic acid (3.76 g, 21.15 mmol), 2 M K2CO3 (6.55 g, 47.52 mmol), PPh3 (461 
mg, 1.760 mmol), Pd(OAc)2 (99 mg, 0.4420 mmol) and 1,2 dimethoxyrthane (20 mL).  The crude 
material was purified by flash chromatography using hexane:ethyl acetate (0-5 % EtOAc for 40 
cv and ramped to 100 % EtOAc for 40-70 cv and then held at 100% EtOAc 70-80 cv on a 24 g 
silica column) to afford 2f in 79% yield (2.76 g, 13.09 mmol) as a colorless oily liquid. The 1H 
NMR (Chloroform-d, 400 MHz): δ = 8.75 – 8.71 (m, 1H), 8.07 (t, 1H, J=1.8 Hz), 7.83 – 7.71 (m, 
3H), 7.53 – 7.41 (m, 2H), 7.25 (ddd, 1H, J=6.7, 4.8, 2.1 Hz), 1.42 (s, 9H) ppm. 
2g, General procedure A was followed using 2-chloro-5-(trifluoromethyl) pyridine (2.0 g, 11.02 
mmol), (2,4-difluorophenyl) boronic acid (2.09 g, 13.22 mmol), 2 M K2CO3 (4.11g, 29.75 mmol), 
PPh3 (288 mg, 1.099 mmol), Pd(OAc)2 (62 mg, 0.2881 mmol) and 1,2 dimethoxyrthane (20 mL).  
The crude material was purified by flash chromatography using hexane:ethyl acetate (0-5 % 
EtOAc for 40 cv and ramped to 100 % EtOAc for 40-70 cv and then held at 100% EtOAc 7080 
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cv on a 24 g silica column) to afford 2g in 79% yield (2.58 g, 9.961 mmol) as white solid. The 1H 
NMR matched the literature values.58 
Procedure for the synthesis of 2h 
 
A two necked 250 mL round bottom flask was equipped with a magnetic stir bar, 4-tert-butyl 
pyridine (1.00 g, 7.41 mmol, 1 equiv) and 40 mL of dichloromethane.  Trifluoroacetic acid (567 
uL, 7.41 mmol 1 equiv), 40 mL of an aqueous silver nitrate solution (0.03 M), 4-
fluorophenylboronic acid (1.54 mg, 11.1 mmol, 1.5 equiv), and potassium persulfate (3.09 g, 22.2 
mmol, 3 equiv) were separately added. The reaction was stirred vigorously at room temperature 
for 6 hours and a second addition of silver nitrate (252 mg, 1.48 mmol, 0.2 equiv) and potassium 
persulfate (3.09 g, 22.2 mmol, 3 equiv) were added. After 18 h, another addition of 4-fluorophenyl 
boronic acid (515 mg, 3.71 mmol, 0.5 mmol) and potassium persulfate (1.03 g, 7.41 mmol, 1 
equiv) were added.  The progress of reaction was monitored by TLC (hexane:EtOAc 90:10). Upon 
completion, the reaction mixture was diluted with a 5% sodium bicarbonate solution and extracted 
with DCM (3 x 20 mL).  The combined organic layer was dried over anhydrous magnesium sulfate 
and concentrated in vacuo.  The crude material was purified by flash chromatography using 
hexane:ethyl acetate (0-5 % EtOAc for 40 cv and ramped to 100 % EtOAc for 40-70 cv and then 
held at 100% EtOAc 70-80 cv on s 24 g silica column) to afford 2h in 29% (492 mg, 2.15 mmol) 
as a colorless oil.  The 1H NMR matched the literature values.54 
 




A Parr reactor (1 L model 4533) was charged with iridium (III) chloride (1 equiv), ligand (12 
equiv), sodium carbonate (6 equiv) and DI water (0.03 M).  The reaction mixture was pressurized 
(30 psi) and depressurized with Ar (3x) and finally charged again with Ar before sealing.  The 
reaction mixture was heated at 200 °C for 24-48 h.  After cooling to room temperature, reaction 
mixture was extracted with DCM (3 x 20 mL).  The combined organic portion was filtered through 
a celite pad which was then concentrated to the obtain crude product.  The pure compound 3a-3f 
was obtained by performing flash chromatography.  For most complexes, (3a-3d) crude samples 
were dry loaded on silica prior to running the column due to low solubility of the complex.  After 
elution of the ligand with hexane/ethyl acetate the eluting solvent was switched to 
dichloromethane, which faciliated the elution of the iridium complexes (3a-3f). 
3a, General procedure B was followed at 260 °C using iridium (III) chloride (192 mg, 0.64 mmol), 
2-phenylpyridine (1.19 g, 7.7 mmol), Na2CO3 (407 mg, 3.8 mmol), and DI water (850 mL).  The 
crude material was purified by flash chromatography (dry loaded) using hexane:ethyl acetate (0-
10 % EtOAc for 40 cv to isolate ligand and then switched to DCM as well as ramped to 100 % 
DCM for 40-70 cv and then held at 100% DCM 70-80 cv) on a 24 g silica column to afford 3a in 
79% yield (311 mg, 0.47 mmol) as a yellow solid, which matched with the literature.55  LC/MS 
M+ (m/z) calculated for C33H24IrN3 655.16 found, 654.50. 
3b, General procedure B was followed except that no sodium carbonate was used, using iridium 
(III) chloride (100 mg, 0.33 mmol), 2-(4-(trifluoromethyl) phenyl) pyridine 2b (896 mg, 4.0 
mmol) and DI water (100 mL).  The crude material was purified by flash chromatography (dry 
loaded) using hexane:DCM (0 % DCM for 16 cv and ramped to DCM 100 % for 16-20 cv and 
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then held at 100% DCM for 20-23 cv) on an 80 g silica column) to afford 3b in 78 % yield (221 
mg, 0.26 mmol) as a yellow solid.  1H NMR(Chloroform-d, 400 MHz): δ = 7.99 (d, 3H, J=8.3 
Hz), 7.77 – 7.69 (m, 6H), 7.55 (dd, 6H, J=6.0, 1.3 Hz), 7.20 – 7.15 (m, 3H), 7.02 (ddd, 3H, J=7.1, 
5.2, 1.1 Hz), 6.96 (b, 3H) ppm.  13C NMR (Methylene Chloride-d2, 101 MHz): δ = 165.0, 159.2, 
147.5 – 147.4 (m), 147.3, 137.0,132.4 (m), 130.6, 123.9, 123.4, 120.0, 117.3 – 117.2 (m), 100.0.  
19F NMR (376 MHz, Chloroform-d) δ -62.76 (s).  LC/MS (m/z) M+ calculated for C36H21F9IrN3 
859.12 found: 858.70 
3c, the general procedure B was followed except that no sodium carbonate was used, using 
iridium (III) chloride (100 mg, 0.33 mmol), 2-(4-fluorophenyl)pyridine 2c (678 mg, 3.9 mmol) 
and DI water (100 mL).  The crude material was purified by flash chromatography (dry loaded) 
using hexane: DCM (0-50 % DCM for 25 cv, held at 50% for 25-35 cv and ramped to 100 % DCM 
for 35-36 cv and then held at 100% DCM 36-41 cv) on a 40 g silica column to afford 3c in 78 % 
yield (202 mg, 0.29 mmol) as a yellow- green solid.  1H NMR(Methylene Chloride-d2, 400 MHz): 
δ = 7.88 (d, 3H, J=8.2 Hz), 7.72 – 7.64 (m, 6H), 7.52 (ddd, 3H, J=5.5, 1.6, 0.8 Hz), 6.94 (ddd, 3H, 
J=7.1, 5.6, 1.3 Hz), 6.63 (td, 3H, J=8.7, 2.7 Hz), 6.39 (dd, 3H, J=10.3, 2.7 Hz) ppm.  13C 
NMR(Methylene Chloride-d2, 101 MHz): δ = 165.3 (d,  J=5.4 Hz), 163.4 (d,  J=5.7 Hz), 162.8, 
147.2,  140.2, 136.6, 125.8 (d, J=9.2 Hz), 122.0, 121.8 (d, J=16.4 Hz), 118.9,  107.4 (d, J=23.6 
Hz) ppm.  19F NMR (376 MHz, Methylene Chloride-d2) δ -112.33 (ddd, J = 10.3, 9.1, 5.7 Hz). ).  
LC/MS (m/z) M+  calculated for C33H21F3IrN3 709.13 found, 708.60. 
3d, General procedure B was followed except that no sodium carbonate was used, using iridium 
(III) chloride (50 mg, 0.16 mmol), 2-(2,4-difluorophenyl)pyridine 2d (184 mg, 0.96 mmol) and 
DI water (100 mL).  The crude material was purified by flash chromatography (dry loaded) using 
hexane:ethyl acetate (0-40% EtOAc for 30 cv, changed EtOAc to DCM and ramped to 100 % 
DCM for 30-31 cv and then held at 100% DCM 31-39 cv) on a 40 g silica column to afford 3d in 
56 % yield (68 mg, 0.09 mmol) as a pale yellow solid.  The NMR specta matched with the 
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literature.49 1H NMR (400 MHz, DMSO-d6) δ 8.27 (d, 3H, J = 8.6 Hz), 7.95 (t, 3H, J = 7.5 Hz), 
7.54 (d, 3H J = 5.1 Hz), 7.26 (t, 3H, J = 6.4 Hz), 6.70 (td, 3H, J = 10.1, 9.2, 5.0 Hz), 6.06 (dd, 3H, 
J = 8.7, 2.2 Hz).  13C NMR(Methylene Chloride-d2, 101 MHz): δ = 162.9 (d, J=7.5 Hz), 162.5 (d,  
J=11.5 Hz), 161.3, 147.2, 137.4, 123.3 (d, J=20.9 Hz), 122.4, 117.8 (dd, J=16.1, 2.8 Hz), 96.6 (t, 
J=27.2 Hz) ppm.  19F NMR (376 MHz, Methylene Chloride-d2) δ -109.68 (q, 3F, J = 9.3 Hz), -
110.86 (ddd, 3F, J = 12.6, 9.9, 2.3 Hz).  LC/MS (m/z) M+ calculated for C33H18F6IrN3 763.10 
found 763.00. 
3e, General procedure B was followed using iridium (III) chloride (100 mg, 0.33 mmol), 2-(4-
(tert-butyl)phenyl)pyridine 2e (844 mg, 4.0 mmol), sodium carbonate (210 mg, 2.0 mmol) and DI 
water (200 mL).  The crude material was purified by flash chromatography using hexane:ethyl 
acetate (0-20 % EtOAc for 40 cv, switched EtOAc to DCM and ramped to 100 % DCM for 40-60 
cv and then held at 100% DCM 60-65 cv) on a 24 g silica column to afford 3e in 92 % yield (249 
mg, 0.30 mmol) as a yellow solid.  1H NMR (400 MHz, Chloroform-d) δ 7.79 (d, 3H, J = 8.2 Hz), 
7.60 – 7.48 (m, 9H), 6.93 – 6.86 (m, 6H), 6.83 (ddd, 3H, J = 7.0, 5.6, 1.1 Hz), 1.10 (s, 27H).  13C 
NMR (101 MHz, Chloroform-d) δ 167.5, 161.5, 152.4, 147.5, 141.6, 136.0, 134.9, 123.5, 121.8, 
118.8, 117.2, 34.8, 31.8.  LC/MS (m/z) M+ calculated for C45H48IrN3 823.35 found 822.65. 
3f, General procedure B was followed using iridium (III) chloride (25 mg, 0.083 mmol), 2-(3-
(tert-butyl) phenyl)pyridine 2f (200 mg, 0.95 mmol), and DI water (50 mL).  The crude material 
was purified by flash chromatography using hexane:EtOAc (0-10 % EtOAc for 32 cv, switched 
EtOAc to DCM and ramped to 100 % DCM for 32-42 cv and then held at 100% DCM 42-44 cv) 
on a 24 g silica column to afford 3f in 16 % yield (11 mg, 0.013 mmol) as a yellow solid.   1H 
NMR (400 MHz, Methylene Chloride-d2) δ 7.99 (dd, 3H, J = 8.3, 5.6 Hz), 7.82 – 7.56 (m, 9H), 
6.95 (ddd, 6H, J = 10.2, 6.0, 1.8 Hz), 6.67 (dd, 3H, J = 7.8, 5.7 Hz), 1.35 (s, 27H).  13C NMR (101 
MHz, Methylene Chloride-d2) δ 167.1, 157.3, 147.4, 143.3, 142.4, 136.4, 136.1, 127.6, 122.0, 
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120.7, 118.9, 34.2, 31.4.  Anal. Calcd for C45H48IrN3: C, 65.66; H, 5.88; N, 5.11. Found: C, 64.82; 
H, 4.98; N, 5.57.  LC/MS (m/z) M+ calculated for C45H48IrN3 823.35 found 822.90. 
3h, the general procedure B was followed except that no sodium carbonate was used, using 
iridium (III) chloride (25 mg, 0.083 mmol), 4-(tert-butyl)-2-(4-fluorophenyl)pyridine 2h (230 mg, 
1 mmol) and DI water (100 mL).  The crude material was purified by flash chromatography (dry 
loaded) using hexane: DCM (0-50 % DCM for 25 cv, held at 50% for 25-35 cv and ramped to 100 
% DCM for 35-36 cv and then held at 100% DCM 36-41 cv) on a 40 g silica column to afford 3h 
in 84 % yield (61 mg, 0.070 mmol) as a yellowish green solid. 1H NMR (400 MHz, Chloroform-
d) δ 7.73 – 7.69 (m, 3H), 7.56 (dd, 3H, J = 8.6, 5.7 Hz), 7.28 (d, 3H, J = 5.9 Hz), 6.83 (dd, 3H, J 
= 5.9, 1.8 Hz), 6.53 (td, 3H, J = 8.7, 2.6 Hz), 6.44 – 6.38 (m, 3H), 1.26 (s, 27H). 13C NMR (101 
MHz, Chloroform-d) δ 164.0 , 163.0 (d, J = 251.5 Hz), 163.0 (d, J = 5.6 Hz), 159.1, 145.4, 139.2, 
124.2 (d, J = 9.1 Hz), 121.3 (d, J = 16.1 Hz), 118.3, 114.37, 106.1 (d, J = 23.7 Hz), 33.9, 29.5. 19F 
NMR (376 MHz, Chloroform-d) δ -112.01 (s, 1F). LC/MS (m/z) M+ calculated for C45H45F3IrN3 
877.32 found 877.20. 
 
General Procedure C for the synthesis of cationic heteroleptic [ Ir (C^N)2(bpy)]+ PF6 - complexes 
(4xy)  
 
Heteroleptic iridium complexes 4xy were synthesized in a two-step procedure.58 In the first step, 
chloro-bridged dimer was synthesized by charging a two-necked reaction flask with magnetic stir 
bar, iridium(III) chloride (1 equiv), ligand (2.26 equiv), and a 2:1 v:v mixture of 2-
methoxyethanol/water.  The mixture was degassed with Ar (via Ar bubbling) and heated under 
reflux at 120 oC with constant stirring overnight.  The reaction mixture was cooled to room 
32 
 
temperature and filtered.  The precipitate was washed with water (3 x 10 mL), dried in air and 
taken onto the second step without further purification unless noted.  In the second step, the chloro-
bridging dimer (1equiv), bipyridyl ligand (2.2 equiv) and ethylene glycol were placed in a two-
necked flask and flushed with Ar.  The mixture was heated at 150 oC for 15 h and then cooled.  
The cooled reaction mixture was washed with hexaned (3 x 10 mL) and mixture was heated to 85 
oC for 5 min. to remove residual hexane.  Aqueous ammonium hexafluorophosphate (sat. solution) 
was added to the reaction mixture causing the iridium-PF6 salt to precipitate, which was filtered, 
dried and recrystallized (acetone/ether). 
4ga, General procedure C was followed using iridium(III) chloride (178 mg, 0.60 mmol), 2-(2,4-
difluorophenyl)-5-(trifluoromethyl)pyridine pyridine 2g (352 mg, 1.4 mmol) and a 2:1 mixture of 
2-methoxyethanol/water (12 mL) to obtain the dimer in 74% yield (326 mg, 0.22 mmol) as yellow 
solid.  4ga was synthesized using the dimer (50 mg, 0.034 mmol), phenanthroline (5a, 14 mg, 
0.075 mmol) and ethylene glycol (2 mL).  4ga was obtained in 91% yield (64 mg, 0.062 mmol) 
as yellow crystals after recrystallization from acetone and hexane.  1H NMR (400 MHz, Acetone-
d6) δ 9.01 (dd, 2H, J = 8.3, 1.4 Hz), 8.68 (dd, 2H, J = 5.1, 1.4 Hz), 8.62 (dd, 2H J = 8.8, 2.6 Hz), 
8.46 (s, 2H), 8.35 (dd, 2H, J = 8.8, 1.8 Hz), 8.15 (dd, 2H, J = 8.3, 5.1 Hz), 7.92 – 7.83 (m, 2H), 
6.92 (ddd, 2H, J = 12.7, 9.3, 2.3 Hz), 6.08 (dd, 2H, J = 8.5, 2.3 Hz).  13C NMR (101 MHz, Acetone-
d6) δ 167.7 (d, J = 6.8 Hz), 164.8 (dd, J = 209.3, 13.1 Hz), 162.2 (dd, J = 212.7, 12.9 Hz), 154.7 
(d, J = 7.3 Hz), 152.3, 146.8, 146.4 (q, J = 4.7 Hz), 139.7, 137.2, 131.9, 128.6, 127.4, 127.1 (dd, 
J = 4.5, 2.6 Hz), 125.2 (d, J = 34.9 Hz), 123.8 (d, J = 20.9 Hz), 114.7 (dd, J = 18.0, 3.0 Hz), 99.4 
(apparent t, J = 27.1 Hz).  19F NMR (376 MHz, Acetone-d6) δ -63.68 (s, 6F), -72.66 (d, 6F, J = 
707.3 Hz), -104.86 (q, 2F J = 10.3, 9.3 Hz), -108.12 (td, 2F, J = 12.4, 2.7 Hz).  31P NMR (162 
MHz, Acetone-d6) δ -130.00 – -157.36 (hept, J = 701.46 Hz).  Anal. Calcd for C36H18F16IrN4P: C, 
41.83; H, 1.76; N, 5.42. Found: C, 41.96; H, 1.89; N, 5.23.  LC/MS (m/z) M+ calculated for 
C36H18F10IrN4 889.10 found M+, 888.60. 
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4gb, General procedure C was followed using iridium(III) chloride (178 mg, 0.60 mmol), 2-(2,4-
difluorophenyl)-5-(trifluoromethyl)pyridine 2g (352 mg, 1.4 mmol) and a 2:1 mixture of 2-
methoxyethanol/water ( 12 mL) to the obtain dimer in 74% yield (326 mg, 0.22 mmol) as yellow 
solid.  4gb was synthesized using the dimer (100 mg, 0.067 mmol), 2,2’-bipyridyl (5b, 23 mg, 
0.15 mmol) and ethylene glycol (4 mL).  4b was obtained in 78 % yield (105 mg, 0.10 mmol) as 
yellow-green solid.  1H NMR (400 MHz, Acetone-d6) δ 9.01 (d, 2H, J = 7.6 Hz), 8.64 (dd, 2H, J 
= 8.8, 2.5 Hz), 8.47 – 8.38 (m, 4H), 8.31 (d, 2H, J = 5.3 Hz), 8.00 (s, 2H), 7.81 (t, 2H, J = 8.0 Hz), 
6.87 (ddd, 2H, J = 12.7, 9.3, 2.3 Hz), 5.98 (dd, 2H, J = 8.5, 2.3 Hz).  13C NMR (101 MHz, Acetone-
d6) δ 167.7 (d, J = 6.9 Hz), 164.8 (dd, J = 210.8, 12.9 Hz), 162.2 (dd, J = 214.1, 12.9 Hz), 156.1, 
155.2 (d, J = 7.0 Hz), 151.4, 146.2 (q, J = 4.7 Hz), 140.7, 137.5 – 137.1 (m), 129.1, 126.9 (dd, J 
= 4.3, 2.6 Hz), 125.7, 125.3, 123.9 (d, J = 21.0 Hz), 122.1 (d, J = 271.6 Hz), 114.5 (dd, J = 18.0, 
3.0 Hz), 99.4 (apparent t, J = 27.1 Hz).  19F NMR (376 MHz, Acetone-d6) δ -63.56 (s, 6F), -72.65 
(d, 6F, J = 707.3 Hz), -104.62 – -104.81 (m, 2F), -107.74 – -108.15 (m, 2F).  31P NMR (162 MHz, 
Acetone-d6) δ -131.24 – -157.38 (hept, J = 707.94 Hz).  LC/MS (m/z) M+ calculated for 
C34H18F10IrN4 865.10 found M+, 864.50. 
4gc, General procedure C was followed using iridium(III) chloride (178 mg, 0.60 mmol), 2-(2,4-
difluorophenyl)-5-(trifluoromethyl)pyridine 2g (352 mg, 1.4 mmol) and a 2:1 mixture of 2-
methoxyethanol/water (12 mL) to obtain the dimer in 74% yield (326 mg, 0.22 mmol) as a yellow 
solid.  4gc was synthesized using the dimer (100 mg, 0.067 mmol), 4,4’-di-tbutyl-2,2’-bipyridyl 
(5c, 39 mg, 0.147 mmol) and ethylene glycol (4 mL).  4c was obtained in 81% yield (121 mg, 0.11 
mmol) as yellow solid.  1H NMR (400 MHz, Acetone-d6) δ 8.95 (d, 2H, J = 1.8 Hz), 8.63 (dd, 2H, 
J = 8.8, 2.6 Hz), 8.42 (dd, 2H, J = 8.8, 1.9 Hz), 8.20 (d, 2H, J = 5.9 Hz), 7.85 – 7.81 (m, 4H), 6.88 
(ddd, 2H, J = 12.7, 9.3, 2.3 Hz), 5.98 (dd, 2H, J = 8.4, 2.3 Hz), 1.45 (s, 18H).  13C NMR (101 
MHz, Acetone-d6) δ 167.9 (d, J = 7.5 Hz), 165.4, 164.6 (dd, J = 258.5, 12.7 Hz), 162.5 (dd, J = 
261.8, 13.1 Hz), 156.0, 155.8 (d, J = 7.0 Hz), 151.1, 145.7 (q, J = 4.8 Hz), 137.2 (d, J = 3.0 Hz), 
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126.8 (dd, J = 4.4, 2.5 Hz), 126.0, 125.3 (d, J = 35.3 Hz), 123.9 (d, J = 21.0 Hz), 122.6, 122.2 (d, 
J = 271.7 Hz), 114.5 (dd, J = 17.8, 3.0 Hz), 99.3 (apparent t, J = 27.1 Hz), 35.7, 29.5.  19F NMR 
(376 MHz, Acetone-d6) δ -63.69 (s, 6F), -72.68 (d, 6F, J = 707.3 Hz), -104.76 (dt, 2F, J = 11.9, 9.0 
Hz), -108.09 (td, 2F, J = 12.4, 2.4 Hz).  31P NMR (162 MHz, Acetone-d6) δ -131.17 – -157.37 
(hept, J = 706.32 Hz).  LC/MS (m/z) M+ calculated for C42H34F10IrN4 977.23 found M+, 977.20. 
4db, General procedure C was followed using iridium(III) chloride (89 mg, 0.30 mmol), 2-(2,4-
difluorophenyl)pyridine 2d (130 mg, 0.68 mmol) and a 2:1 mixture of 2-methoxyethanol/water (6 
mL) to obtain the dimer in 82% yield (150 mg, 0.12 mmol) as yellow solid.  4db was synthesized 
using the dimer (5b, 150 mg, 0.12 mmol), 2,2’-bipyridyl (34 mg, 0.22 mmol) and ethylene glycol 
(6 mL).  4d was obtained in 57% yield (100 mg, 0.11 mmol) as a yellow solid.  1H NMR (400 
MHz, Acetone-d6) δ 8.89 (d, 2H, J = 8.1 Hz), 8.46 – 8.33 (m, 4H), 8.24 (ddd, 2H, J = 5.4, 1.5, 0.6 
Hz), 8.11 – 8.05 (m, 2H), 7.94 (ddd, 2H, J = 5.8, 1.5, 0.7 Hz), 7.77 (ddd, 2H, J = 7.6, 5.5, 1.2 Hz), 
7.27 (ddd, 2H, J = 7.4, 5.9, 1.4 Hz), 6.78 (ddd, 2H, J = 12.7, 9.3, 2.4 Hz), 5.82 (dd, 2H, J = 8.5, 
2.4 Hz).  13C NMR (101 MHz, Acetone-d6) δ 164.8 (d, J = 7.1 Hz), 163.5 (dd, J = 39.4, 12.7 Hz), 
163.5 (dd, J = 476.4, 12.7 Hz), 156.8, 155.6 (d, J = 6.6 Hz), 152.0, 150.8, 141.2, 140.8, 130.0, 
128.9 (dd, J = 4.5, 2.8 Hz), 126.1, 125.2, 124.6 (d, J = 20.2 Hz), 114.7 (dd, J = 17.7, 3.0 Hz), 99.7 
(apparent t, J = 27.1 Hz).  19F NMR (376 MHz, Acetone-d6) δ -72.67 (d, 6F, J = 707.2 Hz), -107.74 
– -107.86 (m, 2F), -110.00 – -110.13 (m, 2F).  31P NMR (162 MHz, Acetone-d6) δ -131.16-157.38 
(hept, J = 707.94 Hz).  LC/MS (m/z) M+ calculated for C32H20F4IrN4 729.13 found M+, 728.55. 
4dc, General procedure C was followed using iridium(III) chloride (89 mg, 0.29 mmol), 2-(2,4-
difluorophenyl)pyridine 2d (130 mg, 0.68 mmol) and a 2:1 mixture of 2-methoxyethanol/water (6 
mL) to obtain the dimer in 82% yield (150 mg, 0.12 mmol) as a yellow solid.  4dc was synthesized 
using the dimer (126 mg, 0.10 mmol), 4,4’-di-tbutyl-2,2’-bipyridyl (5c, 59 mg, 0.22 mmol) and 
ethylene glycol (6 mL).  4e was obtained in 88% yield (174 mg, 0.18 mmol) as yellow solid.  1H 
NMR (400 MHz, Acetone-d6) δ 8.79 (d, 2H, J = 1.8 Hz), 8.27 (d, 2H, J = 8.4 Hz), 7.98 – 7.90 (m, 
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4H), 7.76 – 7.72 (m, 2H), 7.62 (dd, 2H, J = 5.9, 2.0 Hz), 7.09 (ddd, 2H, J = 7.4, 5.9, 1.3 Hz), 6.64 
(ddd, 2H, J = 12.6, 9.4, 2.4 Hz), 5.65 (dd, 2H, J = 8.6, 2.4 Hz), 1.28 (s, 18H).  13C NMR (101 
MHz, Acetone-d6) δ 164.6, 165.4 – 163.8 (m), 162.5 (dd, J = 37.2, 12.6 Hz), 160.1 (d, J = 12.8 
Hz), 155.7, 155.2 (d, J = 6.2 Hz), 150.5, 149.6, 139.7, 125.8, 124.1, 123.6 (d, J = 20.5 Hz), 122.4, 
113.6 (dd, J = 17.6, 2.9 Hz), 98.6 (apparent t, J = 27.2 Hz), 35.6, 29.5.  19F NMR (376 MHz, 
Acetone-d6) δ -72.61 (dd, 6F, J = 707.2, 8.6 Hz), -107.90 (q, 2F, J = 9.7 Hz), -110.17 (t, 2F, J = 
11.7 Hz).  31P NMR (162 MHz, Acetone-d6) δ -130.58 – -157.12 (hept, J = 707.94 Hz).  LC/MS 
(m/z) M+ calculated for C40H36F4IrN4 841.25 found M+, 840.60. 
4cb General procedure C was followed using iridium(III) chloride (89 mg, 0.30 mmol), 2-(4-
fluorophenyl)pyridine 2c, and a 2:1 mixture of 2-methoxyethanol/water (6 mL) to obtain the dimer 
in 82% yield (150 mg, 0.12 mmol) as a yellow solid.  4f was synthesized using the dimer (35 mg, 
0.031 mmol), 2,2’-bipyridyl (5b, 10.5 mg, 0.067 mmol) and ethylene glycol (5 mL).  4cb was 
obtained in 94% yield (48 mg, 0.070 mmol) as yellow solid.  1H NMR(400 MHz, Acetone-d6): δ 
= 8.87 (d, 2H, J= 8.2 Hz), 8.33 (td, 2H, J= 8.0, 1.6 Hz), 8.24 (d, 2H, J= 8.1 Hz), 8.17 (ddd, 2H, 
J= 5.4, 1.5, 0.7 Hz), 8.05 – 7.95 (m, 4H), 7.83 (ddd, 2H, J= 5.8, 1.4, 0.7 Hz), 7.75 (ddd, 2H, J= 
7.6, 5.5, 1.2 Hz), 7.23 – 7.14 (m, 2H), 6.84 (td, 2H, J= 8.9, 2.6 Hz), 5.95 (dd, 2H, J= 9.5, 2.6 Hz) 
ppm 13C NMR(101 MHz, Acetone-d6): δ = 167.6, 166.0, 157.0, 154.5 (d, J= 5.9 Hz), 151.9, 150.3, 
141.5 (d, J= 2.1 Hz), 140.9, 140.1, 129.8, 128.3 (d, J= 9.4 Hz), 126.0, 124.7, 121.2, 118.4 (d, J= 
17.9 Hz), 110.7 (d, J=23.3 Hz) ppm 19F NMR(376 MHz,Acetone-d6): δ = -72.63 (d, 6F, J=707.4 
Hz), -110.75 (s, 2F) ppm 31P NMR(162 MHz, Chloroform-d): δ = -129.39 – -148.65 (m) ppm. 
Anal. calcd for C32H22F8IrN4P: C, 45.88; H, 2.65; N, 6.69. Found: C, 45.75; H, 7.48; N, 7.08. 
LC/MS (m/z) M+ calculated for C32H22F2IrN4 693.14 found, 692.60.   
4cc, General procedure C was followed using iridium(III) chloride (89 mg, 0.31 mmol), 2-(4-
fluorophenyl)pyridine 2c, and a 2:1 mixture of 2-methoxyethanol/water (6 mL)to obtain the dimer 
in 82% yield (150 mg, 0.12 mmol) as yellow solid.  4cc was synthesized using the dimer (106 mg, 
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0.10 mmol), 4,4’-di-tbutyl-2,2’-bipyridyl (5c, 54 mg, 0.20 mmol) and ethylene glycol (5 mL).  4g 
was obtained in 83% yield (158 mg, 0.19 mmol) as yellow solid.  1H NMR(400 MHz, Acetone-
d6): δ = 8.90 (d, 2H, J=1.7 Hz), 8.24 (d, 2H, J=8.1 Hz), 8.05 – 7.95 (m, 6H), 7.80 – 7.77 (m, 2H), 
7.74 (dd, 2H, J=5.9, 2.0 Hz), 7.16 (ddd, 2H, J=7.3, 5.9, 1.4 Hz), 6.83 (td, 2H, J=8.9, 2.6 Hz), 5.94 
(dd, 2H, J=9.5, 2.6 Hz), 1.41 (s, 18H) ppm 13C NMR (101 MHz, Acetone-d6) δ 167.7, 165.3, 164.7 
(d, J = 252.8 Hz), 156.8, 155.1 (d, J = 5.8 Hz), 151.4, 150.0, 141.5 (d, J = 2.0 Hz), 140.0, 128.2 
(d, J = 9.4 Hz), 126.7, 124.5, 123.1, 121.1, 118.3 (d, J = 17.8 Hz), 110.5 (d, J = 23.2 Hz), 36.5 . 
19F NMR (376 MHz, Acetone-d6) δ -72.61 (d, 6F, J = 707.4 Hz), -110.86 (s, 2F).31P 
NMR(Chloroform-d, 162 MHz): δ = -139.08 (p, J=707.6 Hz) ppm. LC/MS (m/z) M+ calculated 
for C40H38F2IrN4 805.27 found M+, 804.70. 
4fd, General procedure C was followed using iridium(III) chloride (178 mg, 0.60 mmol), 2-(3-
(tert-butyl)phenyl)pyridine 2f (287 mg, 1.4 mmol), and a 2:1 mixture of 2-methoxyethanol/water 
(12 mL) to obtain the dimer in 60% yield (232 mg, 0.18 mmol) as a yellow solid.  4fd was 
synthesized using the dimer (28 mg, 0.022 mmol), 4,4’-di-methoxy-2,2’-bipyridyl (5d, 11 mg, 
0.048 mmol) and ethylene glycol (2 mL).  4h was obtained in > 99% yield (43 mg, 0.044 mmol) 
as orange solid.  1H NMR (400 MHz, Acetone-d6) δ 8.35 (d, 2H, J = 2.6 Hz), 8.32 (d, 2H, J = 8.1 
Hz,), 7.99 – 7.92 (m, 4H), 7.91 – 7.87 (m, 2H), 7.83 (d, 2H, J = 6.4 Hz), 7.24 (dd, 2H, J = 6.4, 2.6 
Hz), 7.17 (ddd, 2H, J = 7.3, 5.8, 1.4 Hz), 7.02 (dd, 2H, J = 8.0, 2.1 Hz), 6.32 (d, 2H, J = 8.0 Hz), 
4.09 (s, 6H), 1.32 (s, 18H).  13C NMR (101 MHz, Acetone-d6) δ 168.5, 168.1, 157.7, 151.5, 149.3, 
147.3, 144.9, 143.9, 138.4, 131.6, 128.0, 123.4, 121.9, 119.9, 114.1, 111.6, 56.6, 34.2, 31.0.  31P 
NMR (162 MHz, Acetone-d6) δ -130.19 – -157.39 (hept, J = 707.94 Hz ).  Anal. calcd for 
C42H44F6IrN4O2P: C, 51.79; H, 4.55; N, 5.75.  Found: C, 51.61; H, 4.38; N, 5.94.  LC/MS (m/z) 




Electrochemical Measurements: Ground state redox potential of all complexes were 
determined (Table 2.3) by CV. Measured  Eox
1/2, Ered
1/2 and Egap (value determined by 
CV) was utilized to calculate excited state  potentials using equation 2 and 3.  
E1/2 Ir
+/Ir* = E1/2 ox – E gap= (eq 2) 
E1/2 Ir
*/Ir- = E gap + E1/2 red (eq 3)   
 















4b 473 60.4 1.23 -1.23 2.2 -0.97 0.97 
4a 475 60.2 1.81 -1.25 2.64 -0.83 1.39 
4c 476 60.1 1.77 -1.35 2.77 -1.0 1.42 
3d 476 60.1 0.98 -1.82 2.21 -1.23 0.39 
















3b 507 56.4 1.11 -2.13 2.76 -1.65 0.63 
4e 516 55.4 1.63 -1.42 2.56 -0.93 1.14 
3a 518 55.2 0.78 -2.2 2.75 -1.97 0.55 
3e 525 54.5 0.69 -2.27 2.59 -1.90 0.32 
3f 528 54.2 0.70 -2.03 2.28 -1.59 0.25 
4d 528 54.2 1.66 -1.32 2.46 -0.80 1.14 
4g 540 53.0 1.49 -1.45 2.52 -1.04 1.07 
4f 556 51.4 1.51 -1.37 2.40 -0.89 1.03 
4h 560 51.2 1.17 -1.50 2.35 -1.12 0.85 
 






































Figure 2.6 Chapter II NMR Spectrum Graphs 


































































































































































































































































































































































































2.6 Second generation method for homoleptic complexes 
 
Scheme 2.5 Second generation method for homoleptic iridium complexes 
 
While we and others have used the method described previously to make gram scale 
quantities of these complexes, there are some notable shortcomings.  Namely, purification of the 
complexes via column chromatography was time intensive, required copious amounts of organic 
solvents, and was particularly challenging because of the low solubility.  Often the isolation of the 
complex was more challenging than its synthesis.  Since this publication, we have worked to 
improve the method (Scheme 2.5), in particular we have focused on making the reaction more 
scalable.  The three main objectives were to maintain high purity of the complex on a gram scale, 




Scheme 2.6 Synthesis of facial-homoleptic iridium complexes 
Herein, we report (Scheme 2.6) a modified method which has been applied to 
photocatalysts to obtain multigram quantities of photocatalysts (up to 2.85 g) in high purity 
(>97%), without the use of a column, and with excellent recovery of excess ligand in good yield 
(up to 97.0%).  The method is demonstrated in the synthesis of 1a and 1d as an example.  
Additionally, while we did not demonstrate the recovery of the organic solvent, it is conceivable 
that the DCM could also be recovered in high purity.  We believe this method to be quite general 
to this family of photocatalysts.  Consequently, this method will facilitate exploration of the 
chemistry of these Ir-complexes, as well as enable applications, which may require more 
substantial quantities of Ir-photocatalysts.   
 
A. Fac-tris(2-phenylpyridinato) iridium(III) (A). Iridium (III) chloride anhydrous (1.30 g, 
4.36 mmol, 1 equiv, Note 1), 2-phenylpyridine (7.47 mL, 52.2 mmol, 12.0 equiv, Note 2), and 
1.30 L of DI water (0.003 M with respect to IrCl3) is added to a 2 L Parr reactor (Note 3).  The 
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reaction mixture is then pressurized with argon (10.0 PSI, stirred and then depressurized three 
times and finally charged again with argon before sealing, (Note 4).  The reaction mixture is heated 
to 205 oC for 48.0 h (Note 5). The reactor is cooled to room temperature with an ice bath, and after 
cooling, the reactor is opened revealing an insoluble yellow solid on the surfaces and dispersed in 
the aqueous phase (Note 6). All contents are transferred slowly to a 6 L separatory funnel aided 
by a large 5 cm glass funnel. The interior of the reactor is mechanically scraped (to extract the 
yellow material), with metal tongs, cotton balls (25 in total), and 500 mL of DCM from a spray 
bottle, and again all contents are added to the separatory funnel. (Note 7). While still in the funnel, 
the cotton is rinsed with 25 mL of DCM from a spray bottle and evenly pressed with tongs to 
release the yellow material from the cotton (Note 7). After removing the cotton, the solution is 
then diluted with 2.5 L of DCM (see notes 13 and 14).  The separatory funnel is shaken vigorously, 
allowed to settle and again shaken, and the organic layer (Note 8) is then slowly separated from 
the aqueous layer (Note 9) and the aqueous layer is further extracted with more DCM (3 x 10 mL), 
and the organic layers are combined (Note 10). The aqueous layers are kept for future ligand 
recovery. The combined organic layer is washed with a 1 M HCl solution, with vigorous mixing 
prior to separation (3 x 900 mL) (Note 11).  Each HCl wash is then back extracted with DCM (3 
x 10 mL) to insure complete recovery of the product (Note 10). After the final wash (Note 12), the 
organic layer is filtered slowly (20 min) through a Celite® (35 g) pad on top of a 150 mL medium 
porosity sintered glass funnel, into a 3 L round-bottom flask, and then dried with 30 g of MgSO4. 
After filtering the drying reagent using a 4 L Erlenmyer flask fitted with a 5 cm funnel/cotton plug, 
a homogenous aliquot is removed for NMR analysis (Note 13).  Finally, the solvent is removed in 
batches by transferring to a 2.5 L round-bottomed flask by rotary evaporation (35 °C, 30 mm Hg, 
150 rpm) to afford Ir(ppy)3 as a bright yellow solid (Note 14) in 97.5-99.1% yield (2.78 g) in 
96.3%-97.5% purity as compared to a standard signal (1,3,5 trimethoxybenzene) in the 1H NMR 
(see Note 19 for wt % experiments and Note 20 for characterization). 
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Further purification of Ir(ppy)3 can be performed by adding 2.78 g of the yellow solid to a 1 
L round-bottom flask and adding 600 mL of distilled hexanes. The solid material is then sonicated 
until a uniform slurry is achieved, and 5 mL of dichloromethane is added (Note 15). The liquid is 
swirled giving a slight yellow tint to the solution indicating successful dissolution of a colored 
compound, and selective extraction of the impurities. Then the slurry is slowly poured through a 
50 mL fine porosity sintered glass funnel to catch the Ir(ppy)3 solid and the filtrate is collected 
into a 1 L Erlenmeyer flask. The yellow solid is left on the filter to air dry to afford 91.6-93.0% 
yield (2.61g) in 97.8%-99.1% purity compared to integrations of a standard signal (1,3,5 
trimethoxybenzene) in the 1H NMR (see Note 19 for wt % experiments and Note 20 for 
characterization). 
2-Phenylpyridine recovery: The previously retained aqueous layers are added to a 4 L 
Erlenmeyer flask with a 60 mm PTFE octagon stir bar. The solution is stirred and slowly brought 
to pH 10 by adding 119 g of NaOH pellets in 10 portions (Note 16). The solution is added to a 6 
L separatory funnel and the ligand is extracted from the salty water with DCM (6 x 1.2 L). The 
combined organic extracts are added to a 20 L metal canister and are dried with 20 g of MgSO4. 
After filtering the drying reagent through a 5 cm funnel with a cotton plug into another 20 L 
canister the solvent is removed in batches by utilizing a continuous rotary evaporation setup (35 
°C, 130 mm Hg, 100 rpm, Note 17) to afford 5.90 g 96.4-97.0% (based on excess 9 equiv) of 2-
phenylpyridine is recovered in 97.7-98.5% purity compared to a standard signal 
(trimethoxybenzene) in the 1H NMR (see Note 19 for wt % experiments and Note 20 for 
characterization) 
B. Fac-tris(2-(4,6-difluorophenyl)pyridinato) iridium(III) (A). Iridium (III) chloride 
anhydrous (1.00 g, 3.35 mmol, 1 equiv, Note 1), 2-(4,6-difluoro)phenylpyridine (6.13 mL, 40.2 
mmol, 12 equiv) (Note 2), and 1.00 L of DI water (0.003 M with respect to IrCl3) is added to a 2 
L Parr reactor (Note 3).  The reaction mixture is then pressurized with argon (10.0 PSI, stirred and 
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then depressurized three times and finally charged again with argon before sealing (Note 4). The 
reaction mixture is heated to 205 oC for 48.0 h (Note 5). The reactor is cooled to room temperature 
with an ice bath, and after cooling the reactor is opened revealing an insoluble yellow solid on the 
surfaces and dispersed in the aqueous phase (Note 6). All contents are transferred slowly to a 6 L 
separatory funnel aided by a large 5 cm glass funnel. Then the interior of the reactor is 
mechanically scraped (to extract the yellow material), with metal tongs, cotton balls (25 in total), 
and 500 mL of DCM from a 500 mL spray bottle, and again all contents are added to the separatory 
funnel (Note 7). While still in the funnel, the cotton is rinsed with 25 mL of DCM from a spray 
bottle and evenly pressed with tongs to release the yellow material from the cotton (Note 7). After 
removing the cotton, the solution is then diluted with 2.5 L of DCM (see Notes 13 and 14).  The 
separatory funnel is shaken vigorously, allowed to settle and again shaken, the organic layer (Note 
8) is then slowly (Note 9) separated from the aqueous layer, the aqueous layer is further extracted 
with DCM (3 x 10 mL), and the organic layers are combined (Note 10). The aqueous layers are 
kept for future ligand recovery. The combined organic layer is washed with a 1 M HCl solution 
with vigorous mixing (4 x 1 L) (Note 11). Each HCl wash is back extracted with DCM (3 x 10 
mL) to insure complete recovery of the product (Note 10). After the final wash (Note 12), the 
organic layer is filtered slowly (20 min) through a Celite® (35 g) pad on top of a 150 mL medium 
porosity sintered glass funnel, into a 3 L round-bottomed flask, and dried with 50 g of MgSO4. 
The drying reagent is filtered using a 4 L Erlenmyer flask fitted with a 5 cm funnel/cotton plug.  
At this point, a homogenous aliquot is removed for NMR analysis (Note 13).  Finally, the solvent 
is removed in batches by transferring to a 2.5 L round-bottomed flask by rotary evaporation (35 
°C, 30 mm Hg, 150 rpm) to afford Ir(diFppy)3 as a yellow solid (Note 14) in 90.9% yield (2.32 g) 
in 90.8% purity compared to a standard signal in the 19F NMR (see Note 19 for wt % experiments 
and Note 20 for characterization). 
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Further purification of Ir(diFppy)3 can be performed by adding 2.32 g of the yellow solid to a 
1-L round-bottomed flask and adding 600 mL of distilled hexanes. The solid material is sonicated 
until a uniform slurry is achieved and 5 mL of dichloromethane is added (Note 15). The liquid is 
swirled giving a slight yellow tint to the solution indicating successful dissolution of a colored 
compound and selective extraction of the impurities. The product slurry is then slowly filtered 
through a 50 mL fine porosity sintered glass funnel and the filtrate is collected into a 1 L 
Erlenmeyer flask. The yellow solid is left on the filter to air dry to afford 71.4% yield (1.82 g) in 
97.2% purity compared to integrations of a standard signal in the 19F NMR (see Note 19 for wt % 
experiments and Note 20 for characterization).  
2-(4,6-Difluoro)phenylpyridine recovery: The previously retained aqueous layers are  split equally 
between two 4 L Erlenmeyer flasks containing a 60 mm PTFE octagon stir bar. Each solution is 
stirred and slowly brought to pH 10 by adding 101 g of NaOH pellets (Note 16). In two batches, 
each solution is added to a 6 L separatory funnel and the ligand is extracted from the salty water 
with DCM (6 x 800 mL). The combined organic extracts are added to a 20 L metal canister and 
are dried with 20 g of MgSO4. After filtering the drying reagent through a 5 cm funnel with a 
cotton plug into another 20 L canister, the solvent is removed in batches by utilizing a continuous 
rotary evaporation setup (35 °C, 130 mm Hg, 100 rpm) (Note 17) to afford 5.90 g, 96.8% yield of 
2-(4,6-difluoro)phenylpyridine.  The purity is determined to be 90.5% pure compared to a standard 
signal (1,3,5 trimethoxybenzene) in the 1H NMR (see Note 19 for wt % experiments and Note 20 
for characterization). 
C. Fac-Tris[5-fluoro-2-(2-pyridinyl-N)phenyl-C]iridium(III)). Iridium 
(III) chloride anhydrous (0.47 g , 1.36  mmol, 1 equiv) 2-(4-fluorophenyl)-pyridine (2.83  g, 16.4  
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mmol, 12.0 equiv) , and 0.41  L of DI water (0.003 M with respect to IrCl3) is added to a 1 L Parr 
reactor.  The reaction mixture is pressurized with argon (10.0 psi), stirred and then depressurized 
three times, and finally charged again with argon before sealing. The reaction mixture is heated to 
205 °C for 48 h. Then the reactor is cooled and after cooling, the reactor is opened revealing an 
insoluble yellow solid on the surfaces and dispersed in the aqueous phase. All contents are 
transferred slowly to a 4 L separatory funnel aided by a large 5 cm glass funnel. Then the interior 
of the reactor is mechanically scraped (to extract the yellow material), with metal tongs, cotton 
balls, and 250 mL of dichloromethane (DCM) from a spray bottle, and again all contents are added 
to the separatory funnel. 
 
While still in the funnel, the cotton is rinsed with 25 mL of DCM from a spray bottle and evenly 
pressed with tongs to release the yellow material from the cotton. After removing the cotton, the 
solution is then diluted with 1.0 L of DCM. The separatory funnel is shaken vigorously, allowed 
to settle and again shaken, and the organic layer is then slowly separated from the aqueous layer 
and the aqueous layer is further extracted with more DCM (3 x 10 mL), and the organic layers are 
combined. The aqueous layers are kept for future ligand recovery. The combined organic layer is 
washed with a 1 M HCl solution, with vigorous mixing prior to separation (3 x 500 mL).  Each 
HCl wash is then back extracted with DCM (3 x 10 mL) to insure complete recovery of the 
product. After the final wash, the organic layer is filtered slowly (20 min) through a Celite® (25 
g) pad on top of a 150 mL medium porosity sintered glass funnel, into a 3 L round-bottomed flask, 
and then dried with 30 g of MgSO4. After filtering the drying reagent using a 4 L Erlenmyer flask 
fitted with a 5 cm funnel/cotton plug, a homogenous aliquot is removed for NMR analysis. Finally, 
the solvent is removed in batches by transferring to a 2.5 L round-bottomed flask by rotary 
evaporation (35 °C, 30 mm Hg, 150 rpm) to afford 963 mg (96%) of Ir(Fppy)3 as a bright yellow 
solid. 1H NMR(Methylene Chloride-d2, 400 MHz): d δ 7.88 (d, 3H, J = 8.2 Hz), 7.72-7.64 (m, 
6H), 7.52 (ddd, 3H, J = 5.5, 1.6, 0.8 Hz), 6.94 (ddd, 3H, J = 7.1, 5.6, 1.3 Hz), 6.63 (td, 3H, J = 8.7, 
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2.7 Hz), 6.39 (dd, 3H, J = 10.3, 2.7 Hz) ppm. 13C NMR(Methylene Chloride-d2, 101 MHz): d δ 
165.3 (d, J = 5.4 Hz), 163.4 (d, J = 5.7 Hz), 162.8, 147.2, 140.2, 136.6, 125.8 (d, J = 9.2 Hz), 
122.0, 121.8 (d, J = 16.4 Hz), 118.9, 107.4 (d, J = 23.6 Hz) ppm. 19F NMR (376 MHz, Methylene 
Chlorided2) d 112.33 (ddd, J = 10.3, 9.1, 5.7 Hz). 
 
2-(4-fluorophenyl)-pyridine recovery The solution is stirred and slowly brought to pH 10 by 
adding 56 g of NaOH pellets in 10 portions .The solution is added to a 6 L separatory funnel and 
the ligand is extracted from the salty water with DCM (4 x 900 mL). The combined organic 
extracts are added to a 20 L metal canister and are dried with 20 g of MgSO4. After filtering the 
drying reagent through a 5 cm funnel with a cotton plug into another 20 L canister the solvent is 
removed in batches by utilizing a continuous rotary evaporation setup (35 °C, 130 mm Hg, 100 




C]iridium(III). Iridium (III) chloride anhydrous (1.16 g , 3.89  mmol, 1 equiv) 2-(4- 
trifluoromethyl phenyl)-pyridine (10.4  g, 46.6  mmol, 12.0 equiv) , and 1.16  L of DI water (0.003 
M with respect to IrCl3) is added to a 1 L Parr reactor.  The reaction mixture is pressurized with 
argon (10.0 psi), stirred and then depressurized three times, and finally charged again with argon 
before sealing. The reaction mixture is heated to 205 °C for 48 h. Then the reactor is cooled and 
after cooling, the reactor is opened revealing an insoluble yellow solid on the surfaces and 
dispersed in the aqueous phase. All contents are transferred slowly to a 4 L separatory funnel aided 
by a large 5 cm glass funnel. Then the interior of the reactor is mechanically scraped (to extract 
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the yellow material), with metal tongs, cotton balls, and used acetone (100 mL to get residual 
compound(s) from parr and transfered to a different 250 mL round bottom flask and concentrated 
down. 
 
The solid was placed on a filter frit, and washed with 1 M HCl to wash away ligand. Yellow solid 
from frit was taken into 200 mL of acetone and dry loaded with 40 g of silica and column ran with 
5-6 column volumes to separate reamaining ligand. The column was then ran with 60:40 
Hexanes:EtOAc to pull of dimer and then the solvent system were switched to 100 % DCM to 
recover the catalyst as a yellow solid in 67.58 % yield 2.26 g. 1H NMR(Chloroform-d, 400 MHz): 
δ = 7.99 (d, 3H, J = 8.3 Hz), 7.77–7.69 (m, 6H), 7.55 (dd, 6H, J = 6.0, 1.3 Hz), 7.20–7.15 (m, 3H), 
7.02 (ddd, 3H, J = 7.1, 5.2, 1.1 Hz), 6.96 (b, 3H) ppm. 13C NMR (Methylene Chloride-d2, 101 
MHz): δ = 165.0, 159.2, 147.5–147.4 (m), 147.3, 137.0.132.4 (m), 130.6, 123.9, 123.4, 120.0, 
117.3–117.2 (m), 100.0. 19F NMR (376 MHz, Chloroform-d) δ −62.76 (s). LC/MS (m/z) 




1. IrCl3 was obtained from Beantown Chemicals (BTC), available through VWR. 
2. 2-Phenylpyridine was obtained from AK scientific and 2-(4,6-difluorophenylpyridine was 





Figure 2.7 Parr reactor  
 
3. A 2 L Parr stirred reactor was fitted with an inlet and outlet valve, a Duro United pressure 
gauge (0-5000 psi), and a 526HCPH rupture disc was used for the reaction (Figure 2.7a). In 
series with a 4843 controller the reactor was heated with a Parr heater assembly (model no. 
A1445HC3EE) controlled by a type J thermocouple (15.5 in. length) (Figure 2.7b). We have 
found that the stirring and glass sleeve options are unnecessary for the success of the reaction. 
We also discovered that headspace in the reactor is very important (1/4 headspace to water). 
We found that if the same 2 L Parr reactor was loaded with 1.75 L water the reactor leaked 
and displays a significant amount of pressure.  Again, further safety precautions must be taken 
when changing the headspace to water ratio.  
4. If the Parr reactor is not equipped with a stirring mechanism, after pressurizing the reactor 
with argon one can gently rock the reactor back and forth to mix the contents.  
5. The primary cause for incomplete or failed reactions stems from equipment failure. Since the 
reaction is highly dependent on temperature it is important to insure probes and controllers 
are working properly, and leak checks are performed on the entire system before every 
reaction. Insure all valves are free of obstruction and all areas are clean. It is imperative that 
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the reactor temperature stays above 200 oC The reactor used in the above reactions had shown 
significant temperature deviation +/-  5 oC. So we set our controller to 205 oC to insure the 
reactor stays above 200 oC.  
 
 
Figure 2.8 An example of the insoluble yellow solid found on the internal components 
after a successful reaction 
 
6. Suspended dull yellow colored water mixtures is indicative of an unsuccessful reaction, while 
insoluble yellow colored (Figure 2.8) water mixtures are indicative of a successful reaction.  
For the Ir(ppy)3 catalyst, the primary contaminant after the workup is the chloro-bridging 
dimer which is a dull yellow color intermediate en-route to the desired product.  This was 





Figure 2.9 Photograph of extraction  
 
7. Yellow solid around the walls, probe shafts, and stirring impellers should be examined for 
yellow residue and any residue should be scraped or extracted with DCM to insure high 
accurate yields (Figure 2.9). 
8. There may be yellow solid that did not dissolve completely into the DCM. This is normal; as 
the 1 M HCl washes are performed and ligand is removed the catalyst will eventually partition 
fully into the organic layer. 
9. In this large scale workup, the aqueous layer tends to swirl into the organic layer, if separation 
is done quickly. It is important to insure the separation of the organic layer from the aqueous 
layer is slow in all separations.  
10. There tends to be a small emulsion layer in between the organic and aqueous layers during the 
workup which contains some black material. Care should be taken to avoid the inclusion of 
this emulsion layer. The extra DCM rinses serve to fully extract the product that remains in 
the emulsion and on the walls of the separatory funnel.  
11. Because it builds up pressure, it is important to vent the separatory funnel to avoid loss of 
product and to avoid injury. Some loss of product is apparent when venting the large 6 L 
separatory funnel through the stopcock, while not the standard technique, venting was 
performed by securing the separatory funnel back to the ring stand and carefully removing the 
stopper.  
12. Thin-layer chromatography (TLC) was used to insure all ligand was extracted from the 
organic layer. TLC was performed using Sorbent Technologies Silica Gel XHL normal phase 
plates and utilizing an eluent system of hexanes/EtOAc (9:1). See Note 18 for Rf values. 
13. The solubility of the catalysts is relatively low in dichloromethane (thus a large volume of 
solvent was used to dilute the compound), yet the impurities (the chloro-bridging dimer and 
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the excess ligand) are significantly more soluble. Removing an aliquot while the entire mixture 
is homogenous will insure an accurate NMR analysis. 
14. Since the solubility of the catalyst is low in most volatile solvents transferring the material to 
a smaller container can be laborious and require copious amounts of solvent. It is 
recommended to scrape the sides of the round-bottomed meticulously and transfer all the 
material possible as a solid.  Then any remaining solid material can be dissolved with solvent 
and transferred to the smaller container, thus, minimizing the solvent use.  
15. To insure high yields of product, the purification step must be performed with care. The 
amount of DCM that is added to the hexanes can vary depending on the purity of the sample. 
Lower amounts of DCM are added for purer samples and larger amounts are used for 
compounds of lower purity. The ratio for the purification technique is typically 1/120 
(DCM/Hexanes).  
16. One must slowly add the NaOH to avoid excessive heat generation and potential injury. We 
observed that extraction of ligand becomes difficult, and yields suffer when using a NaOH 
solution in comparison to direct addition of NaOH pellets. The use of pellets minimizes the 





Figure 2.10 Diagram of a continuous rotary evaporation setup 
 
17. See above (Figure 2.10) for a diagram for a continuous rotary evaporation setup 
18. Rf values are measured using thin layer chromatography (TLC), (obtained from sorbent 
technologies Silica XHL TLC Plates, w/UV254, glass backed, 250 µm, 20 x 20 cm) see Table 
below. 
Table 2.4 Rf values of the photocatalysts and ligands. 
 
Compound Rf: 1/9 EtOAc/Hexanes Rf: 1/1 
DCM/Hexanes 
Fac-tris(2-phenylpyridinato) iridium(III) 0.028 0.43 




2-(4,6-difluoro)phenylpyridine 0.33 0.23 
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19. The weight percent was determined by quantitative NMR. The solubility of I(rppy)3 and 
Ir(diFppy)3 in most deuterated solvents is low, which makes weighing out the necessarily 
small amounts of dissolvable compound challenging.  It is best to accurately weigh out a larger 
sample (>100 mg of the standard or compound) and dissolve the compound into protio-
dichloromethane using a volumetric flask to give an accurate molar solution. Then appropriate 
volumes of the standard and compound solutions can be mixed. Next, the protio-solvent 
removed and the mixture redissolved in the appropriate deuterated solvent. A proton NMR 
spectrum is thus obtained for the mixture with a minimum relaxation delay of 30 s. The weight 















 Wt% = purity of the sample 
 Icpd = proton integral area of a known peak on the compound being analyzed 
 nHcpd = number of hydrogens associated with the compound NMR peak 
 Istd = proton integral area of a known peak on the standard 
 nHcpd = number of hydrogens associated with the standard NMR peak 
 mgstd = amount in milligrams of the standard compound weighed for analysis 
 mgcpd = amount in milligrams of the compound being analyzed 
 MWstd = molecular weight of the standard 
 MWcpd = molecular weight of the compound being analyzed 
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Pstd = wt% purity of the standard expressed as a decimal value. For the purposes of most 
calculations, a value of 1.00 may be assumed 
 
Wt % of fac-tris(2-phenylpyridinato) iridium(III) 
(before purification step) 
 
1.0 mL of a 0.004464 M solution (in DCM) of Irppy3 was added to a vial, and then 1.0 mL of 
0.04464 M solution (in DCM) of 1,3,5 trimethoxybenzene was added. Then the solution was 
concentrated and then diluted with CD2Cl2 and 1H NMR was taken. The NMR parameters 
consisted of a 30 second delay with 128 scans,and a spectrum width of 16 to -4 ppm. Purity 
calculations with known masses were performed by MestReNova purity/wt % script (see 
NMR spectra for values).  
 
Wt % of fac-tris(2-phenylpyridinato) iridium(III)  
(after purification step) 
 
1.0 mL of a 0.007504 M solution (in DCM) of Ir(ppy)3 was added to a vial, and then 0.35 mL 
of 0.020215 M solution of 1,3,5 trimethoxybenzene was added. Then the solution was 
concentrated, then diluted with CDCl3, and the 1H NMR was taken. The NMR parameters 
consisted of a 30 second delay, with 128 scans, the spectra transmission was moved to the 
center of the desired signals (irradiated at the 7.1 ppm position) to improve integrals (movetof 
on VNMRJ software) and a spectrum width of 16 to -4 ppm. Purity calculations with known 
masses were performed by MestReNova purity/wt % script.  
 




152.7 mg of 2-phenylpyridine was added to a vial, and then 173.8 mg of 1,3,5 
trimethoxybenzene was added. Then the solution was then diluted with CDCl3 and 1H NMR 
was taken. The NMR parameters consisted of a 30 second delay with 16 scans, and a spectrum 
width of 16 to -4 ppm. Purity calculations with known masses were performed by 
MestReNova purity/wt % script.  
 
Wt % of fac-tris(2-(4,6-difluorophenyl)pyridinato) iridium(III) 
(before purification step) 
 
0.50 mL of a 8.391x10-4 M solution (in DCM) of Ir(diFppy)3 was added to a vial, and then 7.9 
uL of 0.05333 M solution of fluorobenzene was added. The solution was added to a NMR 
tube fitted with a benzene capillary (C6D6 sealed into a capillary for locking purposes) and 19F 
NMR was taken. The NMR parameters consisted of a 30 second delay with 256 scans 
(insuring a 90 º pulse width), and a spectrum width of -40 to -180 ppm. Purity calculations 
with known masses were performed by MestReNova purity/wt % script (see NMR spectra for 
values).  
 
Wt % of fac-tris(2-(4,6-difluorophenyl)pyridinato) iridium(III)   
(after purification step) 
 
0.50 mL of a 0.0008457 M solution (in DCM) of Ir(diFppy)3 was added to a vial, and then 30 
μL of a 0.05333 M solution of fluorobenzene was added. Then the solution was added to a 
NMR tube fitted with a benzene capillary (C6D6 sealed into a capillary for locking purposes) 
and 19F NMR was taken. The NMR parameters consisted of a 30 second delay, with 1200 
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scans (insuring a 90 º pulse width), and a spectrum width of -40 to -180 ppm. Purity 
calculations with known masses were performed by MestReNova purity/wt % script.  
 
Wt % of 2-(4,6-difluoro)phenylpyridine 
 
28.6 mg of 2-(4,6-difluoro)phenylpyridine was added to a vial, and then 22.28 mg of 1,3,5 
trimethoxybenzene was added. Then the solution was diluted with C6D6 and 1H NMR was 
taken. The NMR parameters consisted of a 30 second delay, with 16 scans, and a spectrum 
width of 16 to -4 ppm. Purity calculations with known masses were performed by 
MestReNova purity/wt % script. 
20.  NMR spectra were obtained on a 400 MHz Bruker Avance III spectrometer and 400 MHz 
Varian spectrometer.  1H, 19F and 13C NMR chemical shifts are reported in ppm relative to the 
residual protio solvent peak (1H, 13C).  IR spectra were recorded on Varian 800 FT-IR. Due to the 
C-F splitting, carbons that couple with fluorine were reported as multiplets. 13C spectra for the 
catalysts were taken in protio NMP (best solvent we found to dissolve catalysts), and for locking 
purposes a sealed capillary with C6D6 was added to the NMR tube. 
Characterization of compounds 
Characterization of fac-tris(2-phenylpyridinato) iridium(III) 
 
1H NMR (400 MHz, Methylene Chloride-d2) δ 9.86 (d, J = 8.2 Hz, 1H), 9.60 (td, J = 8.1, 1.8 
Hz, 2H), 9.51 (d, J = 5.5 Hz, 1H), 8.93 – 8.77 (m, 1H), 8.71 (dt, J = 14.1, 7.0 Hz, 1H). 13C 
NMR (101 MHz, C6D6/NMP) δ 166.9, 161.8, 147.8, 144.9, 137.5, 137.3, 129.6, 124.7, 123.3, 




Characterization of 2-phenylpyridine 
 
1H NMR (400 MHz, Benzene-d6) δ 8.58 (d, J = 4.7 Hz, 1H), 8.15 (d, J = 7.2 Hz, 1H), 7.32 (d, 
J = 8.0 Hz, 1H), 7.25 (t, J = 7.5 Hz, 1H), 7.19 – 7.12 (m, 2H), 7.09 (td, J = 7.7, 1.9 Hz, 1H), 
6.63 (ddd, J = 7.4, 4.8, 1.0 Hz, 1H). 13C NMR (101 MHz, C6D6) δ 157.7, 150.3, 140.1, 136.6, 
129.4, 129.2, 127.5, 122.3, 120.3. FT-IR (neat) cm-1 3061,1579,1293,743. 
 
Characterization of fac-tris(2-(4,6-difluorophenyl)pyridinato) iridium(III) 
 
1H NMR (400 MHz, Methylene Chloride-d2) δ 8.31 (d, J = 8.3 Hz, 1H), 7.73 (t, J = 7.8 Hz, 
1H), 7.51 (d, J = 5.4 Hz, 1H), 7.04 – 6.91 (m, 2H), 6.42 (ddd, J = 11.7, 9.1, 2.5 Hz, 1H), 6.24 
(dd, J = 9.2, 2.4 Hz, 1H). 19F NMR (376 MHz, Chloroform-d) δ -108.64 (q, J = 9.2 Hz), -
110.54 (ddd, J = 13.0, 9.8, 2.6 Hz). 13C NMR (101 MHz, Benzene-d6/NMP) δ 165.4 (d, J = 
5.6 Hz), 165.3 (d, J = 11.7 Hz), 163.1 (dd, J = 64.4, 11.8 Hz), 162.4 (d, J = 6.8 Hz), 160.8 (d, 
J = 12.7 Hz), 148.6, 139.2, 128.7, 124.4, 123.7 (d, J = 20.8 Hz), 117.9 (d, J = 16.3 Hz). FT-IR 
(neat) cm-1 3009, 1555, 1160, 786. 
 
Characterization of 2-(4,6-difluoro)phenylpyridine 
 
1H NMR (400 MHz, Benzene-d6) δ 8.52 (d, J = 4.0 Hz, 1H), 8.16 (td, J = 8.9, 6.8 Hz, 1H), 
7.57 (d, J = 7.1 Hz, 1H), 7.07 (td, J = 7.8, 1.8 Hz, 1H), 6.59 (td, J = 7.9, 3.2 Hz, 2H), 6.52 
(ddd, J = 11.4, 8.8, 2.5 Hz, 1H). 19F NMR (376 MHz, Benzene-d6) δ -109.56 (p, J = 8.3 Hz), 
-112.56 (q, J = 10.7, 9.9 Hz). 13C NMR (101 MHz, Benzene-d6) δ 164.7 (d, J = 12.1 Hz), 
162.3 (dd, J = 13.8, 12.0 Hz), 159.9 (d, J = 11.9 Hz), 152.6 (d, J = 2.7 Hz), 150.0, 136.2, 132.8 
(dd, J = 9.5, 4.6 Hz), 124.1 (d, J = 11.0 Hz), 122.4, 111.9 (dd, J = 21.0, 3.6 Hz), 104.4 (dd, J 




*2-(4,6-difluoro)phenylpyridine is the only reagent according to vendors should be kept in a 
sealed air tight vial inside a refrigerator (5 ºC). All other products while neat and in a dark 




Working with Hazardous Chemicals 
 
The procedures in Organic Syntheses are intended for use only by persons with proper training in 
experimental organic chemistry.  All hazardous materials should be handled using the standard 
procedures for work with chemicals described in references such as "Prudent Practices in the 
Laboratory" (The National Academies Press, Washington, D.C., 2011; the full text can be accessed 
free of charge at http://www.nap.edu/catalog.php?record_id=12654).  All chemical waste should 
be disposed of in accordance with local regulations.  For general guidelines for the management 
of chemical waste, see Chapter 8 of Prudent Practices.  
In some articles in Organic Syntheses, chemical-specific hazards are highlighted in red 
“Caution Notes” within a procedure.  It is important to recognize that the absence of a caution note 
does not imply that no significant hazards are associated with the chemicals involved in that 
procedure.  Prior to performing a reaction, a thorough risk assessment should be carried out that 
includes a review of the potential hazards associated with each chemical and experimental 
operation on the scale that is planned for the procedure.  Guidelines for carrying out a risk 




The procedures described in Organic Syntheses are provided as published and are conducted 
at one's own risk.  Organic Syntheses, Inc., its Editors, and its Board of Directors do not warrant 











3.1 Introduction  
Azoles are a privileged scaffold that have been investigated as therapeutics for numerous 
diseases72 additionally 2-alkyl azoles have proven to be remarkable ROCK II inhibitors.73-75 There 
are however relatively few rapid syntheses of these targets. Consequently, in order to facilitate 
thorough SAR studies methods that allow the rapid construction of complex 2-alkyl azoles have 
grown in demand.  
The classic method for making 2-alkyl azoles is via cyclodehydration76 This is still the 
most commonly used, but it is limited to carboxylic acid derivatives (eqn 1, Scheme 3.1). Another 
drawback of using this method is that it only works with benzo- fused rings not simple azoles. 
Typically, the scope of this methodology’s is limited,and its success depends on the reactivity of 
the substrates and the availability of the required starting materials. However, in contrast to 
formation of the heterocycle, cross-coupling has the ability to expedite diversification and recent 
efforts have provided such strategies. The first is to couple bromoazoles4 and prefunctionalized 
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Csp3–zincates (eqn 2). Alternatively, alkyl-halides77 and hydrazones78 have also been used along 
with 2H-benzothiazoles (eqn 3). While these methods have expedited diversification by cross-
coupling the partners directly, they still possess limitations. Prefunctionalized zincates must be 
formed in situ which limits the substrates that can be used and the functional group tolerance of 
the reaction. Also, these preformed organometallics, which are often basic, are difficult to store 
and handle.  
Scheme 3.1 Accessing 2-alkyl benzothiazoles 
 
Even more recently, oxidative methods have been used to generate a radical, either by 
C–H abstraction or by  radical decarboxylation (eqn 4) and have proven quite selective for 
addition of the alkyl radical to the 2-position of an azole.79-80 However, Csp3–halides, Csp3–
organometallics or tosyl hydrazones represent a relatively small set of coupling partners that can 
be used as inputs for the cross-coupling.  
Radical addition to alkenes is well known81 and represents a promising strategy for the 
reductive alkylation of alkenes. Pioneering work in this area has shown that an aryl bromide can 
be converted to the aryl radical,82 most often by use of Bu3SnH83 or SmI2/HMPA.81, 84 Aside from 
toxicity issues associated with the organotin and HMPA, the major drawback is the limitation in 
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scope, which is due to fast over reduction of the desired aryl radical.81 Consequently, almost all 
synthetically useful examples of aryl radical addition to unactivated alkenes are intramolecular 
cyclizations that can outcompete fast reduction.83 
With the current research possessing limitations, we considered a strategy that would 
allow direct coupling of an azole or other heteroarene with a desirable partner. We hoped to exploit 
a mechanistic pathway in which an electron transfer to an azole- or heteroarene-halide iwas 
achieved via photoredox catalysis, which we anticipated would produce reactive azolyl or 
heteroaryl intermediates (eqn 5).85-86 We presumed that these intermediates would engage pi-
bonds to form C–C bonds giving rise to the desired products. With this late stage coupling, we 
further envisioned that this methodology would broaden the overall scope of azole bearing motifs 
and serve as a unique yet useful strategy for synthesizing these specific types of compounds. Also 
given the ubiquity of alkenes, this transformation had the immediate potential to significantly alter 
the types of motifs that could be synthetically accessed by rapid cross-coupling. In 2012, 
Stephenson and co-workers33 had shown that a photocatalyst such as Ir(ppy)3, an amine, in the 
presence of visible light could perform hydrodeiodination of an aryl iodide (Scheme 3.2). Much 
was learned from this example. One being that the amine of the reaction was quenching the 
photocatalyst and this reduced catalyst was adding electrons to the LUMO of the iodoarene. 
Secondly, that the amine or formate ion is supplying the H-atom.  




In 2014, MacMillan and coworkers demonstrated that 2-chlorobenzothiazoles could be 
coupled with 1-phenylpyrrolidine forming a C–C bond (Scheme 3.3). While the mechanism was 
not clear, it did suggest that these halogenated azoles were capable of also accepting electrons 
photocatalyically resulting in the formation of a desirable C–C bond.  
Scheme 3.3 Photocatalytic aryl carbinamine formation 
 
Previously, Arora and co-workers in our group41 proposed that 2-chloroazoles upon the 
delivery of a single electron transfer (SET) results in the generation of the chloro azolyl radical 
anions (Scheme 3.4),and  the bond-forming reactive intermediate can be applied to the C–H 
functionalization of tertiary amines aliphatic amines to synthesize α-azolyl carbinamines.87  
 
Scheme 3.4 Coupling of tertiary aliphatic amines with 2-chloroazoles 
 
The work depicted here in this chapter suggests that the halogen at the 2-position displays 
contrasting reactivity, thereby giving substantial control over the reaction. In contrast to this, 2-
bromoazoles as well and other related heteroaryl bromides, undergo rapid mesolytic fragmentation 
of bromide and give rise to the relatively long-lived azolyl or heteroaryl radical intermediates 
which appear to be responsible for C–C bond formation, as opposed to the radical anions in the 
case of chlorides. 
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The LUMO of the haloarene is the π* orbital.88-89 After delivery of the electron and 
formation of the radical anion, an intramolecular electron transfer takes place from the π* to the 
σ* orbital resulting in C–X fragmentation.12, 90-92 If the π-type radical anion is planar such 
monomolecular fragmentation is forbidden, since the orbitals are orthogonal (Figure 3.1A). The 
leaving group and its effect on the rate of fragmentation is depicted in Figure 3.1B. The larger 
and less electronegative atoms lower the σ* energy and in return promote facile fragmentation. 
For bimolecular reactions to be possible, the πRA must be generated and long-lived. 
Electronegative atoms or heteroatoms within the ring stabilize or lower the energy of the π*-orbital 
(LUMO).19  
Figure 3.1 Energy diagrams for radical anion fragmentation 
 
3.2 Optimization studies 
Initial experiments consisted of optimizing the reaction conditions. The next set of tables 
illustrate the results of the experiments. Initially solvent was examined for the reaction in Table 
3.1. Various solvents were screened including polar protic, polar aprotic, and non-polar solvents. 
The reaction performs best under polar aprotic conditions and CH3CN was chosen as the solvent 
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choice due to the overall reduction was low. Next, temperature was investigated and 45 oC was 
the optimal temperature (Table 3.2). It is important to note; that the table depicts that 
regioselectivity is thermalyl dependent, giving the best rr (6:1, 70%). The next table displays 
concentration dependence, at 0.25 M the reduction is also at the lowest (Table 3.3).  Finally, in 
Table 3.4 a catalyst screen was performed and out of the catalyst screen Ir(ppy)3 proved to be the 
optimal catalyst.  
 
 
Table 3.1 Solvent screening 
 
Entry Solvent NMR Conversion Reduction Alkylated product (rr = 1a : 1a’) 
1 Dichloromethane 100% 37% 63% (5:1) + unidentified side 
product 
2 DMA 100% 60% 40% (6:1) 
3 DMF 100% 58% 42% (5:1) 
4 DMSO 68% 23% 45% (4:1) 
5 THF 50% 35% 15% (4:1) 
6 Toluene 0 % na na 
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7 MeOH 19% 7% 12% (3:1) 
8 Nitromethane 0% na na 
9 NMP 100% 72% 28% (7:1) 
10 CH3CN 100% 30% 70% (6:1) 
rr =  regioisomeric ratio 
na = not applicable 
CH3CN was chosen as the solvent for further optimization. 
 




NMR conversion Reduction Alkylated Product (rr = 1a : 1a’) 
1 30 oC 100% 51% 49% (4:1) 
2 45 oC 100% 34% 66% (6:1) 
3 60 oC 100% 40% 40% (5:1) +  unidentified side 
product 




Table 3.3 Effect of Concentration 
 
Entry Concentration NMR conversion Reduction Alkylated product (rr = 1a : 1a’) 
1 0.10 M 100% 55% 45% (5:1) 
2 0.15 M 100% 52% 48% (4:1) 
3 0.20 M 100% 47% 53% (5:1) 
4 0.25 M 100% 38% 62% (5:1) 
5 0.30 M 100% 40% 60% (5:1) 
6 0.35 M 100 % 42% 58%(5:1) 
7 0.40 M 100% 48% 52% (5:1) 






Table 3.4 Catalysts screening 
 
Entry Catalyst NMR 
conversion 




















































































Ir(ppy)3 was chosen as the catalyst for the reaction 
With initial results in hand, we decided to look at other factors that could affect the overall 
reactivity. Previously, the Weaver group showed that 2-chloroazoles39 could be used to 
functionalize the α-C–H of tertiary aliphatic amines.  However, after experimentation, addition of 
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electron-rich dihydropyran to 2-chlorothiazole (entry 3, Table 3.5) yielded only reduced azole 
(1b) and carbinamine (1c) as the major products. Whereas, the use of the 2-bromothiazole resulted 
in a complete change in reactivity (entry 2) in which the reductively coupled product was the major 
C–C-product and the carbinamine (1c) was not observed. Based on the work of Bunnett15 and 
Rossi93 who have shown that radical anions will fragment a bromide faster than the corresponding 
chloride, it is reasonable to think that the observed change in reactivity is due to the nature of the 
reactive intermediates involved. Specifically, we postulated that 2-chloroazoles underwent C–C 
formation via the radical anion while 2-bromoazoles underwent C–C formation via the azolyl 
radical. We next sought to increase the amount of C–C bond forming product to reduction product 
(i.e., 1a+1a’ vs. 1b). Exchanging the ethyl of DIPEA for an isobutyl group (entry 3 vs. 2) resulted 
in a significant increase in the desired product, albeit at the expense of reaction time. Furthermore, 
we observed that the product ratio was not constant throughout the course of the reaction (entry 4 
vs. 5), with relative increases of 1a as the reaction progressed. We suspected that this might be a 
result of acidic species generated under the reaction conditions that could be reducing the amount 
of free amine in solution and possibly accelerating the formation of the desired product via a proton 
coupled electron transfer.94  Thus, we explored some acidic additives  and found that the best 
mixture was NBu3/HCOOH (1:1) (entry 7).  
Table 3.5 Optimization of Reaction Conditions 
 
entry X modifications conva 1a:1a’:1b:1cb time 
1. Cl  100% 0:0:31:69 23 h 
2. Br none 100% 38:10:52:0 22 h 
118 
 
3. Br used (iPr)2NiBu instead 
of DIPEA 
100% 52:13:35:0 2 d 
4. Br used NBu3 instead of 
DIPEA 
24% 17:8:75:0 2 h 
5. Br used NBu3 instead of 
DIPEA 
69% 30:8:62:0 23 h 
6. Br used (iPr)2NiBu w/ 
HCO2H (1:1) 
100% 44:6:50:0 22 h 
7. Br used NBu3 w/ HCO2H 
(1:1) 
100% 51:8:41:0 22 h 
8. Br entry 7, but 1.2 equiv 
alkene 
100% 17:3:80:0 22 h 
9. Br entry 7, but 2.0 equiv 
alkene 
100% 26:6:67:0 22 h 
10. Br entry 7, but 3.0 equiv 
alkene 
100% 39:9:52:0 22 h 
11. Br entry 7, but 5.0 equiv 
alkene 
100% 57:13:32:0 22 h 
12. Br entry 11, at 0.25 M 100% 65:10:25:0 22 h 
13. Br same as entry 12, with 
20% v:v H2O 
100% 60:10:30:0 22 h 
14. Br entry 12, no Ir(ppy)3 0%  22 h 
15. Br entry 12, no light or 
amine 
0%  22 h 
a. Conversion determined by 1H NMR. b. product ratio determined by GCMS. 
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We next explored the concentration of alkene. Consistent with a process in which there is 
a competition for reduction and alkylation of the azolyl radical, increased concentration of alkene 
led to more alkylated products (1a + 1a’ entries 8-11). Further concentrating the reaction also led 
to a slight improvement. In an attempt to check the operational flexibility of the reaction, we added 
water, which resulted in only a slight decrease of the desired products. Finally, control experiments 
(entries 14 and 15) indicated that photocatalyst, light, and amine were all necessary components 
of the reaction. In retrospect, 2-bromothiazole was an ideal substrate for optimization since we 
have empirically observed it to have the greatest tendency to undergo reduction of all the azoles 
that we have studied.  In other words, it provided a highly sensitivity substrate facilitating 
optimization of the reaction conditions. Using 0.3 mol% fac-tris-(2-phenylpyridine) (Ir(ppy)3), a 
1:1 mix of amine and formic acid (3 equiv), and 5 equivalents of alkenes, we began to explore the 
scope of the reaction. 
3.3 Substrate scope 
Initially, we reacted a series of thiazoles with dihydropyran. We obtained a 65% yield 
with a 6:1 regioisomeric ratio (rr) for simple 2-bromothiazole (1a, Scheme 3.5). In most cases, 
substitution of the thiazole increased the selectivity (1a vs. 2a-7a). Products 5a and 6a highlight 
an important feature of electron-addition induced fragmentation events which can be very 
selective and in these cases display perfect chemoselectivity for the 2-bromo over the 4-bromo 
and 5-bromo positions. The reaction works well for benzothiazole (7a).  However, the inclusion 
of a 5-chloro or 5,7-difluoro slightly reduces the regioselectivity (8a, and 9a). In contrast to 
thiazoles, we do not observe competitive reduction of 2-bromobenzimidazoles (10a) and 
consequently, yields are higher. Additionally, under these conditions 2-bromooxazole (11a) does 
not undergo reductive alkylation and highlights the impact that the nature of the heterocycle has 
on the reaction. 
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Next, we evaluated the nature of the alkene that could participate in the reductive 
alkylation. In general, we found the addition to be remarkably sensitive to the substitution pattern 
of the alkene. Specifically, the addition typically occurred at the less substituted carbon to provide 
the alkylated azoles in high regioselectivity. The reaction works for mono-substituted- (13a), 1,1-
disubstuted (16a, 18a, 21a, 22a, 24 and 26a), 1,2-disubstituted (5a-10a, 17a, 19a, 20a, 23a), 
trisubstituted- (12a, 14a, 15a), and bridged-alkenes (17a-23a). A number of functional groups that 
likely would be sensitive to basic organometallics work well in this method, including free 
alcohols (12a, 15a), acetates (16a), esters (23a), and enones (24a). Believing that we were forming 
an azolyl radical, we were pleased to see that weaker bonds, such as benzylic (26a), allylic (25a, 
26a) as well as acetal C–H’s (13a) were well tolerated. Furthermore, we saw no addition to the 


















Additionally, in more complex molecules containing multiple alkenes we observed 
synthetically useful selectivities (24a-26a). Interestingly, comparison of perillyl alcohol 
derivatives (25a, 26a) suggests that the presence of the free hydroxyl group can alter the inherent 
regioselectivity. 
When these reaction conditions were applied to terpenoids containing a vinyl cyclobutane 
motif, we observed clean, reductive ring opening in good yields, high regioselectivity and 
diastereoselectivity. Addition of difluorobenzothiazole to α-pinene provided a 68% yield of an 
enantio- and diastereomerically pure trisubstituted cyclohexene (eqn 6, Scheme 3.6). The reaction 
of caryophyllene oxide afforded a single stereoisomeric product in good yield (eqn 7) with the 
epoxide functional group remaining unchanged.  The selectivity of the ring opening event suggests 
that reductive azolylation of vinyl cyclobutanes may be a general and convenient method for the 
formal allylic substitution with concomitant ring enlargement. 
Scheme 3.6 Ring opening of vinylcyclobutanes 
 
The ability to easily and directly expand the carbon framework of an alkene situated 
within a complex molecule presents an exciting possibility as a late stage functional group handle. 
Thus, we examined the thiazolylation of unprotected cholesterol, which gave a single 
stereoisomeric product (eqn 8, Scheme 3.7). 
Next, we wanted to address a scenario in which the alkene was more precious than the 
azole. Thus, we were forced to look at the underlying problematic reduction that necessitated the 
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use of an excess of 2-bromothiazole. The amine is the stoichiometric reductant and is essential to 
the reaction. We speculated that it could also be facilitating undesired reduction of the bromoazole. 
Scheme 3.7 Thiazolation of cholesterol 
 
3.4 Reduction pathway studies: lowering parasitic HAT  
We speculated that the rate of the undesired reduction reaction might depend upon the 
concentration of the amine and we probed this by keeping the amine concentration artificially low 
via iterative addition of amine. We decided it was best to experiment to approve reaction 
conditions further.  
 
In the experiment, a 5 mm NMR tube capped with NMR septum (Ace glass, part no. 9096-
25) was charged fac-tris(2-phenyl pyridinato-C2, N) Iridium(III) (Ir(ppy)3) (0.4 mL [0.75 mM 
stock solution of catalyst in MeCN]).  2-bromothiazole (15 mg, 0.10 mmol) and cyclooctene (11.5 
mg, 0.50 mmol) as well as tributylamine (9 mg, 0.05 mmol) and formic acid (2 mg, 0.05 mmol) 
were added in the beginning of reaction.  A sealed glass capillary containing C6D6 was placed in 
NMR tube for locking purposes.  Then the reaction tube was degassed via Ar bubbling for 10 min. 
and then the exit needle and Ar line were removed and reaction tube was sealed with parafilm.  
The NMR tube was placed in a light bath (as described above) and the lower portion of the tube 
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was submerged under the water bath which was maintained at 45 oC.  1H NMR was recorded after 
24 h, followed by addition of 0.05 mmol of tributylamine and 0.05 mmol of formic acid.  Then 
the reaction mixture was again degassed and placed in the light bath.  After an additional 24 h, the 
1H NMR was once again recorded.  This incremental addition of tributylamine and formic acid 
was repeated until a total of 0.3 mmol of tributylamine and formic acid were added to the reaction.  
The results have been tabulated, below (Table 3.6). 
Table 3.6 Iterative addition of amine 
Entry Total mmol of 
formic acid 






1 0.05 0.05 0% na na 
2 1 1 0% na na 
3 1.5 1.5 20% 9% 11% 
4 2.0 2.0 36% 17% 19% 
5 2.5 2.5 74% 32% 42% 
6 3.0 3.0 100% 48% 52% 
7 Single addition of 
HCOOH (3.0 mmol) 
Single addition of 
Bu3N (3.0 mmol) 
100% 72% 28% 
By comparison, when a single addition of tributylamine (3.0 equiv) and formic acid (3.0 
equiv) is initially added, all at once, the reaction undergoes 100% conversion, out of which 72% 
is reduction and 28% is alkylated product 34a (entry 7) in 12 h (reaction time) while incremental 
addition leads to a 48% reduction and 52% alkylated product (entry 6).  This experiment suggests 
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that the rate of reduction of the azole has a greater amine concentration dependency than the 
alkylated product and encouraged further exploration of this question. 
Alternatively, we could take advantage of the poor solubility of tertiary amine with long 
alkyl chains (in MeCN), which can provide a convenient method for keeping a low concentration 
over time.  Thus we evaluated the solubility of various amines derivatives, which is given below 
(Figure 3.2). 
Figure 3.2 Experimentally determined solubility of several amines at 23 °C 
(iPr)2Nn-Oct amine was chosen for second round of optimization.  
Based on the previous experiment, we believed that maintaining a low concentration of 
amine in solution could improve product ratio.  Furthermore, we speculated that a lower amine 
concentration might require a more oxidizing photocatalyst to compensate for the decreased 
concentration of amine.  The next set of experiments (Table 3.7) tested several photocatalysts 
while using the less soluble amine. Ir(ppy)3 and (Cat-1) were selected for further optimization, 
which have been summarized and discussed next (Table 3.8).  




Entry Catalyst NMR conversion 





















































Lowering the concentration of free amine did indeed decrease the undesired reduction 
pathway, since the reduction was likely directly dependent on the amine concentration. Iterative 
addition of the amine improved the product ratio (entry 2 vs. 1) and supported our hypothesis. 
 
Table 3.8 Amine Dependent Reduction Pathway Study 
 
entry cat. amine conv 30a:1b 
 
1. Ir(ppy)3 Bu3N 100% 25:75 
2. Ir(ppy)3 Bu3N* 100% 52:48 
3. Ir(ppy)3 (iPr)2Nn-Oct 84% 36:64 
4. Cat. 1 Bu3N 100% 22:78 
5. Cat. 1 (iPr)2Nn-Oct 48% 44:56 
      
*(iterative incremental addition) 
We were pleased to find that the use of the less soluble amine did lead to an improved 
ratio of the desired product (entry 3 vs. 1). We also recognized that decreasing the amine 
concentration might affect the rate of the photocatalytic reaction. We found that several more 
oxidizing photocatalysts resulted in increased alkylated product ratios, with Cat-155 providing the 
fastest reaction among these catalysts.  
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Using 2 sets of conditions, conditions A-tributylamine (3 equiv), HCOOH (3 equiv), fac-
Ir(ppy)3 (0.3 mol%) in 14 h and conditions B-N, N-diisopropyloctan-1-amine (3 equiv), HCOOH 
(3 equiv), cat-1 (0.3 mol%) in 5 days, we investigated the effect of changing the equivalents of 
alkene (Table 3.9). 
 








Reduction Alkylated product 
1 Cond. A 1.2 equiv 100% 82% 18% 
2 Cond. B 1.2 equiv 100% 56% 44% 
3 Cond. A 2.4 equiv 100% 67% 33% 
4 Cond. B 2.4 equiv 100% 32% 68% 
5 Cond. A 5 equiv 100% 39% 61% 
6 Cond. B 5 equiv 100% 20% 80% 
 
Comparison of the two sets of conditions (Conditions A and B) at various alkene 
loadings, showed significant enhancements in the desired product formation by using the less 




Using our modified conditions, we investigated more valuable 2-bromo-4,6-
difluorobenzothiazole as well as several of the poorer yielding substrates from Table 2 (Scheme 
3.8).  In all cases, we observed increases in yield. We expect that these conditions will be ideal in 
cases where the azole is more precious and reaction time is not. 
Scheme 3.8 Reduction minimizing conditions 
 
Finally, we suspected that this type of reactivity should be possible with other reducible 
bromoarenes. In our initial attempt, we subjected electron deficient bromopyrimidnes and 
benzenes to unoptimized conditions (Scheme 3.9). We found that all underwent reductive 
alkylation, allowing isolation of the alkylated pyrimidine (32a) and benzenes (33a, 34a). 
Importantly, these preliminary results suggest that photocatalytic reductive alkylation may be a 
general strategy for Csp2–Csp3 cross-coupling. Furthermore, it warrants development of substrate 
specific conditions, which will likely be unique given the significant electronic differences 








Scheme 3.9 Reductive alkylation as a general strategy 
 
3.5 Mechanistic findings 
In regards to the mechanism fluorescence quenching experiments were conducted (Figure 
3.3A-F). The results suggest that as an individual component 2-bromothiazole provides the fastest 
quenching (Table 3.10).  The nonlinearity of the slope when bromoazole is used is interesting 
(Figure 3.3A).  However, the rate of quenching is significantly reduced when other reaction 
components are included with the bromoazole (Figure 3.3E and F) and make interpretation of 
the quenching event uncertain given the relatively small differences in rates of quenching event 
and leave open the possibility of multiple types of quenching events occurring simultaneously. 
Figure 3.3A Ir(ppy)3 emission quenching by 2-bromothiazole (Q) 
 
Figure 3.3B Ir(ppy)3 emission quenching by dihydropyran (Q) 
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Figure 3.3D Ir(ppy)3 emission quenching by tributylamine and formic acid (1:1) (Q) 











0 10 20 30 40 50
Io/I
Conc. of Q (mM)








0 10 20 30 40 50
Io/I












Figure 3.3F Ir(ppy)3 emission quenching by 2-bromothiazole and tributylamine with formic 
acid (1:3:3) (Q) 









0 10 20 30 40 50
Io/I
Conc. of Q (mM)










0 10 20 30 40 50
Io/I




Table 3.10 Tabulated slopes of potential quenchers 




Tributylamine and formic acid (1:1) 0.0066 
2-Bromothiazole and formic acid (1:3) 0.0024 




During our investigation, we speculated that problematic reduction might depend upon 
amine concentration in the reaction mixture.  To address this problem, we began by considering 
the mechanism (Scheme 3.10).  We posited that upon absorption of a photon in the visible region, 
the Ir(ppy)3 is capable of being quenched either oxidatively by the bromoazole or reductively by 
the amine, followed by electron transfer to the azole.  In either scenario, the ultimate outcome 
being the formation of the radical anion (int-A).  The radical anion is expected to undergo bromide 
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extrusion to give an azoyl radical (int-B) 90 The azoyl radical (int-B) then undergoes addition to 
the alkene with a significant preference for the less substituted terminus to give the more stable 
alkyl radical (int-C).  The alkyl radical ultimately undergoes HAT (hydrogen atom transfer) to 
give the alkylated azole.  It was envisioned that the undesired reduced azole arose from a parasitic 
propagation reaction.  In this scenario, the azoyl radical (int-B) undergoes HAT from the amine 
to give the reduced azole and an α-amino radical (int-D). Based on the work of Scaiano,95 we 
believed that int-D may play an active role in the reaction.  Specifically, we suspected that it may 
be transferring an electron to the bromoazole to give an imminium and another radical anion and 
completing the parasitic pathway.  Several experiments were designed to test this hypothesis. 
 
Scheme 3.10 Possible mechanism 
 
Our postulated mechanism assumed that the H-atom source was the amine and not the 
formate.  However, given that formate has been used as an H-atom source within related 
photocatalytic work,96 we assessed the H-atom source by performing several photocatalytic 
reactions using deuterium labeled reagents.  GC-MS was used to determine the ratio of M+1/M+ 
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for each of reactions below via selected ion monitoring (SIM) mode.  Increases in the M+1 peak 
are due to deuterium incorporation. 
The first experiment evaluated the solvent as the source of H-atoms by changing the 
solvent from CH3CN to CD3CN in the reaction (eqn 1).  Absorption intensity of each of the M+ 
and M+1 of 1a was determined by using SIM mode on GCMS. 





X = H 
Entry Selected ion m/z Abs. int. M+1/M+  
1 M+1 170 410  
2 M+ 169 798 0.339 (H solvent) 
 
X = D 
3 M+1 170 313  
4 M+ 169 589 0.347 (D solvent) 




The second experiment demonstrates effect of changing HCOOH to DCOOD in the 
reaction (eqn 2).  Absorption intensity of each of the M+ and M+1 of 2a is determined as described 
above. 
Table 3.12 Deuterium from acid 
 
 
X = H 
Entry Selected ion m/z Abs. int. M+1/M+  
1 M+1 226 5098  
2 M+ 225 23541 0.1780 (H acid) 
 
X = D 
3 M+1 226 4556  
4 M+ 225 20982 0.1784 (D acid) 
The ratio of D solvent/ H solvent  = 0.2%.  It appears that the role of the formic acid is not as a 
deuterium source, since very little was found to be incorporated.  The formic acid is likely 
functioning as a Bronsted acid. 
The third experiment demonstrates effect of changing HCOOH to DCOOD in the reaction 
(eqn 3).  Absorption intensity of each of the M+ and M+1 of SI-1 is determined as described above. 
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Table 3.13 Deuterium from amine 
 
 
X = H 
Entry Selected ion m/z Abs. int. M+1/M+  
1 M+1 186 7554  
2 M+ 185 48136 0.1356 (H amine) 
 
X = D 
3 M+1 186 14118  
4 M+ 185 61589 0.1864 (D amine) 
The ratio of D solvent/ H solvent  = 37.5%.  It is an interesting observation that under these conditions 
(note, the absence of the bromoazole) significant H-atom scrambling occurs. 
We conclude that the amine is infact serving as the primary reductant while the solvent 
serves to provide a small percentage of the H-atom.  Additionally, in the absence of the substrate 
significant deuterium incorporation is seen in the amine.  
Demonstrating that this is indeed possible, MacMillan and coworkers97 two years later 
exploited this reaction mechanism to incorporate deuterium and tritium into pharmaceutical 
compounds (Scheme 3.11). This method was applied to 18 drug molecules and incorporation of 
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deuterium and tritium were observed. The report supports our proposed mechanism and portrays 
the overall utility of photoredox catalyzed reactions. 
Scheme 3.11 Photoredox-catalyzed deuteration and tritiation of pharmaceutical 
compounds
 
In conclusion, we have shown that photocatalysis has the ability to deliver Csp2–Csp3 
cross-coupled products directly from 2-bromoazoles and unactivated alkenes. The ability to utilize 
alkenes directly as a surrogate for the corresponding alkyl group is a powerful synthetic strategy. 
In addition, the scope of the azole is general for thiazoles, benzothiazoles, and benzimidazoles, 
and in many cases, couples with excellent selectivity for the less substituted terminus of the alkene.  
The optional use of either alkene or azole as the limiting reagent is an attractive feature that should 
further enhance the utility. We have shown that this concept can be extended to other bromoarenes 
to generate both aryl and heteroaryl radicals in a controlled fashion, giving a sufficiently long-
lived radical that it is capable of undergoing intermolecular C–C bond formation. Further 
exploration will expand the scope of the photocatalytic reductive coupling. 
 
 
3.6 Experimental section 
All reagents were obtained from commercial suppliers (Aldrich, VWR, TCI Chemicals, 
and Oakwood Chemicals) and used without further purification unless otherwise noted.  2-
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bromoazoles were purchased from Sigma-Aldrich, except 2-bromobenzo[d]thiazole, 2-bromo-4-
chlorobenzo[d]thiazole, 2-bromo-4,6-difluorobenzo[d]thiazole, 2,5-dibromo-4-methylthiazole, 
ethyl 2-bromothiazole-4-carboxylate, 2,6-dibromo-1H-benzo[d]imidazole and 2-bromo-6-chloro-
1H-benzo[d]imidazole which were synthesized according to literature procedures.98, 2, 3 Alkenes 
A-14, A-25 and A-36 were synthesized according to literature procedure and all other 
corresponding alkenes were purchased from Sigma-Aldrich, Oakwood Chemicals, and VWR.  
N,N-diisopropyloctan-1-amine was synthesized according to a literature procedure.7  
Tributylamine was purchased from VWR and N,N-diisopropylethylamine from Sigma-Aldrich.  
Photocatalyst fac-tris(2-phenyl pyridinato-C2, N)iridium(III) (Ir(ppy)3) and all other 
photocatalysts were synthesized according to the literature procedure.8  Reactions were monitored 
by thin layer chromatography (TLC), (obtained from sorbent technology Silica XHL TLC Plates, 
w/UV254, glass backed, 250 µm, 20 x 20 cm) and were visualized with ultraviolet light, potassium 
permanganate stain, GC-MS (QP 2010S, Shimadzu equipped with auto sampler) and 1H NMR. 
Photocatalytic reactions were set up in a light bath as described below.  Blue LEDs (in the 
form of strips i.e., 18 LEDs/ft from Solid Apollo) were wrapped around the walls of glass 
crystallization dish and secured with masking tape and then wrapped with aluminum foil.  A lid 
which rest on the top was fashioned from cardboard and holes were made such that reaction tubes 
(5mm NMR tube) were held firmly in the cardboard lid which was placed on the top of bath.  
Water was added to the bath such that the tubes were submerged in the water which was 









Isolations were carried out using Teledyne Isco Combiflash Rf 200i flash chromatograph 
with Redisep Rf normal phase silica (4 g, 12 g, 24 g, 40 g) with product detection at 254 and 288 
nm and evaporative light scattering detection.  NMR spectra were obtained on a 400 MHz Bruker 
Avance III spectrometer and 600 MHz Unity Inova spectrometer.  1H and 13C NMR chemical 
shifts are reported in ppm relative to the residual protio solvent peak (1H, 13C).  IR spectra were 
recorded on Varian 800 FT-IR.  Melting points were determined on Stuart Digital (SMP10), 
Melting point-apparatus, 120 VAC.  Mass spectra (HRMS) analysis was performed on LTQ-
OrbitrapXL by Thermo Scientific ltd.  Quenching studies were performed on Varian Carey Eclipse 
fluorescence spectrophotometer.  Optical rotation was measured on an Autopol V polarimeter by 
Rudolph Research Analytical. 
 
General procedure A for synthesis of 2-bromothiazoles and 2-bromobenzothiazoles99 
 
 
The aminoazole (1.0 equiv) and CuBr2 (1.5 equiv) in CH3CN was added to a round bottom flask 
and cooled to 0 0C under argon.  Next, tert-butyl nitrite (1.5 equiv) was added drop wise to the 
reaction flask.  The reaction mixture was stirred at 0 oC for 1 h and then at room temperature for 
another 20 minutes until full consumption of the starting material.  The reaction was monitored 
by TLC.  After consumption of the starting material, the mixture was diluted with H2O (15 mL) 
and acidified with 12 N HCl (until pH<1 by indicator paper) then extracted with CH2Cl2 (3×20 
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mL).  The organic layers were combined and dried with MgSO4.  The crude product was 
concentrated in vacuo and purified via normal phase chromatography. 
S-1 
The general procedure A was followed using benzothiazol-2-amine (3.00 g, 
19.0 mmol), tert-butyl nitrite (3.09 g, 29.0 mmol), CuBr2 (6.36 g, 29.0 mmol) 
and 95.0 mL of MeCN to afford S-1 in 63% yield after isolation (2.60 g, 12.0 mmol) as an orange 
solid.  The substrate was purified via automated flash chromatography using EtOAc in hexanes 
(0% to 100%) with product eluting at 8% on a 40 g silica column.  
S-2 
The general procedure A was followed using 4,6-difluorobenzothiazol-2-amine 
(100 mg, 0.54 mmol), tert-butyl nitrite (83.1 mg, 0.81 mmol), CuBr2 (180 mg, 
0.81 mmol) and 2.6 mL of MeCN to afford S-2 in 65% yield after isolation (87.0 mg, 0.35 mmol) 
as white solid.  The substrate was purified via automated flash chromatography using EtOAc in 
hexanes (0% to 100%) with product eluting at 10% on 4 g silica column. 
S-3 
The general procedure A was followed using 4-chlorobenzothiazol-2-amine 
(500 mg, 2.72 mmol), tert-butyl nitrite (420 mg, 4.08 mmol), CuBr2 (910 mg, 
4.08 mmol) and 13.5 mL of MeCN to afford S-3 in 52% yield after isolation 
(349 mg, 1.41 mmol) as white solid.  The substrate was purified via automated flash 





The general procedure A was followed using 4-methylthiazol-2-amine (500 
mg, 4.38 mmol), tert-butyl nitrite (678 mg, 6.58 mmol), CuBr2 (1.47 g, 6.58 
mmol) and 22.0 mL of MeCN to afford S-4 in 68% yield after isolation (766 mg, 2.98 mmol) as 
colorless oil.  The substrate was purified via automated flash chromatography using EtOAc in 
hexanes (0% to 100%) with product eluting at 8% on a 24 g silica column.  
S-5 
The general procedure A was followed using ethyl 2-aminothiazole-4-
carboxylate (200 mg, 1.16 mmol), CuBr2 (389 mg, 1.74 mmol), isoamyl nitrite 
(204 mg, 1.74 mmol) and 5.8 mL of MeCN to afford S-5 in 70% yield (192 mg, 0.81 mmol) as 
colorless oil.  The substrate was purified via automated flash chromatography using EtOAc in 
hexanes (0% to 100%) with product eluting at 12% on a 24 g silica column.  1H-NMR and GC-
MS matched previous literature.100 
 
General procedure B for synthesis of 2-bromobenzoimidazoles101 
 
(Step 1) To a round bottom flask equipped with a magnetic stir bar containing 1:1 mix of H2O and 
MeOH, cyanogen bromide (1.0 equiv of 5 M solution in MeCN) and benzodiamine (1.0 equiv) 
was added.  The reaction was stirred for 16 h at room temperature and monitored by TLC.  After 
full consumption of the starting material, the reaction mixture was concentrated and extracted with 
EtOAc.  The organic layer was then washed with a saturated NaHCO3 solution.  The organic layer 
was dried with MgSO4, concentrated in vacuo, and purified via normal phase chromatography. 
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(Step 2) The aminoazole (1.0 equiv) and CuBr2 (1.5 equiv) were added to a round bottom flask 
and cooled to 0 oC and the flask was flushed with argon.  Next, tert-butyl nitrite (1.5 equiv) was 
added drop wise to the flask.  After consumption of starting material, as monitored by TLC, the 
mixture was diluted with H2O (20 mL) and acidified with 12 N HCl (until pH<1 by indicator 
paper), then extracted with CH2Cl2 (3×20 mL).  The combined organic layers were dried over 
MgSO4 and concentrated in vacuo and purified via normal phase chromatography.  
S-5 
(Step 1) The general procedure B was followed using 4-bromobenzene-1,2-diamine (2.00 g, 16.9 
mmol), cyanogen bromide (2.2 mL, 5 M in MeCN, 16.9 mmol), H2O (30 
mL) and MeOH (30 mL).  Upon completion, the reaction was worked up 
(general procedure B, step 1) and purified via automated flash chromatography using MeOH in 
CH2Cl2 (0% to 40%) with product eluting at 11% on a 40 g silica column to afford 6-bromo-1H-
benzoimidazol-2-amine in 80% yield (1.82 g, 8.59 mmol).  (Step 2) Using 6-bromo-1H-
benzoimidazol-2-amine (1.82 g, 8.59 mmol), tert-butyl nitrite (1.07 g, 12.9 mmol), CuBr2 (2.87 g, 
12.9 mmol) and 43.0 mL MeCN to afford S-5 in 63% (1.50 g, 5.4 mmol).  The substrate was 
purified via automated flash chromatography using EtOAc in hexanes (0% to 100%) with product 
eluting at 9% on a 40 g silica column. 
S-6 
(Step 1) The general procedure B was followed using 4-chlorobenzene-
1,2-diamine (3.00 g, 21.0 mmol), cyanogen bromide (4.2 mL, 5 M in 
MeCN, 21.0 mmol) H2O (40 mL), and MeOH (40 mL).  Upon completion, the reaction was 
worked up (general procedure B, step 1) and purified via automated flash chromatography using 
MeOH in CH2Cl2 (0% to 40%) with product eluting at 12% on a 40 g silica column to afford 6-
chloro-1H-benzoimidazol-2-amine in 81% yield (2.86 g, 17.1 mmol).  (Step 2) Using 6-chloro-
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1H-benzoimidazol-2-amine (2.86 g, 17.1 mmol), tert-butyl nitrite (2.64 g, 25.6 mmol), CuBr2 
(5.73 g, 25.6 mmol) and MeCN (85.5 mL) to afford S-6 in 38 % (1.51 g, 6.47 mmol).  The substrate 
was purified via automated flash chromatography using EtOAc in hexanes (0% to 100%) with 
product eluting at 10% on a 40 g silica column. 
 
Synthesis of alkenes (A-16, A-23, A-26) 
Procedure C-1 for the synthesis of alkene A-16102 
 
(1R, 2S, 5R)-5-methyl-2-(prop-1-en-2-yl)cyclohexan-1-ol (500 mg, 3.1 mmol) was combined with 
acetic anhydride (373 mg, 3.66 mmol), triethylamine (555 mg, 5.49 mmol), and DMAP (1.86 mg, 
0.015 mmol) in THF (6.1 mL, 0.5 M) at 0 °C.  The reaction mixture was maintained at 0 °C for 1 
h and then was allowed to stir at room temperature overnight.  TLC analysis (30% EtOAc in 
hexanes) revealed full consumption of the starting material.  The solvent was removed by rotary 
evaporation, and the resulting material was diluted with EtOAc and washed with water and brine 
and dried over MgSO4 resulting in a 92% (550 mg, 2.8 mmol) yield as a colorless oil. 
 




(Step 1) Furan (18 mL, 172 mmol) and maleic anhydride (5.10 g, 52.0 mmol) were added to a 
round bottom flask and the reaction mixture was stirred at room temperature.  After 12 h, the slurry 
was filtered and the white solid was recrystallized using acetone, affording 49% yield of the 
cycloaddition adduct (4.2 g, 25.3 mmol).  (Step 2) 40 mL of MeOH and catalytic amount of 12 N 
HCl (86 µL, 1.02 mmol) was added to cycloaddition adduct from the first step (1.71 g, 10.2 mmol).  
After 3 h, the mixture was concentrated and the substrate was purified via automated flash 
chromatography using EtOAc in hexanes (0% to 100%) with product eluting at 50% on a 40 g 
silica column, yielding 50% (1.09 g, 5.14 mmol) as a white solid.  
 
Procedure C-3 for the synthesis of alkene A-26104 
 
(S)-peryllylalchol (800 mg, 5.26 mmol) in THF (10 mL, 0.52 M) was added quickly to a 
vigorously stirring suspension of NaH (163 mg, 6.83 mmol) at 0 °C.  After the reaction was stirred 
for 60 min at rt, the reaction mixture was cooled to 0 °C and Bn-Br (988 mg, 5.78 mmol) was 
added drop-wise via syringe (over 30 minutes) and allowed to warm to rt.  After stirring for 12 h, 
the reaction was quenched with sat. NH4Cl (70 mL) and water (40 mL) and was extracted with 
Et2O (2 x 80 mL).  The combined organic extracts were dried over MgSO4 and concentrated under 
reduced pressure to yield 94% (1200 mg, 4.95 mmol) as a colorless oil. 
 




An oven dried round bottomed flask equipped with a magnetic stir bar and an Ar inlet was charged 
with diisopropylamine (788 mg, 7.8 mmol) and octyl aldehyde (500 mg, 3.9 mmol) in 1,2-
dichloroethane (DCE) (14 mL, 0.28 M), then sodium triacetoxyborohydride (NaBH(OAc)3) (1.2 
g, 5.5 mmol) was added.  The reaction was monitored by GC-MS.  After the complete consumption 
of the aldehyde, the reaction mixture was quenched by adding saturated aqueous NaHCO3 (15 
mL) and extracted with ethyl acetate (3×20 mL).  The combined organic layer was dried over 
MgSO4.  The solvent was evaporated to give the free base, yielding 92% (766 mg, 3.6 mmol) as 
colorless oil. 
Emission Quenching Experiment 
Emission intensities were recorded on Varian Carey Eclipse fluorescence spectrophotometer.  All 
solutions of Ir(ppy)3 in MeCN were excited at 370 nm and the emission intensities were observed 
at 520 nm.  In this experiment, a 0.5 μM solution of Ir(ppy)3 in MeCN was added to the appropriate 
amount of the quencher (Q) in a 1.0 cm quartz cuvette.  After degassing each solution with a 
stream of argon for 15 minutes, the emission spectra were recorded. 
 
 
Photocatalytic reductive coupling 
General procedure E for the photocatalytic reductive alkylation of bromoazoles with alkenes 
(limiting azole) 
A 5 mm NMR tube fitted with a NMR septum was charged with fac-tris(2-phenyl pyridinato-C2, 
N) Iridium(III) (Ir(ppy)3) (0.003 equiv, X mL of 0.75 mM stock solution of catalyst in MeCN, 
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where X mL of MeCN is used to make 0.25 M with respect to the 2-bromoazoles), 2-bromoazoles 
(1 equiv), alkene (5 equiv), tributylamine (3 equiv) and formic acid (3 equiv) and the reaction 
mixture was degassed via Ar bubbling for 10 min and then the exit needle and Ar line were 
removed and reaction tube was sealed with parafilm.  The tube was placed in a light bath 
(description above) and the lower portion of the tube was submerged under the water bath which 
was maintained at 45 oC.  The reaction was monitored by 1H NMR or GC-MS.  After the complete 
consumption of aryl bromide, CH3CN was removed via rotovap and the residue was treated with 
water (2 mL) and extracted with CH2Cl2 (2 x 5 mL).  The organic portions were combined and 
dried over anhydrous MgSO4.  The crude product was concentrated in vacuo and purified via 
normal phase chromatography.  
 
General procedure F for the photocatalytic reductive alkylation of bromoazoles with alkenes 
(limiting alkene)  
This procedure is identical to general procedure E except with following changes, where, 2-
bromoazole (10 equiv), alkene (1 equiv), tributylamine (12 equiv) and formic acid (12 equiv) were 
used in MeCN (0.25 M with respect to 2-bromoazole).  
 
General procedure G for the photocatalytic reductive alkylation of bromoazoles with alkenes 
(Reduction minimizing conditions)  
This procedure is identical to general procedure E except with following changes, where 
Iridium(+1)(4,4´-dimethoxy-2,2´bipyridine)bis[4-tert-butyl-2-(4-tert-butylpyridinal)phenyl](cat-
1) (0.003 equiv, X mL of 0.75 mM stock solution of catalyst in MeCN, where X mL of MeCN is 
used to make 0.25 M with respect to the 2-bromoazoles) and 2-bromoazole (1 equiv), alkene (5 




General procedure H for the photocatalytic reductive alkylation for heteroaromatic bromide with 
alkene  
This procedure is identical to general procedure E except with following changes, where fac-
tris(2-phenyl pyridinato-C2, N) Iridium(III) (Ir(ppy)3) (0.003 equiv, X mL of 0.65 mM stock 
solution of catalyst in MeCN, where X mL of MeCN is used to make 0.25 M with respect to 
heteroaromatic bromide), heteroaromatic bromide (1 equiv), alkene (5 equiv), N-ethyl-N-
isopropylpropan-2-amine (DIPEA) (2 equiv) were used.  The reaction was monitored by NMR or 
GCMS.  After the complete consumption of heteroaromatic bromide, CH3CN was removed via 
rotovap and the residue was treated with saturated aqueous NaHCO3 solution (5 mL) and extracted 
with CH2Cl2 (2 x 5 mL).  The organic portions were combined and dried over anhydrous MgSO4.  
The crude product was concentrated in vacuo and purified via normal phase chromatography.  
1a 2-(tetrahydro-2H-pyran-3-yl)thiazole 
The general procedure E was followed using 2-bromothiazole (15 mg, 0.09 
mmol), 3,4-dihydro-2H-pyran (38 mg, 0.46 mmol), tributylamine (51 mg, 0.27 
mmol), formic acid (13 mg, 0.27 mmol) and 0.36 mL of stock solution of Ir(ppy)3 in MeCN was 
used  to afford 1a in 65% yield (10 mg, 0.059 mmol), rr 6:1 (based on crude 1H NMR) as an oil.  
After the completion of the reaction, 12 h, the substrate was purified via automated flash 
chromatography using EtOAc in hexanes (0% to 100%) with product eluting at 10% on a 12 g 
silica column.  1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 3.3 Hz, 1H), 7.23 (d, J = 3.3 Hz, 1H), 
4.19 (ddd, J = 11.2, 4.1, 1.8 Hz, 1H), 3.96 (dt, J = 12.3, 3.4 Hz, 1H), 3.59 (dd, J = 11.2, 9.8 Hz, 
1H), 3.56–3.46 (m, 1H), 3.38–3.27 (m, 1H), 2.30–2.21 (m, 1H), 1.96–1.83 (m, 1H), 1.83–1.70 (m, 
2H).  13C NMR (101 MHz, CDCl3) δ 171.3, 142.2, 117.8, 72.1, 68.0, 40.6, 30.0, 25.1.  FT-IR 
149 
 
(neat) cm-1 2933, 2848, 1434, 1085. HRMS (ESI) C8H11NOS calcd. [M+H]+ 170.0635 observed 
170.0629. 
2a 4-(tert-butyl)-2-(tetrahydro-2H-pyran-3-yl)thiazole 
The general procedure E was followed using 2-bromo-4-(tert-
butyl)thiazole (25 mg, 0.11 mmol), 3,4-dihydro-2H-pyran (46 mg, 0.55 
mmol), tributylamine (63 mg, 0.34 mmol), formic acid (16 mg, 0.34 mmol) 
and 0.45 mL of stock solution of Ir(ppy)3 in MeCN was used  to afford 2a in 71% yield (18 mg, 
0.079 mmol), rr 9:1 (based on crude 1H NMR) and isolated as rr 10:1 mixture as a yellow oil.  
After the completion of the reaction, 14 h, the substrate was purified via automated flash 
chromatography using EtOAc in hexanes (0% to 100%) with product eluting at 12% on a 4 g silica 
column.  1H NMR (400 MHz, CDCl3) δ 6.74 (s, 1H), 4.17 (ddd, J = 11.1, 4.0, 1.7 Hz, 1H), 3.94 
(dt, J = 11.0, 3.8 Hz, 1H), 3.58–3.43 (m, 2H), 3.35–3.23 (m, 1H), 2.29–2.18 (m, 1H), 1.90–1.66 
(m, 3H), 1.31 (s, 9H).  13C NMR (101 MHz, CDCl3) δ 170.2, 166.2, 109.0, 72.4, 68.2, 41.1, 34.7, 
30.3, 30.0, 25.4.  FT-IR (neat) cm-1 2957, 2866, 1513, 1150.  HRMS (ESI) C12H19NOS calcd. 
[M+H]+ 226.1261 observed 226.1253.  Note - The regioisomer is marked in all 1H NMR and 13C 
NMR spectra as . 
 
3a 4-phenyl-2-(tetrahydro-2H-pyran-3-yl)thiazole 
The general procedure E was followed using 2-bromo-4-
phenylthiazole (25 mg, 0.10 mmol), 3,4-dihydro-2H-pyran (44 mg, 0.52 
mmol), tributylamine (58 mg, 0.31 mmol), formic acid (14 mg, 0.31 
mmol), and 0.40 mL of stock solution of Ir(ppy)3 in MeCN was used  to afford 3a in 43% yield 
(10 mg, 0.043 mmol), rr 9:1 (based on crude 1H NMR) as yellow oil.  After the completion of the 
reaction, 13 h, the substrate was purified via automated flash chromatography using EtOAc in 
hexanes (0% to 100%) with product eluting at 3% on a 12 g silica column.  1H NMR (400 MHz, 
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CDCl3) δ 7.90 (d, J = 1.4 Hz, 1H), 7.88 (t, J = 1.3 Hz, 1H), 7.42 (t, J = 7.5 Hz, 2H), 7.36 (s, 1H), 
7.32 (t, J = 7.4 Hz, 1H), 4.25 (ddd, J = 11.2, 4.1, 1.7 Hz, 1H), 3.97 (dt, J = 11.1, 3.1 Hz, 1H), 3.65 
(dd, J = 11.1, 9.8 Hz, 1H), 3.58–3.50 (m, 1H), 3.43–3.32 (m, 1H), 2.35–2.24 (m, 1H), 2.01–1.88 
(m, 1H), 1.85–1.73 (m, 2H).  13C NMR (101 MHz, CDCl3) δ 171.3, 155.1, 134.6, 128.7, 128.0, 
126.4, 111.8, 72.3, 68.2, 41.1, 30.2, 25.3.  FT-IR (neat) cm-1 2925, 2859, 1492, 1090.  HRMS 
(ESI) C14H15NOS calcd. [M+H]+ 246.0948 observed 246.0935. 
 
4a ethyl 2-(tetrahydro-2H-pyran-3-yl)thiazole-4-carboxylate 
The general procedure E was followed using ethyl 2-bromothiazole-
4-carboxylate (25 mg, 0.11 mmol), 3,4-dihydro-2H-pyran (44 mg, 
0.53 mmol), tributylamine (58 mg, 0.32 mmol), formic acid (14 mg, 
0.32 mmol), and 0.42 mL of stock solution of Ir(ppy)3 in MeCN was used  to afford 4a in 82% 
yield (22 mg, 0.090 mmol), rr 4:1(based on crude 1H NMR) and isolated as mix of rr 5:1 as yellow 
oil.  After the completion of the reaction, 14 h, the substrate was purified via automated flash 
chromatography using EtOAc in hexanes (0% to 100%) with product eluting at 16% on a 12 g 
silica column. Note - Another regioisomer is marked as  in spectra.  1H NMR (400 MHz, CDCl3) 
δ 8.08 (s, 1H), 4.42 (q, J = 7.1 Hz, 2H), 4.16 (ddd, J = 11.5, 4.0, 1.7 Hz, 1H), 3.92 (dt, J = 11.4, 
4.0 Hz, 1H), 3.63 (dd, J = 11.2, 9.0 Hz, 1H), 3.60–3.50 (m, 1H), 3.47–3.35 (m, 1H), 2.24 (m, 1H), 
1.98–1.84 (m, 1H), 1.75 (m, 2H), 1.40 (t, J = 7.1 Hz, 3H).  13C NMR (101 MHz, CDCl3) δ 172.4, 
161.4, 146.9, 126.7, 71.9, 68.2, 61.5, 41.0, 30.0, 24.8, 14.4.  FT-IR (neat) cm-1 2933, 2851, 1735, 





The general procedure E was followed using 2,4-dibromothiazole (25 mg, 
0.10 mmol), 3,4-dihydro-2H-pyran (44 mg, 0.52 mmol), tributylamine (57 
mg, 0.31 mmol), formic acid (14 mg, 0.31 mmol), and 0.40 mL of stock solution of Ir(ppy)3 in 
MeCN was used  to afford 5a in 82% yield (19 mg, 0.082 mmol), rr 10:1 (based on crude 1H NMR) 
as yellow oil.  After the completion of the reaction, 12 h, the substrate was purified via automated 
flash chromatography using EtOAc in hexanes (0% to 100%) with product eluting at 2% on a 4 g 
silica column.  1H NMR (400 MHz, CDCl3) δ 7.12 (s, 1H), 4.14 (ddd, J = 11.2, 4.1, 1.7 Hz, 1H), 
3.92 (dt, J = 11.3, 3.3 Hz, 1H), 3.59 (dd, J = 11.2, 9.4 Hz, 1H), 3.56–3.47 (m, 1H), 3.34–3.25 (m, 
1H), 2.25–2.16 (m, 1H), 1.95–1.81 (m, 1H), 1.80–1.69 (m, 2H).  13C NMR (101 MHz, CDCl3) δ 
172.6, 124.6, 115.9, 71.9, 68.1, 40.9, 29.8, 24.9.  FT-IR (neat) cm-1 2933, 2841, 1470, 1053, 670. 
HRMS (ESI) C8H10BrNOS calcd. [M+Na]+ 269.9559 observed 269.9551. 
 
6a 5-bromo-4-methyl-2-(tetrahydro-2H-pyran-3-yl)thiazole 
The general procedure E was followed using 2,5-dibromo-4-
methylthiazole (25 mg, 0.097 mmol), 3,4-dihydro-2H-pyran (41 mg, 0.49 
mmol), tributylamine (54 mg, 0.29 mmol), formic acid (13 mg, 0.29 mmol), and 0.40 mL of stock 
solution of Ir(ppy)3 in MeCN was used to afford 6a in 75% yield (19 mg, 0.073 mmol, including 
both isomers), rr 10:1 (based on crude 1H NMR) as an oil.  After the completion of the reaction, 
12 h, the substrate was purified via automated flash chromatography using EtOAc in hexanes (0% 
to 100%) with product eluting at 12% on a 12 g silica column.  1H NMR (400 MHz, CDCl3) δ 
4.10 (dd, J = 11.8, 4.2 Hz, 1H), 3.91 (dt, J = 11.6, 3.9 Hz, 1H), 3.62–3.45 (m, 2H), 3.21 (td, J = 
9.0, 4.4 Hz, 1H), 2.36 (s, 3H), 2.24–2.12 (m, 1H), 1.90–1.79 (m, 1H), 1.78–1.68 (m, 2H).  13C 
NMR (101 MHz, CDCl3) δ 170.6, 151.0, 103.0, 71.9, 68.2, 41.3, 29.7, 25.0, 15.6.  FT-IR (neat) 






The general procedure E was followed using 2-benzobromothiazole (25 
mg, 0.12 mmol), 3,4-dihydro-2H-pyran (49 mg, 0.58 mmol), tributylamine 
(65 mg, 0.35 mmol), formic acid (16 mg, 0.39 mmol), 0.48 mL of stock solution of Ir(ppy)3 in 
MeCN was used  to afford 7a in 78% yield (20 mg, 0.093 mmol), rr 7:1 (based on crude 1H NMR) 
as yellow oil.  After the completion of the reaction, 12 h, the substrate was purified via automated 
flash chromatography using EtOAc in hexanes (0% to 100%) with product eluting at 11% on a 12 
g silica column.  1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 7.9 Hz, 1H), 
7.46 (t. J = 8.1 Hz, 1H), 7.36 (t, J = 8.2 Hz, 1H), 4.30–4.22 (m, 1H), 4.02–3.94 (m, 1H), 3.72 (dd, 
J = 11.2, 9.7 Hz, 1H), 3.60–3.51 (m, 1H), 3.45–3.36 (m, 1H), 2.34-2.31 (m, 1H), 2.06–1.92 (m, 
1H), 1.80 (m, 2H).  13C NMR (101 MHz, CDCl3) δ 172.1, 153.1, 134.5, 126.0, 124.9, 122.7, 121.6, 
71.8, 68.2, 41.7, 30.0, 25.2.  FT-IR (neat) cm-1 2939, 2839, 1513, 1095.  HRMS (ESI) C12H13NOS 
calcd. [M+H]+ 220.0791 observed 220.0787. 
 
8a 4-chloro-2-(tetrahydro-2H-pyran-3-yl)benzo[d]thiazole 
The general procedure E was followed using 2-bromo-4-
chlorobenzo[d]thiazole (25 mg, 0.10 mmol), 3,4-dihydro-2H-pyran (42 
mg, 0.51 mmol), tributylamine (56 mg, 0.30 mmol), formic acid (14 mg, 
0.30 mmol), and 0.40 mL of stock solution of Ir(ppy)3 of MeCN was used  to afford 8a in 60% 
yield (15 mg, 0.060 mmol), rr 3:1 (based on crude 1H NMR) as an oil.  After the completion of 
the reaction, 24 h, the substrate was purified via automated flash chromatography using EtOAc in 
hexanes (0% to 100%) with product eluting at 13% on a 12 g silica column.  1H NMR (400 MHz, 
CDCl3) δ 7.76 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 4.25 (ddd, J 
= 11.5, 4.2, 1.8 Hz, 1H), 3.96 (dt, J = 11.1, 3.9 Hz, 1H), 3.72 (dd, J = 11.3, 9.3 Hz, 1H), 3.66–3.53 
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(m, 1H), 3.57–3.44 (m, 1H), 2.38–2.26 (m, 1H), 2.08–1.91 (m, 1H), 1.86–1.72 (m, 2H).  13C NMR 
(101 MHz, CDCl3) δ 173.4, 150.0, 136.1, 127.6, 126.3, 125.4, 120.1, 71.8, 68.2, 41.8, 30.0, 25.0. 
FT-IR (neat) cm-1 2941, 2842, 1524, 1117, 827.  HRMS (ESI) C12H12ClNOS calcd. [M+H]+ 
254.0401 observed 254.0394. 
 
9a 4,6-difluoro-2-(tetrahydro-2H-pyran-3-yl)benzo[d]thiazole 
The general procedure E was followed using 2-bromo-4,6-
difluorobenzo[d]thiazole (25 mg, 0.10 mmol), 3,4-dihydro-2H-pyran 
(42 mg, 0.50 mmol), tributylamine (55 mg, 0.30 mmol), formic acid (14 
mg, 0.30 mmol), and 0.40 mL of stock solution of Ir(ppy)3 of MeCN was used to afford 9a in 78% 
yield (20 mg, 0.078 mmol), rr 5:1 (based on crude 1H NMR) as an oil.  After the completion of 
the reaction, 18 h, the substrate was purified via automated flash chromatography using EtOAc in 
hexanes (0% to 100%) with product eluting at 11% on a 12 g silica column.  1H NMR (400 MHz, 
CDCl3) δ 7.35 (d, J = 7.5 Hz, 1H), 6.98 (t, J = 10.7 Hz, 1H), 4.23 (ddd, J = 11.7, 4.0, 1.8 Hz, 1H), 
3.96 (dt, J = 11.5, 4.0 Hz, 1H), 3.77–3.70 (m, 1H), 3.63–3.53 (m, 1H), 3.48–3.37 (m, 1H), 2.35–
2.24 (m, 1H), 2.06–1.94 (m, 1H), 1.84–1.73 (m, 2H).  13C NMR (101 MHz, CDCl3) δ 172.8, 160.4 
(dd, J = 247.3, 10.4 Hz), 155.4 (dd, J = 259.0, 13.4 Hz), 139.2 (dd, J = 13.3, 2.6 Hz), 137.9 (dd, J 
= 12.7, 5.0 Hz), 104.1 (dd, J = 26.4, 4.7 Hz), 102.5 (dd, J = 28.3, 21.9 Hz). 72.0, 68.7, 42.1, 30.3, 
25.4.  19F NMR (376 MHz, CDCl3 ) δ -113.0 (td, J = 8.4, 5.5 Hz), -117.7–118.2 (m).  FT-IR (neat) 






The general procedure E was followed using 2-bromo-1H-
benzo[d]imidazole (25 mg, 0.13 mmol), 3,4-dihydro-2H-pyran (53 mg, 
0.63 mmol), tributylamine (70 mg, 0.38 mmol), formic acid (17 mg, 0.38 
mmol), and 0.50 mL of stock solution of Ir(ppy)3 of MeCN was used  to afford 10a in 86% yield 
(22 mg, 0.108 mmol), rr 4:1 (based on crude 1H NMR) as white solid. m.pt 235-238 oC.  After the 
completion of the reaction, 24 h, the substrate was purified via automated flash chromatography 
using EtOAc in hexanes (column was buffered with 1% Et3N in hexane before running) (0% to 
100%) with product eluting at 11% on a 24 g silica column.  1H NMR (400 MHz, Methanol-d4) δ 
7.53–7.46 (m, 2H), 7.18 (dt, J = 6.1, 3.7 Hz, 2H), 4.12 (ddd, J = 11.6, 4.2, 1.8 Hz, 1H), 3.93 (dt, J 
= 11.3, 3.8 Hz, 1H), 3.69 (t, J = 10.6 Hz, 1H), 3.54 (dt, J = 11.4, 6.8 Hz, 1H), 3.34–3.27 (m, 1H), 
3.17 (tt, J = 10.3, 4.1 Hz, 1H), 2.25–2.16 (m, 1H), 2.05–1.92 (m, 1H), 1.75 (dp, J = 7.7, 4.0 Hz, 
2H).  13C NMR (101 MHz, CD3OD) δ 155.2, 122.0, 78.2, 77.9, 77.5, 76.8, 70.5, 67.8, 37.0, 28.0, 
25.0.  FT-IR (neat) cm-1 2931, 2858, 1454, 1109.  HRMS (ESI) calcd. C12H14N2O [M+H]+ 
203.1179 observed 203.1173  
 
12a 3-methyl-2-(thiazol-2-yl)butan-1-ol 
The general procedure E was followed using 2-bromothiazole (50 mg, 0.30 
mmol) (E)-3-methylbut-1-en-1-ol (129 mg, 1.50 mmol), tributylamine (167 mg, 
0.90 mmol), formic acid (41 mg, 0.90 mmol), and 1.2 mL of stock solution of 
Ir(ppy)3 of MeCN was used  to afford 12a in 43% yield (22 mg, 0.13 mmol) rr >20:1 (based on 
crude 1H NMR) as yellow oil.  After the completion of the reaction, 12 h, the substrate was purified 
via automated flash chromatography using EtOAc in hexanes (column was buffered 1% Et3N in 
hexanes before running) (0% to 100%) with product eluting at 26% on a 12 g silica column.  1H 
NMR (400 MHz, CDCl3) δ 7.73 (d, J = 3.3 Hz, 1H), 7.23 (d, J = 3.4 Hz, 1H), 4.05 (dt, J = 11.1, 
6.7 Hz, 1H), 3.92 (ddd, J = 11.2, 5.5, 3.4 Hz, 1H), 3.26–3.16 (m, 1H), 2.96 (td, J = 7.0, 3.4 Hz, 
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1H), 2.23 (h, J = 6.9 Hz, 1H), 1.04 (d, J = 6.8 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H).  13C NMR (101 
MHz, CDCl3) δ 172.8, 142.1, 117.9, 63.2, 52.0, 30.4, 20.9, 20.2.  FT-IR (neat) cm-1 3342, 2962, 
2872, 1512 HRMS (ESI) C8H13NOS calcd. [M+H]+ 172.0791 observed 172.0788. 
 
13a 2-(5-((tetrahydro-2H-pyran-2-yl)oxy)pentyl)thiazole 
The general procedure E was followed using 2-bromothiazole (25 mg, 0.15 
mmol), 2-(pent-4-en-1-yloxy)tetrahydro-2H-pyran (130 mg, 0.76 mmol), 
tributylamine (85 mg, 0.46 mmol), formic acid (21 mg, 0.46 mmol), and 0.60 mL 
of stock solution of Ir(ppy)3 in MeCN was used  to afford 13a in 70% yield (27 mg, 
0.11 mmol) rr>20:1 (based on crude 1H NMR) as yellow oil.  After the completion 
of the reaction, 12 h, the substrate was purified via automated flash chromatography 
using EtOAc in hexanes (column was buffered with 1% Et3N in hexane before running) (0% to 
100%) with product eluting at 4% on a 12 g silica column.  1H NMR (400 MHz, CDCl3) δ 7.67 
(d, J = 3.3 Hz, 1H), 7.18 (d, J = 3.3 Hz, 1H), 4.56 (dd, J = 4.6, 2.6 Hz, 1H), 3.85 (ddd, J = 11.0, 
7.5, 3.4 Hz, 1H), 3.74 (dt, J = 9.6, 6.7 Hz, 1H), 3.54–3.44 (m, 1H), 3.39 (dt, J = 9.6, 6.5 Hz, 1H), 
3.04 (t, J = 7.8 Hz, 2H), 1.90–1.77 (m, 3H), 1.72–1.61 (m, 3H), 1.59–1.46 (m, 6H).   13C NMR 
(101 MHz, CDCl3) δ 171.4, 142.0, 118.0, 98.9, 67.3, 62.4, 33.2, 30.8, 29.9, 29.4, 25.8, 25.5, 19.7.  
FT-IR (neat) cm-1 2938, 2865, 1507, 1032.  HRMS (ESI) C13H21NO2S calcd. [M+Na]+ 278.1185 
observed 278.1183.  
 
14a 2-(2-phenylcyclohexyl)thiazole 
The general procedure E was followed using 2-bromothiazole (25 mg, 0.15 
mmol), 2,3,4,5-tetrahydro-1,1'-biphenyl (120 mg, 0.76 mmol), tributylamine 
(85 mg, 0.46 mmol), formic acid (21 mg, 0.46 mmol) and 0.60 mL of stock 
solution of Ir(ppy)3 in MeCN solution was used  to afford 14a in 74% yield (27 mg, 0.11 mmol), 
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rr>20:1 (based on crude 1H NMR), dr>20:1 (based on crude 1H NMR) as colorless oil.  After the 
completion of the reaction, 14 h, the substrate was purified via automated flash chromatography 
using EtOAc in hexanes (0% to 100%) with product eluting at 0.5% on a 12 g silica column.  1H 
NMR (400 MHz, CDCl3) δ 7.77 (t, J = 3.6 Hz, 1H), 7.40 (d, J = 3.5 Hz, 1H), 7.31 (d, J = 6.7 Hz, 
1H), 7.28–7.21 (m, 1H), 7.19–7.12 (m, 3H), 3.97–3.86 (m, 1H), 3.31 (dt, J = 11.5, 4.1 Hz, 1H), 
2.49–2.37 (m, 1H), 2.35–2.27 (m, 1H), 2.25–2.07 (m, 3H), 2.04–1.94 (m, 1H), 1.85–1.76 (m, 1H), 
1.74–1.62 (m, 1H).  13C NMR (101 MHz, CDCl3) δ 171.7, 144.1, 141.5, 128.0, 127.8, 126.0, 
117.6, 46.4, 45.3, 31.3, 26.7, 25.9, 21.8.  FT-IR (neat) cm-1 2925, 2859, 1681, 1444.  HRMS (ESI) 
C15H17NS calcd. [M+H]+ 244.1154 observed 244.1151. 
 
15a 2-(tetrahydro-2H-pyran-3-yl)benzo[d]thiazole 
The general procedure E was followed using 2-benzobromothiazole 
(25 mg, 0.12 mmol), 2-(4-methylcyclohex-3-en-1-yl)propan-2-ol (90 
mg, 0.58 mmol), tributylamine (65 mg, 0.35 mmol), formic acid (16 
mg, 0.35 mmol) and 0.50 mL of stock solution of Ir(ppy)3 in MeCN was used  to afford 15a in 
73% yield (25 mg, 0.087 mmol, including both diastereomers), rr >20:1 (based on crude 1H NMR), 
dr 1.3:1 (based on crude 1H NMR) and isolated as dr 1.7:1 as pale oil.  After the completion of the 
reaction, 12 h, the substrate was purified via automated flash chromatography using EtOAc in 
hexanes (0% to 100%) with product eluting at 10% (diastereomer a) and 11% (diastereomer b) on 
a 24 g silica column.  Diastereomer a- 1H NMR (400 MHz, CDCl3), δ 8.00 (d, J = 8.1 Hz, 1H), 
7.84 (d, J = 7.8 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 3.66 (dq, J = 4.6, 2.3 
Hz, 1H), 2.14 (dq, J = 13.3, 2.7 Hz, 1H), 2.06–1.95 (m, 2H), 1.89 (ddt, J = 10.6, 6.4, 3.7 Hz, 2H), 
1.64 (td, J = 13.0, 5.2 Hz, 3H), 1.43 (d, J = 2.4 Hz, 1H), 1.17 (s, 3H), 1.15 (s, 3H), 0.92 (d, J = 6.2 
Hz, 3H).   13C NMR (101 MHz, CDCl3) δ 172.7, 152.9, 134.9, 125.7, 124.6, 122.8, 121.2, 72.7, 
45.6, 42.9, 35.2, 32.6, 29.9, 27.2, 27.2, 27.0, 19.9.  Diastereomer b - 1H NMR (400 MHz, CDCl3,) 
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δ 7.98 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.44 (t, 1H), 7.34 (t, J = 8.1 Hz, 1H), 2.80 (td, 
J = 11.2, 3.4 Hz, 1H), 2.39–2.11 (m, 2H), 1.95 (ddt, J = 17.6, 11.8, 2.7 Hz, 2H), 1.88–1.73 (m, 
2H), 1.53–1.43 (m, 3H), 1.19 (s, 6H), 0.87 (d, J = 6.4 Hz, 3H).  13C NMR (101 MHz, CDCl3) δ 
176.6, 153.0, 134.6, 125.8, 124.6, 122.6, 121.6, 72.6, 51.0, 48.8, 38.0, 35.8, 35.2, 27.2, 27.1, 26.9, 
20.3.  FT-IR (neat) cm-1 3546, 2959, 2857, 1504.  HRMS (ESI) C17H23NOS calcd. [M+H]+ 
290.1573 observed 290.1569.  Note - The diastereomer is marked in all 1H NMR and 13C NMR 
spectra.as .  The stereochemical assignment is based on detailed analysis of coupling constants. 
 
16a (1R,2S,5R)-2-(1-(benzo[d]thiazol-2-yl)propan-2-yl)-5-methylcyclohexyl acetate 
The general procedure E was followed using 2-benzobromothiazole (25 
mg, 0.12 mmol), (1R,2S,5R)-5-methyl-2-(prop-1-en-2-yl)cyclohexyl 
acetate (110 mg, 0.58 mmol), tributylamine (65 mg, 0.35 mmol), formic 
acid (16 mg, 0.35 mmol), and 0.45 mL of stock solution of Ir(ppy)3 in 
MeCN was used  to afford 16a in 70% yield (28 mg, 0.084 mmol), rr 
>20:1 (based on crude 1H NMR), dr 1.25:1 (based on crude 1H NMR) and isolated as dr 3:1 
mixture as yellow oil.  After the completion of the reaction, 22 h, the substrate was purified via 
automated flash chromatography using EtOAc in hexanes (0% to 100%) with product eluting at 
12% on a 40 g silica column.  1H NMR [mix of diastereomers] (400 MHz, CDCl3) δ 7.95 (d, J = 
8.3 Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.44 (t, J = 7.7 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 4.83 (td, J 
= 10.9, 4.1 Hz, 1H), 3.20 (dd, J = 14.2, 3.7 Hz, 1H), 2.82 (dd, J = 14.0, 10.9 Hz, 1H), 2.44–2.21 
(m, 2H), 2.14 (s, 3H), 1.77 (dd, J = 32.2, 14.6 Hz, 3H), 1.67–1.47 (m, 4H), 0.98 (d, J = 6.9 Hz, 
3H), 0.92 (d, J = 6.6 Hz, 3H).   13C NMR (101 MHz, CDCl3) δ 171.9, 170.5, 153.0, 135.2, 125.6, 
124.4, 122.4, 121.3, 73.4, 46.7, 40.7, 37.2, 34.5, 34.1, 31.2, 26.7, 25.5, 21.7, 16.9.  FT-IR (neat) 
cm-1 2922, 2841,1732, 1520.  HRMS (ESI) calcd. C19H25NO2S [M+H]+ 332.1679 observed 





The general procedure E was followed using 2-bromo-4-(tert-
butyl)thiazole (25 mg, 0.11 mmol), norbornene (53 mg, 0.57 mmol), 
tributylamine (63 mg, 0.34 mmol), formic acid (16 mg, 0.34 mmol), and 
0.45 mL of stock solution of Ir(ppy)3 in MeCN was used  to afford 17a in 68% yield (18 mg, 0.075 
mmol), rr>20:1 (based on crude 1H NMR), dr>20:1 (based on crude 1H NMR) as colorless oil.  
After the completion of the reaction, 15 h, the substrate was purified via automated flash 
chromatography using EtOAc in hexanes (0% to 100%) with product eluting at 2% on a 24 g silica 
column.  1H NMR (400 MHz,CDCl3) δ 6.69 (s, 1H), 3.08 (dd, J = 8.6, 5.3 Hz, 1H), 2.46 (s, 1H), 
2.36 (s, 1H), 2.01–1.90 (m, 1H), 1.86–1.74 (m, 1H), 1.69–1.50 (m, 5H), 1.40 (tt, J = 9.1, 2.8 Hz, 
1H), 1.32 (s, 9H).  13C NMR (101 MHz, CDCl3) δ 174.0, 164.1, 106.6, 44.5, 42.5, 37.1, 34.6, 34.2, 
32.8, 28.1, 27.8, 26.9.  FT-IR (neat) cm-1 2928, 2851.  HRMS (ESI) C14H21NS calcd. [M+H]+ 
236.1467 observed 236.1460.  Stereochemistry is assigned analogy to literature.9 
 
18a 2-(((1S,4R)-3,3-dimethylbicyclo[2.2.1]heptan-2-yl)methyl)thiazole 
The general procedure F was followed using 2-bromothiazole (288 mg, 1.8 
mmol) camphene (24 mg , 0.18 mmol), tributylamine (400 mg, 2.2 mmol), 
formic acid (101 mg, 2.2 mmol), and 0.72 mL of stock solution of Ir(ppy)3 in MeCN was used  to 
afford 18a in 85% yield (34 mg, 0.15 mmol), rr>20:1 (based on crude 1H NMR), 4:1 
[(reduced:oxidized), based on crude 1H NMR], dr 5:1 (based on crude 1H NMR) and isolated as 
mixture of diastereomers with dr 7:1 and 7:1 (reduced : oxidized) mixture, as a pale oil.  After the 
completion of the reaction, 20 h, the substrate was purified via automated flash chromatography 
using EtOAc in hexanes (0% to 100%) with product eluting at 8% on a 24 g silica column.  1H 
NMR [mix of diastereomers and oxidized product] (400 MHz,CDCl3) δ 7.65 (d, J = 3.3 Hz, 1H), 
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7.16 (d, J = 3.3 Hz, 1H), 3.08–2.92 (m, 2H), 2.07 (s, 1H), 2.01–1.91 (m, 1H), 1.78 (s, 1H), 1.63 (t, 
J = 9.8 Hz, 1H), 1.54–1.44 (m, 1H), 1.33–1.26 (m, 2H), 1.15 (dd, J = 13.2, 7.0 Hz, 2H), 1.00 (s, 
3H), 0.88 (s, 3H).  13C NMR (101 MHz, CDCl3) δ 171.6, 142.0, 117.8, 51.1, 49.2, 41.2, 37.4, 36.9, 
32.2, 30.8, 24.6, 21.6, 20.3.  FT-IR (neat) cm-1 2904, 2872, 1460.  HRMS (ESI) C13H19NS calcd. 
[M+H]+ 222.1311 observed 222.1318.  Diastereoselectivity is based on detailed analysis of 
coupling constants.  Note – The diastereomer and oxidized product is marked in the 1H NMR and 
13C NMR spectra as  and .  
 
19a 2-(bicyclo[2.2.1]heptan-2-ylmethyl)-1H-benzo[d]imidazole 
The general procedure E was followed using 2-bromo-1H-
benzo[d]imidazole (25 mg, 0.13 mmol), norbornene (60 mg, 0.63 mmol), 
tributylamine (70 mg, 0.38 mmol), formic acid (17.3 mg, 0.38 mmol), and 0.50 mL of stock 
solution of Ir(ppy)3 in MeCN was used  to afford 19a in 90% yield (25 mg, 0.12 mmol), rr>20:1 
(based on crude 1H NMR), dr>20:1 (based on crude 1H NMR) as white solid, m.pt 242–245 oC.  
After the completion of the reaction, 24 h, the substrate was purified via automated flash 
chromatography using EtOAc in hexanes (column was buffered with 1% Et3N in hexane before 
running) (0% to 100%) with product eluting at 12% on a 24 g silica column.  1H NMR (400 MHz, 
CDCl3) δ 7.56 (dd, J = 5.2, 3.0 Hz, 2H), 7.21 (dd, J = 5.8, 3.0 Hz, 2H), 2.99 (dd, J = 8.7, 5.2 Hz, 
1H), 2.65–2.59 (m, 1H), 2.41 (s, 1H), 2.24–2.13 (s, 1H), 1.79 (ddd, J = 12.3, 9.2, 2.5 Hz, 1H), 
1.69–1.54 (m, 3H), 1.42–1.27 (m, 3H).  13C NMR (101 MHz, CDCl3) δ 158.7, 137.9, 122.3, 114.6, 
42.7, 41.9, 36.6, 36.3, 36.2, 29.7, 28.7.  FT-IR (neat) cm-1 2931, 2830, HRMS(ESI) calcd. 





The general procedure E was followed using 2-bromo-6-chloro-1H-
benzo[d]imidazole (25 mg, 0.11 mmol), norbornene (51 mg, 0.54 
mmol), tributylamine (60 mg, 0.32 mmol), formic acid (15 mg, 0.32 mmol), and 0.45 mL of stock 
solution of Ir(ppy)3 in MeCN was used  to afford 20a in 79% yield (21 mg, 0.087 mmol), dr >20:1 
(based on crude 1H NMR) as white solid. m.pt. 223 - 225 oC.  After the completion of the reaction, 
24 h, thesubstrate was purified via automated flash chromatography using EtOAc in hexanes 
(column was buffered with 1% Et3N in hexane before running) (0% to 100%) with product eluting 
at 12% on a 24 g silica column.  1H NMR (400 MHz, CD3OD) δ 7.44 (s, 1H), 7.40 (d, J = 11.0 
Hz, 1H), 7.12 (dd, J = 8.6, 2.0 Hz, 1H), 3.29 (p, J = 1.7 Hz, 1H), 2.94 (ddd, J = 8.8, 5.8, 2.9 Hz, 
1H), 2.52 (dd, J = 4.0, 1.7 Hz, 1H), 2.37 (d, J = 4.2 Hz, 1H), 2.09–2.00 (m, 1H), 1.75 (ddd, J = 
12.1, 9.1, 2.4 Hz, 1H), 1.69–1.60 (m, 1H), 1.60–1.54 (m, 1H), 1.46–1.38 (m, 1H), 1.34–1.21 (m, 
2H).  13C NMR (101 MHz, CD3OD) δ 162.0, 128.5, 123.4, 79.6, 79.6, 79.3, 78.9, 43.9, 43.1, 37.6, 
37.2, 36.9, 30.7, 29.7.  FT-IR (neat) cm-1 2931, 2858, 780.  HRMS (ESI) calcd. C14H15ClN2 
[M+H]+ 247.0997 observed 247.0994.  Stereochemistry is assigned based on 17a. 
 
21a 2-((3,3-dimethylbicyclo[2.2.1]heptan-2-yl)methyl)-1H-benzo[d]imidazole 
The general procedure E was followed using 2-bromo-1H-
benzo[d]imidazole (25 mg, 0.13 mmol), (+)-camphene (86 mg, 0.63 
mmol), tributylamine (70 mg, 0.38 mmol), formic acid (17.3 mg, 0.38 
mmol), and 0.52 mL of stock solution of Ir(ppy)3 in MeCN was used  to afford 21a in 93% yield 
(31 mg, 0.12 mmol), rr >20:1 (based on crude 1H NMR), dr>20:1 (based on crude 1H NMR) as 
white solid, m.pt 197–200 oC.  After the completion of the reaction, 24 h, the substrate was purified 
via automated flash chromatography using EtOAc in hexanes (column was buffered with 1% Et3N 
in hexane before running) (0% to 100%) with product eluting at 17% on a 24 g silica column.  1H 
NMR (400 MHz, Methanol-d4) δ 7.47 (dd, J=5.9, 3.2 Hz, 1H), 7.16 (dd, J=6.0, 3.2 Hz, 1H), 3.30 
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(dt, J=3.0, 1.5 Hz, 0H), 2.94–2.77 (m, 1H), 2.09 (ddd, J = 10.2, 6.5, 3.6 Hz, 1H), 1.78 (s, 0H), 
1.75–1.56 (m, 2H), 1.36–1.24 (m, 2H), 1.18 (d, J=9.6 Hz, 1H), 1.01 (s, 1H), 0.91 (s, 1H).  13C 
NMR (101 MHz, CD3OD) δ 155.5, 138.0, 121.7, 113.8, 49.5, 49.1, 41.4, 36.8, 36.4, 31.1, 25.8, 
24.2, 20.6, 19.7.  FT-IR (neat) cm-1 3086, 2964, 1635, 1591.  HRMS (ESI) calcd. C17H22N2 [M+H]+ 




The general procedure E was followed using 2,6-dibromo-1H-benzo[d]imidazole (25 mg, 0.10 
mmol), (+)-camphene (61 mg, 0.45 mmol), tributylamine (50 mg, 
0.27 mmol), formic acid (13 mg, 0.27  mmol), and 0.36 mL of stock 
solution of Ir(ppy)3 in MeCN was used  to afford 22a in 87% yield 
(29 mg, 0.087 mmol), rr>20:1 (based on crude 1H NMR), dr>20:1 (based on crude 1H NMR) as 
white solid. m.pt 200–203 oC.  After the completion of the reaction, 12 h, the substrate was purified 
via automated flash chromatography using EtOAc in hexanes (column was buffered with 1% Et3N 
in hexanes before running) (0% to 100%) with product eluting at 12% on a 4 g silica column.  1H 
NMR (400 MHz, CDCl3) δ 7.67 (d, J = 1.8 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.31 (dd, J = 8.5, 
1.9 Hz, 1H), 2.90 (dd, J = 7.8, 4.9 Hz, 2H), 2.05 (dt, J = 10.6, 3.0 Hz, 2H), 1.74 (s, 1H), 1.52 (t, J 
= 9.6 Hz, 2H), 1.42 (t, J = 8.2 Hz, 1H), 1.29–1.19 (m, 2H), 1.13 (d, J = 9.7 Hz, 1H), 0.82 (s, 6H).  
13C NMR (101 MHz, CDCl3) δ 156.7, 140.1, 137.4, 125.2, 117.6, 115.8, 115.1, 49.7, 48.8, 41.3, 
37.2, 36.9, 31.9, 26.7, 24.6, 21.6, 20.2.  FT-IR (neat) cm-1 3021, 2954, 1625, 1596, 650.  HRMS 
(ESI) calcd. C17H21BrN2 [M+H]+  333.0962 observed 333.0961.  Diastereoselectivity is based on 




23a dimethyl 5-(4-chlorobenzo[d]thiazol-2-yl)-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylate 
The general procedure E was followed using 2-bromo-4-
chlorobenzo[d]thiazole (25 mg, 0.10 mmol), dimethyl 7-
oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate (106 mg, 0.51 
mmol), tributylamine (56 mg, 0.30 mmol), formic acid (14 mg, 
0.30 mmol), and 0.40 mL of stock solution of Ir(ppy)3 in MeCN was used to afford 23a in 53% 
yield (19 mg, 0.053 mmol), rr >20:1 (based on crude 1H NMR), dr>20:1 (based on crude 1H NMR) 
as an oil.  After the completion of the reaction, 14 h, the substrate was purified via automated flash 
chromatography using EtOAc in hexanes (0% to 100%) with product eluting at 17% on a 12 g 
silica column.  1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 7.7 Hz, 1H), 
7.30 (t, J = 8.0 Hz, 1H), 5.12 (d, J = 5.4 Hz, 1H), 5.10 (s, 1H), 3.77 (dd, J = 8.8, 4.5 Hz, 1H), 3.70 
(d, J = 8.7 Hz, 6H), 3.18 (q, J = 9.6 Hz, 2H), 2.29 (dd, J = 13.2, 8.8 Hz, 1H), 2.17 (dq, J = 15.0, 
5.0 Hz, 1H).  13C NMR (101 MHz, CDCl3) δ 175.4, 170.9, 170.6, 149.2, 136.9, 127.5, 126.4, 
125.6, 120.3, 83.3, 78.5, 52.4, 52.3, 51.8, 51.3, 47.8, 39.5.  FT-IR (neat) cm-1 2946, 1742, 1200, 
1163.  HRMS (ESI) calcd. C17H16ClNO5S [M+H]+ 382.0510 observed 382.0506.  Stereochemistry 
is assigned based on 19a. 
 




The general procedure E was followed using 2-bromothiazole 
(25 mg, 0.15 mmol), 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-
1-one (110 mg, 0.76 mmol), tributylamine (85 mg, 0.46 mmol), 
formic acid (21 mg, 0.46 mmol), and 0.65 mL of stock solution of 
Ir(ppy)3 in MeCN was used to afford 24a in 78% yield [28 mg ( 
20 mg (major also contains small amount of minor) and 8 mg 
(minor, mix of diastereomers), 0.12 mmol], rr 2:1 (major : minor) (based on crude 1H NMR), dr 
(major) 1.2:1 (based on crude 1H NMR).  After the completion of the reaction, 19 h, the substrate 
was purified via automated flash chromatography using EtOAc in hexanes (0% to 100%) with 
minor product eluting at 12% and major product eluting at 17% on a 24 g silica column.  Major 
isomer-1H NMR, [mix. of diastereomers and minor isomer] (400 MHz, CDCl3) δ 7.67 (t, J = 3.0 
Hz, 1H), 7.19 (t, J = 3.1 Hz, 1H), 6.73 (dq, J = 5.8, 1.7 Hz, 1H), 3.10 (ddd, J = 14.4, 9.2, 5.2 Hz, 
1H), 2.86 (dt, J = 14.5, 8.3 Hz, 1H), 2.59–2.47 (m, 1H), 2.45–2.33 (m, 1H), 2.30–2.16 (m, 2H), 
2.15–2.00 (m, 2H), 1.75 (dd, J = 2.6, 1.3 Hz, 3H), 0.94 (dd, J = 6.5, 2.6 Hz, 3H).  13C NMR (101 
MHz, CDCl3) δ 199.7, 199.7, 144.7, 144.6, 142.2, 142.2, 135.3, 135.3, 118.1, 118.1, 117.8, 113.5, 
42.2, 40.5, 39.6, 39.4, 38.1, 37.9, 37.3, 37.2, 30.2, 28.0, 15.7, 15.6, 15.5, 15.5. Note - The 
diastereomer and regioisomer are marked as  in spectra.  Minor Isomer -1H NMR, [mixture of 
diastereomers] (400 MHz, CDCl3) δ 7.70 (d, J = 3.4 Hz, 1H), 7.18 (d, J = 3.3 Hz, 1H), 4.74 (d, J 
= 21.5 Hz, 2H), 3.91 (dt, J = 6.0, 4.0 Hz, 1H), 2.80–2.72 (m, 1H), 2.68 (ddd, J = 14.4, 4.1, 1.2 Hz, 
1H), 2.51–2.42 (m, 1H), 2.37–2.27 (m, 1H), 2.18–2.11 (m, 2H), 1.70 (s, 3H), 0.97 (d, J = 6.7 Hz, 
3H).  13C NMR (101 MHz, CDCl3) δ 210.3, 169.6, 147.2, 142.8, 117.9, 110.2, 47.3, 45.5, 40.3, 
35.8, 29.4, 22.7, 14.1.  Note - The diastereomer is marked as  in spectra.  FT-IR (neat) cm-1 2962, 
1706, 1666, 1655.  HRMS (ESI) calcd. C13H17NOS [M+H]+ 236.1104 observed 236.1102. 
 
25a ((1S,2R,4S)-2-(benzo[d]thiazol-2-yl)-4-(prop-1-en-2-yl)cyclohexyl)methanol  
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The general procedure E was followed using 2-benzobromothiazole 
(25 mg, 0.12 mmol), (4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methanol 
(89 mg, 0.58 mmol), tributylamine (65 mg, 0.35 mmol), formic acid 
(16 mg, and 0.50 mL of stock solution of Ir(ppy)3 in MeCN was used  to afford 25a in 82% yield 
(28 mg, 0.097 mmol), rr 9:1 (based on crude 1H NMR), dr 7:1 (based on crude 1H NMR) and 
isolated as dr 8.1:1 (mixture) as pale oil.  After the completion of the reaction, 21 h, the substrate 
was purified via automated flash chromatography using EtOAc in hexanes (0% to 100%) with 
product eluting at 8% on a 12 g silica column.  1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.1 Hz, 
1H), 7.86 (d, J = 7.9 Hz, 1H), 7.46 (t, J = 7.7 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 4.75 (s, 2H), 3.88 
(s, 1H), 3.73–3.61 (m, 1H), 3.56–3.41 (m, 1H), 2.47 (t, J = 12.3 Hz, 1H), 2.29 (d, J = 14.0 Hz, 
1H), 2.17–2.02 (m, 1H), 1.92 (d, J = 12.7 Hz, 1H), 1.83 (td, J = 13.5, 4.9 Hz, 1H), 1.76 (s, 3H), 
1.61 (q, J = 14.1, 13.1 Hz, 2H), 1.45–1.30 (m, 1H).  13C NMR (101 MHz, CDCl3) δ 174.0, 152.0, 
149.5, 134.5, 126.1, 125.0, 122.6, 121.4, 109.0, 65.2, 43.3, 41.9, 40.4, 36.5, 31.0, 24.6, 21.0.  FT-
IR (neat) 3435, 2985, 2854cm-1.  HRMS (ESI) C17H21NOS calcd. [M+H]+ 288.1417 observed 
288.1414. Diastereoselectivity is based on detailed analysis of coupling constants. 
 
26a 2-(2-(4-((benzyloxy)methyl)cyclohex-3-en-1-yl)propyl)-4-chlorobenzo[d]thiazole 
The general procedure E was followed using 2-bromo-
4-chloro-1H-benzo[d]thiazole (25 mg, 0.10 mmol), (4-
(prop-1-en-2-yl)cyclohex-1-en-
yl)methoxy)methyl)benzene (120 mg, 0.51 mmol), 
tributylamine (56 mg, 0.30 mmol), formic acid (14 mg, 0.30 mmol), and 0.40 mL of stock solution 
of Ir(ppy)3 in MeCN solution was used  to afford 26a in 80% yield (33 mg, 0.08 mmol), rr >20:1 
(based on crude 1H NMR), dr 4:1 (based on crude 1H NMR) and isolated dr 5:1 (mixture) as an 
oil.  After the completion of the reaction, 17 h, the substrate was purified via automated flash 
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chromatography using EtOAc in hexanes (0% to 100%) with product eluting at 12% on a 12 g 
silica column.  1H NMR (400 MHz, CDCl3) [mix of diastereomers] δ 7.96 (d, J = 8.1 Hz, 1H), 
7.86 (d, J = 7.9 Hz, 1H), 7.46 (t, J = 7.7 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 4.75 (s, 2H), 3.88 (s, 
1H), 3.73–3.61 (m, 1H), 3.56–3.41 (m, 1H), 2.47 (t, J = 12.3 Hz, 1H), 2.29 (d, J = 14.0 Hz, 1H), 
2.17–2.02 (m, 1H), 1.92 (d, J = 12.7 Hz, 1H), 1.83 (td, J = 13.5, 4.9 Hz, 1H), 1.76 (s, 3H), 1.61 (q, 
J = 14.1, 13.1 Hz, 2H), 1.45–1.30 (m, 2H).  13C NMR (101 MHz, CDCl3) δ 174.0, 152.0, 149.5, 
134.5, 126.1, 125.0, 122.6, 121.4, 109.0, 65.2, 43.3, 41.9, 40.4, 36.5, 31.0, 24.6, 21.0.  FT-IR 
(neat) cm-1.  HRMS (ESI) C24H26NClOS calcd. [M+H]+ 412.1496 observed 412.1492.  The 
diastereomer is marked as  in spectra. 
 
27a 4,6-difluoro-2-(5-isopropyl-2-methylcyclohex-2-en-1-yl)benzo[d]thiazole 
The general procedure E was followed using 2-bromo-4,6-
difluorobenzo[d]thiazole (25 mg, 0.10 mmol), alpha-pinene (68 mg, 
0.50 mmol), tributylamine (56 mg, 0.30 mmol), formic acid (14 mg, 
0.30 mmol), and 0.40 mL of stock solution of Ir(ppy)3 in MeCN was used to afford 27a in 68% 
yield (21 mg, 0.068 mmol), rr >20:1 (isolated) as yellow oil.  After the completion of the reaction, 
16 h, the substrate was purified via automated flash chromatography using EtOAc in hexanes (0% 
to 100%) with product eluting at 4% on a 12 g silica column.  1H NMR (400 MHz, CDCl3) δ 7.32 
(d, J = 7.5 Hz, 1H), 6.96 (t, J = 9.7 Hz, 1H), 5.76 (s, 1H), 3.89 (d, J = 6.1 Hz, 1H), 2.21 (d, J = 
17.8 Hz, 2H), 2.08 (d, J = 13.1 Hz, 1H), 1.73 (s, 3H), 1.57 (s, 2H), 1.44 (dt, J = 12.7, 6.4 Hz, 1H), 
0.84 (dd, 6H).  13C NMR (101 MHz, CDCl3) δ 176.8 (d, J = 3.0 Hz), 159.6 (dd, J = 246.8, 10.4 
Hz), 154.7 (dd, J = 258.7, 13.4 Hz),138.8 (dd, J = 13.2, 2.5 Hz), 138.1 (dd, J = 12.6, 5.1 Hz), 
132.0, 126.6 103.3 (dd, J = 26.2, 4.7 Hz), 101.5 (dd, J = 28.3, 21.9 Hz).45.0, 34.7, 33.2, 31.9, 28.6, 
22.4, 19.7, 19.1.  19F NMR (376 MHz, CDCl3) δ -113.6 (dd, J = 7.9 Hz), -117.8–-118.3 (m).  FT-
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IR (neat) cm-1 2956, 1617, 1585.  HRMS (ESI) C17H19F2NS calcd [M+H]+ 308.1279 observed 
308.1278. [α]D20 = +87.17 (c 0.016, CHCl3). 
 
28a 2-(((1S,11S,Z)-7,7,11-trimethyl-12-oxabicyclo[9.1.0]dodec-4-en-4-yl)methyl)thiazole 
The general procedure E was followed using 2-bromothiazole (25 mg, 
0.15 mmol) (-) caryophylleneoxide (170 mg, 0.76 mmol), tributylamine (85 
mg, 0.46 mmol), formic acid (21 mg, 0.46 mmol), and 0.65 mL of stock 
solution of Ir(ppy)3 in MeCN solution was used  to afford 28a in 71% yield 
(32 mg, 0.106 mmol) rr >20:1 (based on crude 1H NMR), Z:E>20:1 as colorless oil.  After the 
completion of the reaction, 19 h, the substrate was purified via automated flash chromatography 
using EtOAc in hexanes (0% to 100%) with product eluting at 14% on a 12 g silica column.  1H 
NMR (400 MHz, CDCl3) δ 7.67 (d, J = 3.3 Hz, 1H), 7.19 (d, J = 3.3 Hz, 1H), 5.49 (dd, J = 11.1, 
2.6 Hz, 1H), 3.93 (d, J = 15.1 Hz, 1H), 3.52 (d, J = 15.2 Hz, 1H), 2.82 (dd, J = 11.1, 1.8 Hz, 1H), 
2.50–2.38 (m, 1H), 2.36–2.21 (m, 2H), 2.18–1.97 (m, 2H), 1.83 (dt, J = 15.2, 2.7 Hz, 1H), 1.66–
1.39 (m, 4H), 1.27 (s, 3H), 1.23 (d, J = 2.7 Hz, 1H), 1.12 (dd, J = 10.9, 7.2 Hz, 1H), 0.98 (s, 3H), 
0.89 (s, 3H).  13C NMR (101 MHz, CDCl3) δ 170.3, 142.9, 134.8, 128.4, 119.2, 63.2, 63.1, 41.3, 
38.9, 38.0, 35.5, 33.6, 33.5, 30.0, 28.7, 24.8, 19.0, 18.4.  FT-IR (neat) cm-1 2952, 1595, 850.  
HRMS (ESI) C18H27NOS calcd [M+H]+  306.1886 observed 306.1877. [α]D20 = -490.7 (c 0.013, 






The general procedure F was followed using 2-
bromothiazole (110 mg, 0.65 mmol) cholesterol (25 mg, 
0.064 mmol), tributylamine (140 mg, 0.77 mmol), formic 
acid (35 mg, 0.77 mmol), Ir(ppy)3 (0.006 equiv, 0.64 mL 
of 0.6 mM stock solution of catalyst in MeCN, where 
0.64 mL of MeCN is used to make 0.1 M with respect to 
cholesterol) was used to afford 29a in 65% yield (19 mg, 0.042 mmol). After the completion of 
the reaction, 24 h, the substrate was purified via automated flash chromatography using EtOAc in 
hexanes (0% to 100%) with product eluting at 60% on a 12 g silica column as yellow oil.  (Note 
– reaction went only up to 80% conversion with respect to  cholesterol) rr >20:1 (based on crude 
1H NMR) dr> 20:1 (based on crude 1H NMR).  1H NMR (599 MHz, CDCl3) δ 7.66 (d, J = 3.3 Hz, 
1H), 7.17 (d, J = 3.3 Hz, 1H), 3.63 (tt, J = 11.0, 4.6 Hz, 1H), 3.26–3.19 (m, 1H), 2.34 (ddd, J = 
13.8, 3.5, 1.8 Hz, 1H), 2.16–2.05 (m, 2H), 1.98 (ddt, J = 12.6, 5.2, 2.7 Hz, 2H), 1.89–1.82 (m, 1H), 
1.82–1.75 (m, 1H), 1.72–1.62 (m, 3H), 1.57–1.47 (m, 3H), 1.45–1.37 (m, 2H), 1.34 (dd, J = 7.4, 
4.0 Hz, 2H), 1.33–1.28 (m, 3H), 1.27–1.23 (m, 2H), 1.18–1.12 (m, 3H), 1.11–1.05 (m, 2H), 1.03–
0.95 (m, 3H), 0.91 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 2.8 Hz, 3H), 0.86 (d, J = 2.8 Hz, 3H), 0.71 (s, 
3H), 0.51 (s, 3H).   13C NMR (101 MHz, CDCl3) δ 173.3, 141.5, 117.2, 71.9, 56.3, 56.1, 55.2, 
47.6, 42.6, 42.5, 39.8, 39.4, 38.7, 37.9, 36.7, 36.0, 36.0, 35.7, 32.1, 31.3, 28.1, 27.8, 24.0, 23.7, 
22.6, 22.4, 21.0, 18.5, 14.5, 12.1.  FT-IR (neat) cm-1 3465, 2933, 1680.  HRMS (ESI) C30H49NOS 
calcd [M+H]+ 472.3607 observed 472.3608.  [α]D20 = + 5.54 (c 0.011, CHCl3).  





The general procedure E was followed using 2-bromothiazole (25 mg, 0.15 
mmol) cis-cyclooctene (84 mg, 0.75 mmol), tributylamine (85 mg, 0.46 
mmol), formic acid (21 mg, 0.46 mmol), and 0.65 mL of stock solution of Ir(ppy)3 in MeCN 
solution was used to afford 30a in 23% yield (7 mg, 0.035 mmol) as yellow oil.  After the 
completion of the reaction, 12 h, the substrate was purified via automated flash chromatography 
using EtOAc in hexanes (0% to 100%) with product eluting at 7% on a 12 g silica column.  1H 
NMR (400 MHz, CDCl3) δ 7.66 (d, J = 3.3 Hz, 1H), 7.16 (d, J = 3.3 Hz, 1H), 3.37–3.22 (m, 1H), 
2.16–2.03 (m, 2H), 1.96–1.84 (m, 2H), 1.83–1.70 (m, 2H), 1.66–1.57 (m, 8H).  13C NMR (101 
MHz, CDCl3) δ 178.4, 141.8, 117.3, 42.7, 32.9, 27.1, 26.0, 25.3.  FT-IR (neat) cm-1 2872, 2920.  
HRMS (ESI) C11H17NS calcd. [M+H]+ 196.1154 observed 196.1150. 
 
31a 2-cyclooctyl-4,6-difluorobenzo[d]thiazole 
The general procedure G was followed using 2-bromo-4,6-
difluorobenzo[d]thiazole (25 mg, 0.10 mmol), cyclooctene (55 mg, 
0.50 mmol), N,N-diisopropyloctan-1-amine (55 mg, 0.30 mmol), 
formic acid (14 mg, 0.30 mmol), and 0.40 mL of stock solution of cat-1 in MeCN was used to 
afford 31a in 73% yield (20 mg, 0.073 mmol) as yellow oil.  After the completion of the reaction, 
48 h, the substrate was purified via automated flash chromatography using EtOAc in hexanes (0% 
to 100%) with product eluting at 3% on a 12 g silica column.  1H NMR (400 MHz, CDCl3 ) δ 6.62 
(dd, J = 19.8, 7.9 Hz, 1H), 6.47 (qd, J = 10.4, 2.5 Hz, 1H), 4.11–3.88 (m, 1H), 2.64 (ddt, J = 85.9, 
7.8, 3.3 Hz, 2H), 2.27–2.06 (m, 2H), 1.90–1.75 (m, 2H), 1.77–1.65 (m, 1H), 1.66–1.48 (m, 7H).  
13C NMR (101 MHz, CDCl3) δ 157.0 (ddd, J = 241.0, 23.8, 10.7 Hz), 148.7 (dt, J = 244.1, 12.6 
Hz), 133.8–127.8 (m), 104.7 (ddd, J = 26.3, 12.6, 3.5 Hz), 99.9 (ddd, J = 27.2, 22.6, 2.5 Hz), 94.1, 
92.7, 48.7, 48.4, 31.6, 31.2, 28.7, 28.1, 24.9, 24.2.  19F NMR (376 MHz, CDCl3) δ -120.7 (dt, J = 
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30.0, 8.6 Hz), -128.6 (dd, J = 188.2, 10.2 Hz).  FT-IR (neat) cm-1 3025, 2927, 2852, 1612, 1438, 




The general procedure H was followed using 5-bromopyrimidine-2-
carbonitrile (25 mg, 0.14 mmol), norbornene (64 mg, 0.68 mmol), N,N-
diisopropylethylamine (21 mg, 0.30 mmol), and 0.56 mL of stock 
solution of Ir(ppy)3 in MeCN was used  to afford 32a in 71% yield (21 mg, 0.10 mmol), dr > 20:1 
(based on crude 1H NMR) as an oil.  After the completion of the reaction, 48 h, the substrate was 
purified via automated flash chromatography using EtOAc in hexanes (0% to 100%) with product 
eluting at 6% on a 12 g silica column.  1H NMR (400 MHz, CDCl3) δ 8.68 (s, 2H), 2.81 (dd, J = 
9.0, 5.5 Hz, 1H), 2.48 (t, J = 4.1 Hz, 1H), 2.43 (dd, J = 3.9, 1.6 Hz, 1H), 1.90 (ddd, J = 11.7, 8.9, 
2.2 Hz, 1H), 1.75–1.57 (m, 3H), 1.48–1.38 (m, 2H), 1.37–1.27 (m, 2H).  13C NMR (101 MHz, 
CDCl3) δ 156.7, 143.0, 142.6, 115.8, 43.2, 37.0, 36.3, 30.3, 28.5.  FT-IR (neat) cm-1 1400, 2225, 
2800, 2950.  
 
33a dimethyl (1R,4S,5R)-5-(4-formylphenyl)-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylate 
The general procedure H was followed using 4-
bromobenzaldehyde (50 mg, 0.27 mmol), dimethyl (1R,4S)-7-
oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate (180 mg, 0.85 
mmol), N,N-diisopropylethylamine (70 mg, 0.54 mmol), and 1.35 
mL of stock solution of Ir(ppy)3 in MeCN was used  to afford 33a in 55% yield (47 mg, 0.149 
mmol), dr > 20:1 (based on crude 1H NMR) as an oil.  After the completion of the reaction, 72 h, 
the substrate was purified via automated flash chromatography using EtOAc in hexanes (column 
was buffered with 0.5% Et3N in hexanes before running) (0% to 100%) with product eluting at 
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32% on a 4 g silica column..  1H NMR (400 MHz, Acetone-d6) δ 10.00 (s, 1H), 7.91–7.79 (m, 2H), 
7.57–7.47 (m, 2H), 4.99 (d, J = 5.3 Hz, 1H), 4.71 (s, 1H), 3.61 (s, 3H), 3.58 (s, 3H), 3.36–3.24 (m, 
3H), 2.32 (dd, J = 12.6, 8.9 Hz, 1H), 1.81 (dt, J = 12.6, 5.1 Hz, 1H).  13C NMR (101 MHz, Acetone-
d6) δ 368.9, 348.4, 348.2, 330.1, 312.5, 306.9, 305.3, 261.5, 255.8, 229.0, 228.6, 228.4, 224.7, 
217.4.  FT-IR (neat) cm-1 2725, 2820, 1720, 1679, 1133. 
 
34a 4-((1S,4R)-bicyclo[2.2.1]heptan-2-yl)benzonitrile 
The general procedure H was followed using 4-bromobenzonitrile 
(75 mg, 0.41 mmol), norbornene (193 mg, 2.1 mmol)), N,N-
diisopropylethylamine (106 mg, 0.82 mmol), and 1.7 mL of stock solution of Ir(ppy)3 in MeCN 
was used  to afford 34a in 47% yield (38 mg, 0.19 mmol), dr>20:1 as an oil.  After the completion 
of the reaction, 72 h, the substrate was purified via automated flash chromatography using EtOAc 
in hexanes (0% to 100%) with product eluting at 5% on a 12 g silica column.  1H NMR (400 MHz, 
CDCl3) δ 7.56 (d, J = 8.2 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 2.78 (t, J = 6.8 Hz, 1H), 2.38 (s, 2H), 
1.82 (t, J = 10.8 Hz, 1H), 1.66–1.53 (m, 3H), 1.47 (d, J = 9.9 Hz, 1H), 1.37 (t, J = 9.0 Hz, 1H), 
1.30 (d, J = 8.7 Hz, 1H), 1.23 (d, J = 10.1 Hz, 1H).  13C NMR (101 MHz, CDCl3) δ 153.3, 132.2, 
128.0, 119.4, 109.3, 47.7, 42.7, 39.3, 37.0, 36.3, 30.6, 28.9.  FT-IR (neat) cm-1 2949, 2874, 2226, 
1608. 
Improvement of percentage yield of substrate 3a and 8a with new modified conditions 
(Conditions B) 
3a 4-phenyl-2-(tetrahydro-2H-pyran-3-yl)thiazole 
The Conditions B were followed using 2-bromo-4-phenylthiazole (25 
mg, 0.10 mmol), 3,4-dihydro-2H-pyran (42 mg, 0.50 mmol), N,N-
diisopropyloctan-1-amine (64 mg, 0.30 mmol), formic acid (14 mg, 
0.30 mmol), 0.40 mL of stock solution of cat-1 in MeCN.  After 3 days, 1,3,5-trimethoxybenzene 
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(8.4 mg, 0.05 mmol) was added as an internal standard and the yield of 3a was calculated as 51% 
(based on 1H NMR) with a rr 9:1 (based on crude 1H NMR).  Note – In comparison to 3a (with 
Conditions A) the yield improved from 43% to 51%. 
8a 4-chloro-2-(tetrahydro-2H-pyran-3-yl)benzo[d]thiazole 
The Conditions B were followed using 2-bromo-4-chlorobenzo[d]thiazole 
(25 mg, 0.10 mmol), 3,4-dihydro-2H-pyran (42 mg, 0.50 mmol), N,N-
diisopropyloctan-1-amine (64 mg, 0.30 mmol), formic acid (14 mg, 0.30 
mmol), and 0.40 mL of stock solution of cat-1 in MeCN.  After 4 days, 1,3,5-trimethoxybenzene 
(8.4 mg, 0.05 mmol) was added as an internal standard and the yield of 8a was calculated as 77% 
yield (based on 1H NMR) and rr 4:1 (based on crude 1H NMR).  Note In comparison to 8a (with 
Conditions A) the yield improved from 60% to 77% with slight improvement of rr 3:1 (with 














Figure 3.4 Chapter III NMR Spectrum Graphs 
















































































































































































































































































































1H NMR (400 MHz, CDCl3) of 24a (Major) 2-methyl-5-(1-(thiazol-2-yl)propan-2-yl)cyclohex-2-





13C NMR (101 MHz, CDCl3) of 24a (Major) 2-methyl-5-(1-(thiazol-2-yl)propan-2-yl)cyclohex-












































































































































































































4.1 Introduction  
Amino acids and derivatives are indispensable building blocks within organic chemistry.  
The addition of an oxazolone enolate to an electrophile is a common strategy to elaborate the alpha 
amino acid motif.106-109  α-Arylation of the oxazolone enolate has been accomplished via Ag-
mediated arylation with diaryliodonium salts (Scheme 4.1, eqn 1),109 Pd-catalyzed cross-coupling 
of aryl-bromides (eqn 2),110 and pyridine addition via nucleophilic addition to N-tosylated 
pyridines (eqn 3).106  However, these methods do little to access amino acids that possess highly 
fluorinated arenes, since the requisite fluorinated starting materials are not available. Additionally, 
while these methods proved useful for accessing tertiary carbons, secondary carbons were never 
obtained.  In other words, it was important that the product be fully substituted at the alpha 
position, likely due to the fact that the product was more reactive than the starting material.  We 
posited that the oxazolone enolate might undergo uncatalyzed substitution of the perfluoroarenes 
(eqn 5), via nucleophilic aromatic substitution (SNAr), and because the product was anticipated to 
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form a more stable anion, we anticipated diminishment of its nucleophilicity when compared to 
the starting material, allowing clean formation of the product without over arylation.  Importantly, 
if successful, this would provide rapid and facile access to non-natural multifluoroarylated amino 
acids.  
Scheme 4.1. Arylation of oxazolones  
 
The oxazolone enolate is a versatile nucleophile which can conceivably undergo addition 
at C2, C4, and even the C5-oxygen bond (eqn 6).111  The only example of SNAr-type reactions 
with oxazolones is the addition to 2-nitroarenes, which undergoes subsequent cyclization with the 
nitro functional group to give indazole products (eqn 4).112  Though the reaction leads to a different 
product, it suggests that oxazolone enolate might be a competent nucleophile in the addition to 
perfluoroarenes (eqn 5). 
4.2 Optimization studies  
We started our investigation using 2-phenyloxazol-5(4H)-one (1, Table 4.1) derived from 
glycine with pentafluoropyridine and diisopropylamine (DIPEA) in acetonitrile which were 
optimal conditions in the analogous addition of Meldrum’s acid enolate.18  Initially, we ran the 
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reaction at 45 oC (entry 1) but found the reaction gave full conversion at room temperature, giving 
complete conversion to the C4-arylation product within just 20 min (entry 2).  Owing to the 
relatively fast addition, we were able to lower the amount of the arene to 1.025 equiv (entry 3) 
without any detectable diminishment of conversion.  Previously, we have observed DIPEA can 
undergo a slow N–substitution/dealkylation sequence when subjected to highly electrophilic 
perfluoroarenes at elevated temperatures.113  Consequently, by keeping the amount of excess 
perfluoroarene low (0.025 equiv) and reactions at room temperature, the amine substituted product 
was not observed.  A solvent screen (entries 2-7) revealed polar aprotic solvents work best, while 
ethereal, hydrocarbon, and halogenated solvents gave little to no conversion (entries 5-7).  To 
facilitate reaction scale up, we simultaneously reduced the arene loading and concentrated the 
reaction to 1 M (entry 8) which smoothly proceeded to full conversion. Next, we evaluated a less 
activated arene, octafluorotoluene (b), instead of pentafluoropyridine (entry 9), but unfortunately, 
it gave very low conversion under these conditions. 
However, upon switching to stronger base, tetramethyl guanidine (TMG-H+, pKa(MeCN) = 
23.3 compared to ~18.8 for DIPEA-H+).114  We observed complete conversion, even at -20 oC 
(entry 10).  Lower temperatures were necessary to avoid TMG addition to the perfluoroarenes (not 
shown). 
Table 4.1. Optimization of Reaction Conditions  
 
entry conditions Arene (equiv) Amine  (equiv) T (oC) % conv 
1. 0.3 M ACN a (2) DIPEA (3) 45 100 
2. 0.3 M ACN a (2) DIPEA (3) 22 100 
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3. 0.3 M DMF a (2) DIPEA (3) 22 100 
4. 0.3 M DMSO a (2) DIPEA (3) 22 100 
5. 0.3 M THF a (2) DIPEA (3) 22 24 
6. 0.3 M Tol a (2) DIPEA (3) 22 <5 
7. 0.3 M DCM a (2) DIPEA (3) 22 25 
8. 1 M ACN a (1.025) DIPEA (3) 22 100 
9. 1 M ACN b (2) DIPEA (3) 22 <5 
10. 1 M ACN b (2) TMG (2.4) -20  100 
11. 1 M ACN b (1.025) TMG (2.05) -20  100 
12. 1 M ACN  a (1.025) TMG (2.05) -20  100 
a. Conversion determined by 19F NMR after 30 min. 
 It is puzzling why the same acid (i.e. oxazolone) would require a stronger base as a 
function of electrophile.  One potential explanation for this observation is that the ammonium 
enolate is the minor product of an equilibrium (Scheme 4.2A).  Due to the decreased 







Scheme 4.2 A. Equilibria of oxazolone under basic conditions B. π-stacking events of 
pentafluoropyridine and octafluorotoluene 
 
The use of a stronger base accelerates the reaction by shifting the equilibrium in favor of 
the enolate.  An alternative possibility is that pentafluoropyridine undergoes a π-stacking event 
(Scheme 4.2B)115,116 with the phenyl ring of the oxazolone, which could result in an acidification 
of the C4-H. In contrast, when octafluorotoluene is used, it is less prone to undergo this acidifying, 
π-stacking event, presumably due to the steric bulk of the trifluoromethyl group, and thus requires 
a stronger base to generate the requisite enolate.  
 Thus, with the use of tetramethylguanidine (TMG) at -20 oC, we were able achieve full 
conversion of 1, using just 1.025 equivalents of octafluorotoluene (b, entry 11). When we applied 
these reaction conditions to pentafluoropyridine (a, entry 12) we observed quantitative conversion 





4.3 Substrate scope  
With the optimal conditions in hand (entry 12), we were prepared to explore the scope. 
Typically, oxazolones are not easily isolated due to their predisposition for ring opening, and 
instead are usually derivatized immediately to a more stable molecule.107  This is easily 
accomplished under acidic conditions, since the oxazolone behaves as an activated ester. We 
explored the ring opening of the oxazolone with alcohols to form perfluoroaryl N-benzoyl 
protected esters (Scheme 4.3). We found protonation of the oxazolone under anhydrous conditions 
was the key to high yield and that this was best accomplished using catalytic amounts 
trifluoroacetic acid in dry alcohol. 
Scheme 4.3 Arylation and esterification of oxazolone 
 
 The scope of the one pot perfluoroarylation and esterification of the oxazolone was 
explored.  Generally, the reaction scope was very good and worked well with many of the 
commercially available perfluoroarenes. No undesired reactivity was observed with esters (2a) or 
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ketones (2b). Less activated octafluorotoluene, octafluoronapthalene, and decafluorobiphenyl all 
reacted to give the expected product in excellent yields (2c, 2f, and 2g). Both benzoxazoles (2h) 
and benzonitriles (2i) underwent arylation and esterification in good yield. Comparison of pyridine 
products 2d and 2e revealed the preference for substitution of the 4-fluoro over that of 3-chloro 
leaving group. This is consistent with a SNAr reaction, and is expected, as fluorine is the preferred 
nucleofuge and attack of the 4-position maximizes delocalization of the charge in the 
Meisenheimer complex.  
 However, substitution of 4-chlorotetrafluoropyridine (Scheme 4.4) leads primarily to 
substitution of the chloride, rather than substituting at the 2-fluoro position, to give 2d as the major 
product.  This suggests, in this case, that the regioselectivity is primarily dictated by the electronics 
of the arene rather than the nucleofuge.  
Scheme 4.4 Arylation and esterification of oxazolone 
 
 Next, we explored the ring opening of oxazolones with water, which would provide direct 
access to non-natural N-benzoyl protected amino acids in a rapid and facile manner (Scheme 
4.5A).  We were pleased to see that the perfluoroarylated oxazolone intermediates could be 
efficiently hydrolyzed (3a-3e).  Since facilitating access to more elaborate fluorinated building 
blocks was our primary objective, we also developed chromatography-free conditions (Scheme 
4.5B) that were amenable to scaling, and allowed us to synthesize the amino acids derivatives on 
a gram scale with minimal effort.  After initial removal of MeCN, the crude acids were extracted 
with CHCl3, washed with acidic brine, and stripped of solvent in vacuo. Next, the acid was washed 
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with hexanes and trace dichloromethane to selectively extract the impurities and yield pure acids.  
This process was applied successfully on a gram scale for several substrates (3a-3c), suggesting 
the method may be useful for making more sizeable quantities of the N- benzoyl protected acids. 
Scheme 4.5 Telescope reaction to synthesize multifluoroaryl amino acids 
 
4.4 Debenzoylation of amino acids and Schiff base mediated decarboxylation  
Next, we probed the deprotection of the N-benzoyl groups in hopes of accessing the free 
amino acids.  Unfortunately, in the case of pyridine derived (3a), standard deprotection conditions 
of refluxing in concentrated HCl led to the deprotected and decarboxylated ammonium salts.  The 
amino acid derivatives apparently underwent a thermal decarboxylation, however it was not clear 
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whether debenzoylation occurred prior to or following decarboxylation.  Fortunately, after 
lowering the reaction temperature to 60 oC, we found that the amino acids underwent smooth 
debenzoylation, but did not undergo decarboxylation. 
 
Scheme 4.6 Debenzoylation of Amino Acids and Schiff Base Mediated Decarboxylation 
 Thus, by subjecting acids (3a-c, Scheme 4.6) to aqueous HCl carefully heated to 60 oC, 
we acquired the unprotected amino acids in quantitative yields.  Upon exposure to acetone the 
amino acid salts (4a-c) undergo rapid and quantitative decarboxylative protonation.  Presumably, 
this takes place through a transiently formed Schiff base, which facilitates the decarboxylation and 
then undergoes hydrolysis to form (5a-c).117 Given the high yielding and facile nature of each step, 
the addition of oxazolone to perfluoroarenes is an attractive strategy to access highly fluorinated 
benzylic amine derivatives such as 5a-c.  
As mentioned above, upon refluxing the benzoyl protected amino acids (3a-c) in HCl, the 
outcome was the deprotected and decarboxylated product. Two possible pathways are conceivable 
and are shown in Scheme 4.7.  By doping the reaction of 3a with isolated 4a, it is possible to NMR 
doping experiments were performed, in which the isolated hydrochloride salts of amino acids (4a-
c) were added to the refluxing HCl conditions.  This confirmed that debenzoylation occurs prior 
to decarboxylation.  
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Scheme 4.7 Reaction pathways of decarboxylation  
 
During our investigation, we found that under the standard deprotection conditions 
(refluxing the benzoyl protected amino acid (3a) in concentrated HCl) led to the deprotected and 
decarboxylated ammonium salt (5a). While the nature of the final product was apparent, the 
reaction sequence was not clear.  In other words, did debenzoylation precede decarboxylation 




To probe the reaction, 20 mg of 3a (0.061 mmol) and 0.50 mL of 12 M HCl was added to 
a NMR tube and the T0 19F NMR was collected (Figure 4.6, spectrum 7). The reaction was run at 
80 oC and 19F NMR data was collected at 5 h, 12 h, 27 h, 48 h, and 60 h (spectra 2-6, respectively). 
After the last time point, the NMR tube was doped with previously isolated 5a (5 mg) and the 19F 
NMR was taken which confirmed the identity of the second species, and by elimination, the 
structure of 3a as well. 
 
Figure 4.1 Stacked spectra of starting material, product (amino acid) 






The progression of the reaction is displayed in Figure 4.1 and after 5 h the conversion of 
starting material to a new intermediate is apparent and the peak chemical shifts at -88 ppm. With 
prolonged heat, a second intermediate is formed with a chemical shift of -89.5 ppm. Yet, the 
doping of the NMR reaction revealed 5a to be the final product shifting at -89.5 ppm. After a 
typical workup (see general procedure G) of the incomplete reaction (where starting material is 
consumed and only partial conversion of the intermediate to the 5a product), the 19F NMR (Figure 
4.2) and the 1H NMR (Figure 4.3) revealed that the intermediate N-((perfluoropyridin-4-
Figure 4.2 19F NMR after workup 
Figure 4.3 1H NMR after workup 
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yl)methyl)benzamide was neither of the intermediates observed due to the lack of benzoyl 
aromatic signals.  The first intermediate was found to be 4a (seen at -88 ppm) matching of what 
one would expect in the 1H NMR (s, 1H) 19F NMR δ -89.95 – -90.40 (m), -141.50 – -142.06 (m). 
With this evidence, we eliminated pathway B (Scheme 4.7) as the reaction pathway and concluded 
that the most logical route is pathway A, where the benzoyl protected amino acids undergo 
deprotection and then thermally decarboxylate giving the benzylic amine.  This finding is 
consistent with TGA experiments (section 4.5) which show that for 3b and 4b, which differ by the 
deprotection of the N-benzoyl group, that the amide (3b) is less prone to thermal decarboxylation 
than the corresponding ammonium acid (4b).\ 
  
4.5 Thermal gravimetric analysis  
Having generated a strategy to access a novel class of fluorinated amino acids and our own 
experience with the unexpected decarboxylation of the amino acid derivatives, we thought 
it appropriate to explore the thermal stability of several derivatives.  Thus, we performed 
thermal gravimetric analysis on several of the products we had formed (Scheme 4.8).  As 
expected the benzoyl protected esters (2d) were thermally stable and gradually sublimed.  
However, the benzoyl protected acids 3a-c all underwent decarboxylation at 108 oC, 132 
oC, and 159 oC, respectively.  The differences in decarboxylation temperature seem to 
reflect the stability of a benzylic anion, however, it may also correlate to basicity of the 
amide motif.  Comparison of 3b and 4b shows that the HCl salts actually undergo a more 
facile thermal decarboxylation than the N-benzoylated substrate, and is consistent with our 
previous findings in Scheme 4.6.  However, 4c failed to undergo decarboxylation and 
instead gradually sublimed. It may be possible that the 4c is sufficiently acidic that it 





Scheme 4.8 Thermalgravimetric Analysis of α-Multifluoroaryl Amino Acid Derivatives. 
Next, we evaluated the perfluoroarylations of substituted oxazolones, which yield fully 
substituted, non-natural amino acid derivatives (Scheme 4.9).  Upon additional substitution of the 
oxazolone, the carbonyl is permanently formed, which is prone to opening by nucleophiles, 
including TMG. 
 
Scheme 4.9 Fully substituted amino acid esters 
We were pleased to see that even the substituted oxazolone enolate underwent selective 
C4-addition to give the desired amino acids, rather than C2-addition, which has been observed for 
substituted oxazolones.111, 118 However, in order to be able to derivatize in the second step, we 
found it necessary to utilize DIPEA as the base.  Perfluoroarylated amino acid esters were derived 
from alanine, valine, methionine, and phenylalanine in good yield (6a-d). 
4.6 One pot multicomponent synthesis of 2-aminohydantoins 
When we utilized TMG as the base, we found that after arylation the TMG would undergo 
nucleophilic ring opening to form N-acylated guanidines, which upon heating in HCl underwent 
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debenzoylation and cyclization with extrusion of dimethyl amine (Scheme 4.10).  This sequence 
yields 2-aminohydantoins which are currently being studied119-125 as possible inhibitors of BACE1, 
an enzyme believed to play a central role in the formation β-amyloid formation associated with 
Alzheimer’s disease.  Traditionally, 2-aminohydantoins have been synthesized by adding an 
activated carbon to the N-terminus which then serves to bridge the N- and C-termini of the amino 
acid.  In contrast, the guanidine serves in place of the activated carbon and is attached to the C-
terminus.  To our knowledge, this cyclization approach is novel and demonstrates the potential for 
a one-pot, three component coupling that could be used to rapidly explore the chemical space 
surrounding this important motif. 
 
Scheme 4.10 One pot multicomponent synthesis of  2-amino hydantoins 
 In summary, we have shown that the oxazolone enolate is capable of nucleophilic 
aromatic substitution and can be utilized to rapidly form non-natural fluorinated amino acid 
derivatives.  Importantly, the reaction is highly selective both in terms of C–F and oxazolone 
regioselectivity.  Furthermore, we have provided conditions that allow transformation of the 
product to valuable building blocks, namely, N-Bz esters, N-Bz acids, acid-HCl salts, and by way 
of Schiff-base decarboxylation, the benzylic amines.  Furthermore, we have reported the behavior 
of these compounds towards thermal decarboxylation, which indicate that the compounds should 
be stable at room temperature.  Finally, we demonstrate the utility of the reaction and its product 
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by demonstrating its use in a 3-component reaction, which allows rapid access 2-aminohydantoins, 
a biologically relevant motif. 
 
4.7 Experimental section 
General Experimental: 
All reagents were obtained from commercial suppliers (Aldrich, VWR, TCI Chemicals, and 
Oakwood Chemicals) and used without further purification unless otherwise noted.  N-benzoyl 
alanine was purchased from Oakwood Chemicals and all other N-benzoyl amino acids were 
synthesized according to literature procedures.126 Oxazolones were synthesized according to 
literature procedure.127  Reactions were monitored by thin layer chromatography (TLC), (obtained 
from sorbent technology Silica XHL TLC Plates, w/UV254, glass backed, 250 µm, 20 x 20 cm) 
and were visualized with ultraviolet light, potassium permanganate stain, GC-MS (QP 2010S, 
Shimadzu equipped with auto sampler) and 1H NMR 19F NMR. 
Isolations were carried out using Teledyne Isco Combiflash Rf 200i flash chromatograph with 
Sorbent normal phase silica (standard grade) (4 g, 12 g, 24 g, or 40 g) with product detection at 
254 and 288 nm and evaporative light scattering detection.  NMR spectra were obtained on a 400 
MHz Bruker Avance III spectrometer and 400 MHz Varian spectrometer.  1H, 19F and 13C NMR 
chemical shifts are reported in ppm relative to the residual protio solvent peak (1H, 13C).  IR spectra 
were recorded on Varian 800 FT-IR. Due to the C-F splitting, carbons that couple with fluorine 
were reported as multiplets. Melting points were determined on Stuart Digital (SMP10) melting 
point apparatus.  High resolution mass spectrometry (HRMS) analysis was performed on LTQ-
OrbitrapXL by Thermo Scientific ltd.  





Benzoyl chloride (1.2 equiv) was added incrementally in 4 portions over 30 minutes to a solution 
of the amino acid (1 equiv) and 2.5 M  NaOH (3.8 equiv) in distilled water. After the addition 
was complete, the ice bath was removed, and the reaction was quenched by the dropwise addition 
of concentrated aqueous hydrochloric acid until pH 1 was reached, which resulted in precipitation 
of the product. The solid product was isolated by filtration and then recrystallized from water. The 
resulting crystals were air dried to give the desired N-benzoyl amino acid, which showed no trace 
of benzoic acid by 1H NMR.  
 
S-1 in 93% yield after isolation (10.86 g, 60.9 mmol) as a white solid. 
The general procedure A was followed using glycine (5.00 g, 66.6 
mmol), benzoyl chloride (9.30 mL, 79.2 mmol), 2.5 M NaOH (100 mL, 251 mmol). 1H-NMR 
matched that previously reported in the literature.126 
 
 
S-2 in 79% yield after isolation (3.20 g, 11.9 mmol) as a white solid. The 
general procedure A was followed using phenyl alanine (2.50 g, 
15.1mmol), benzoyl chloride (2.11 mL, 18.1 mmol), 2.5 M NaOH (23.0 





S-3 in 66% yield after isolation (2.80 g, 11.1 mmol) as a white solid. The 
general procedure A was followed using methionine (2.50 g, 16.8 
mmol), benzoyl chloride (2.34 mL, 20.1 mmol), 2.5% NaOH (25.5 mL, 
63.8 mmol). 1H-NMR matched that previously reported in the literature.129 
 
 
S-4 in 67% yield after isolation (2.41 g, 10.2 mmol) as a white solid. The 
general procedure A was followed using leucine (2.00 g, 15.2 mmol), 
benzoyl chloride (2.12 mL, 18.3 mmol), 2.5% NaOH (23.1 mL, 57.8 
mmol). 1H-NMR matched that previously reported in the literature.128 
 
General procedure B: for synthesis of oxazolones 
 
To a flame dried round bottom flask a suspension of N-benzoyl amino acid (1 equiv) in dry CH2Cl2 
(0.07 M), under an argon atmosphere, at 0 ºC, was added EDC HCl (1.1 equiv). The materials 
were stirred at 0 ºC for 1 hour. The reaction mixture was diluted with an equal volume of CH2Cl2, 
and washed successively with water, saturated aqueous NaHCO3, and water (each 1/2 the volume 
of the organic phase), then dried over MgSO4 and concentrated under reduced pressure. (Note: the 
oxazolones are moisture and thermally sensitive reagents. As a precaution the oxazolones were 




S-5 in 80% yield after isolation (1.80 g, 11.1 mmol) as a pale white 
solid. The general procedure B was followed using N-benzoyl glycine 
(2.50 g, 14.0 mmol), EDC (2.38 g, 15.3 mmol), CH2Cl2 (200 mL). 1H-
NMR matched that previously reported in the literature.127 
S-6 in >95% yield after isolation (907 mg, 5.18 mmol) as a white solid. 
The general procedure B was followed using N-benzoyl alanine (1.00 
g, 5.18 mmol), EDC (884 mg, 5.69 mmol), CH2Cl2 (74 mL). 1H-NMR 
matched that previously reported in the literature.127 
 
S-7 in 87% yield after isolation (806 mg, 3.21 mmol) as a white solid. 
The general procedure B was followed using N-benzoyl 
phenylalanine (990 mg, 3.68 mmol), EDC (628 mg, 4.04 mmol), 
CH2Cl2 (52.5 mL). 1H-NMR matched that previously reported in the 
literature.127 
 
S-8 in 74% yield after isolation (1.1 g, 4.68 mmol) as a pale white solid. 
The general procedure B was followed using N-benzoyl methionine 
(1.6 g, 6.32 mmol), EDC (1.08 g, 6.95 mmol), CH2Cl2 (90.2 mL). H-
NMR matched that previously reported in the literature.129 
 
S-9 in 95% yield after isolation (553 mg, 2.45 mmol) as a pale white 
solid. The general procedure B was followed using N-benzoyl leucine 
(610 mg, 2.59 mmol), EDC (443 mg, 2.85 mmol), CH2Cl2 (37.0 mL). 










2-(perfluorophenyl)benzo[d]oxazole as a white solid in 33% yield. 2-
(perfluorophenyl)benzo[d]oxazole was prepared by following the literature procedure.40 
Triethylamine (1.7 g, 16.9 mmol) was added dropwise to a solution of 2-aminophenol (1.4 g, 12.7 
mmol) and pentafluorobenzoyl chloride (3.2 g, 14.1 mmol) in ethyl acetate (50 mL). The mixture 
was refluxed overnight and then aq NaOH (1M, 30 mL) was added and stirred for 3 hours at room 
temperature. The resulting mixture was extracted with EtOAc (5 × 20 mL) and washed with H2O 
(25 mL) and brine (25 mL). The organic layer was dried over anhydrous MgSO4 to yield 4 g of 
intermediate. Next, P2O5 (4.0 g, 28 mmol) was added to the intermediate and then heated at 175 
ºC for 1 hour. After the mixture had cooled to room temperature, ice water (50 mL) was added 
and mixture was extracted with EtOAc (5 × 20 mL). The combined organic layers were washed 
with aq NaOH (0.25 M, 50 mL), followed by water, brine and dried over anhydrous MgSO4 and 
then concentrated in vacuo to afford the crude product. The resultant crude residue was purified 
by automated flash chromatography (hexane:EtOAc 90:10) to give the product (1.2 g, 4.2 mmol), 







Halogen selectivity experiment:  
 
 
Under an argon atmosphere, oxazolone (50 mg, 0.310 mmol, 1 equiv), 4-chloro-2,3,5,6-
tetrafluoropyridine (69 mg, 0.372 mmol, 1.2 equiv), and CH3CN (0.310 mL, 1 M) were added to 
small test tube, which was fitted with a septum.  Then a steady stream of 1,8-
diazabicyclo(5.4.0)undec-7-ene (95 uL, 0.651 mmol, 2.1 equiv) was added down the side of the 
test tube glass. The mixture was allowed to react for 30 min. The reaction was quenched by the 
addition of a trifluoroacetic acid/ethanol) solution (47.4 uL, 0.620 mmol, 2 equiv/0.620 mL of 
ethanol). The solution was concentrated and then diluted with CHCl3 (5 mL) which was then 
washed with 1 M HCl brine solution (2.5 mL x 3).  The organic layer was dried with MgSO4, 
filtered, and concentrated to give the crude product, which was purified by column 
chromatography. The para/ortho product ratio was determined by integrations of peaks in the 1H 
and 19F NMR.  
 
Synthesis of perfluoroaryl-N-benzoyl amino acids/esters 
 





Under an argon atmosphere, oxazolone (1 equiv), ArF–F (1.025 equiv), and CH3CN (1 M) were 
added to small test tube, which was fitted with a septum and cooled to -20 ºC.  Then a steady 
stream of tetramethylguanidine (2.05 equiv) was added down the side of the test tube glass which 
facilitated the cooling of the TMG solution prior to dissolution.  The mixture was allowed to react 
for 30 min, then the cooling bath was removed, and the reaction was left to warm to room 
temperature.  The reaction was quenched by the addition of a trifluoroacetic acid/alcohol 
(methanol or ethanol) solution (2 equiv/double volume).  The solution was concentrated and then 
diluted with CHCl3 which was then washed with 1 M HCl brine solution (half the volume of 
organic layer x 3).  The organic layer was dried with MgSO4, filtered, and concentrated to give 
the crude product, which was purified by column chromatography.  
 
 
General procedure D for synthesis of N-benzoyl perfluoroaryl-amino esters 2f, 2g, and 2h. 
 
 
Under an argon atmosphere, oxazolone (1 equiv), ArF–F (1.025 equiv), and CH3CN (1 M) were 
added to small test tube, which was fitted with a septum. Then a steady stream of 1,8-
diazabicyclo(5.4.0)undec-7-ene (2.05 equiv) was added down the side of the test tube glass. The 
mixture was allowed to react for 30 min. The reaction was quenched by the addition of a 
trifluoroacetic acid/alcohol (methanol or ethanol) solution (2 equiv/double volume). The solution 
was concentrated and then diluted with CHCl3 which was then washed with 1 M HCl brine solution 
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(half the volume of organic layer x 3).  The organic layer was dried with MgSO4, filtered, and 
concentrated to give the crude product, which was purified by column chromatography. 
 
General procedure E for synthesis of N-benzoyl perfluoroaryl-amino acids 3a, 3b, 3c, 3d, and 
3e. 
 
Under an argon atmosphere, oxazolone (1 equiv), ArF–F (1.025 equiv), and CH3CN (1 M) were 
added to small test tube, which was fitted with a septum and cooled to -20 ºC.  Then a steady 
stream of tetramethylguanidine (2.05 equiv) was added down the side of the test tube glass which 
facilitated the cooling of the TMG solution. The reaction was left to react for 30 min and then the 
cooling bath was removed, and the reaction was allowed to warm to room temperature and 
subsequently quenched by the addition of 6 M HCl. The solution was concentrated and extracted 
with CHCl3, and then the organic layer was washed with half volumes of a 1 M HCl-brine solution 
x 3. The organic layer was dried with MgSO4 and concentrated giving crude product. Purification 
of the crude product can be accomplished without chromatography by adding hexanes to a round 
bottom flask containing the crude product then carefully adding dichloromethane dropwise until 
the hexanes becomes yellow and a colorless solid is left behind. The solid was filtered and air 








General procedure F for synthesis of N-benzoyl perfluoroaryl-amino esters 6a, 6b, 6c, and 6d. 
 
 
Under an argon atmosphere, oxazolone (1 equiv), ArF-F (1.025 equiv), CH3CN (1 M) were added 
to small test tube which was fitted with a septum.  Then a steady stream of DIPEA (10 equiv) was 
added to mixture. While stirring vigorously (note: the reaction mixture is biphasic), the reaction 
was left to react for 30 min. After 30 min. the bottom layer was separated and quenched by the 
addition of a trifluoroacetic acid/alcohol (methanol or ethanol) solution (20 equiv/20 equiv). The 
solution was concentrated and then diluted with CHCl3 which was then washed with 1 M HCl-
brine solution (half the volume of organic layer x 3).  The organic layer was dried with MgSO4, 
filtered, and concentrated to give the crude product, which was purified by column 
chromatography. 
 
2a methyl 4-(1-benzamido-2-methoxy-2-oxoethyl)-2,3,5,6-tetrafluorobenzoate 
Colorless oil,98.5% yield (122 mg, 0.305 mmol). 
The general procedure C was followed using 2-phenyloxazol-5(4H)-
one (50.0 mg, 0.310 mmol), 2,3,4,5,6 pentafluorobenzoate (67.4 mg, 
0.318 mmol), tetramethylguanidine (73.2 mg, 0.636 mmol), 0.310 mL 
of MeCN and trifluoroacetic acid (70.7 mg, 0.620 mmol)/methanol 
(0.620 mL) was used  to afford 2a. FT-IR (neat) cm-1 1743, 1754, 1680, 
1085.  1H NMR (400 MHz, Chloroform-d) δ 7.80 (d, J = 7.3 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 
7.45 (t, J = 7.6 Hz, 2H), 7.36 (d, J = 6.5 Hz, 1H), 6.22 (d, J = 6.7 Hz, 1H), 3.96 (s, 3H), 3.83 (s, 
3H). 19F NMR (376 MHz, Chloroform-d) δ -138.64 – -139.00 (m), -141.86 (q, J = 11.5 Hz). 13C 
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NMR (101 MHz, Chloroform-d) δ 168.9, 167.0, 160.3, 146.4 (ddt, J = 37.7, 15.2, 4.8 Hz), 143.9 
(ddt, J = 44.6, 15.2, 4.9 Hz), 133.2, 132.8, 129.2, 127.6, 119.9 (t, J = 15.6 Hz), 113.3 (t, J = 16.1 
Hz), 54.3, 53.8, 47.5. HRMS (ESI) C18H13F4NO5 calcd. [M+K]+ 438.0361 observed 438.0337. 
 
2b ethyl 2-(4-acetyl-2,3,5,6-tetrafluorophenyl)-2-benzamidoacetate 
Colorless oil, 80% yield (98.5 mg, 0.248 mmol). 
The general procedure C was followed using 2-phenyloxazol-
5(4H)-one (50 mg, 0.310 mmol), 2’,3’,4’,5’,6’ 
pentafluoroacetophenone (66.8 mg, 0.318 mmol), 
tetramethylguanidine (73.2 mg, 0.636 mmol), trifluoroacetic acid 
(70.7 mg, 0.620 mmol)/ethanol (0.620 mL) and 0.310 mL of MeCN 
was used  to afford 2b. FT-IR (neat) cm-1 1730, 1756, 1655, 1105.  1H NMR (400 MHz, 
Chloroform-d) δ 7.80 (d, J = 7.1 Hz, 2H), 7.53 (t, J = 7.4 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 7.39 
(d, J = 6.4 Hz, 1H), 6.17 (d, J = 6.4 Hz, 1H), 4.32 (dq, J = 10.8, 3.7 Hz, 2H), 2.60 (t, J = 1.6 Hz, 
3H), 1.26 (t, J = 7.1 Hz, 3H). 19F NMR (376 MHz, Chloroform-d) δ -141.34 (dd, J = 22.3, 13.2 
Hz), -141.72 (ddd, J = 21.9, 13.4 Hz. 13C NMR (101 MHz, Chloroform-d) δ 192.3, 168.4, 167.0, 
146.1 (dd, J = 116.6, 6.9 Hz), 144.4 – 142.5 (m), 133.2, 132.7, 129.2, 127.6, 120.1 (t, J = 16.9 
Hz), 119.7 (t, J = 15.6 Hz), 63.7, 47.7, 32.8, 14.4. HRMS (ESI) C19H15F4NO4 calcd. [M+Na]+ 








2c ethyl 2-benzamido-2-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)acetate 
White solid, 81% yield (106 mg, 0.251 mmol). 
The general procedure C was followed using 2-phenyloxazol-
5(4H)-one (50 mg, 0.310 mmol), octafluorotoluene (38 mg, 0.318 
mmol), tetramethylguanidine (73.2 mg, 0.636 mmol), trifluoroacetic 
acid (70.7 mg, 0.620 mmol)/ethanol (0.620 mL) and 0.310 mL of 
MeCN was used  to afford 2c. FT-IR (neat) cm-1 2496, 1756, 1659, 
1095. 1H NMR (400 MHz, Chloroform-d) δ 7.81 (d, J = 7.8 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.49 
– 7.35 (m, 3H), 6.18 (d, J = 6.3 Hz, 1H), 4.32 (qd, J = 10.8, 3.7 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H). 
19F NMR (376 MHz, Chloroform-d) δ -56.48 (t, J = 21.7 Hz), -139.84 (ddt, J = 30.4, 21.7, 11.5 
Hz), -140.84 (td, J = 15.6, 5.6 Hz). 13C NMR (101 MHz, Chloroform-d) δ 167.7, 166.7, 145.9 (dd, 
J = 113.0, 15.4 Hz), 143.3 (dd, J = 121.4, 15.4 Hz), 132.6, 132.4, 128.8, 127.2, 121.0 (t, J = 15.4 
Hz), 120.6 (d, J = 274.7 Hz), 110.7 – 109.0 (m), 63.5, 47.3, 13.9. HRMS (ESI) C18H12F7NO3 calcd. 
[M+]+ 423.0700 observed 423.0698. 
 
2d ethyl 2-benzamido-2-(perfluoropyridin-4-yl)acetate 
Pale white solid,79% yield (87 mg, 0.245 mmol). 
The general procedure C was followed using 2-phenyloxazol-
5(4H)-one (50 mg, 0.310 mmol), pentafluoropyridine (53.8 mg, 0.318 
mmol), tetramethylguanidine (73.2 mg, 0.636 mmol), trifluoroacetic 
acid (70.7 mg, 0.620 mmol)/ethanol (0.620 mL) and 0.310 mL of 
MeCN was used  to afford 2d. FT-IR (neat) cm-1 1756, 1669, 1630, 1090.  1H NMR (400 MHz, 
Acetonitrile-d3) δ 7.83 (d, J = 8.1 Hz, 2H), 7.78 (d, J = 6.0 Hz, 1H), 7.58 (t, J = 7.4 Hz, 1H), 7.48 
(t, J = 7.6 Hz, 2H), 6.27 (d, J = 7.2 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H). 19F 
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NMR (376 MHz, Acetonitrile-d3) δ -92.87 – -93.35 (m), -144.21 – -144.65 (m). 13C NMR (101 
MHz, Acetonitrile-d3) δ 167.9, 167.7, 145.7 – 142.9 (m), 141.7 (dd, J = 258.7, 35.3 Hz), 133.9, 
133.2, 131.3 (t, J = 14.9 Hz), 129.6, 128.4, 63.9, 48.2, 14.1. HRMS (ESI) C16H12F4N2O3 calcd. 
[M+K]+ 395.0416 observed 395.0405. 
 
2e methyl 2-benzamido-2-(3-chloro-2,5,6-trifluoropyridin-4-yl)acetate 
Yellow solid, 85% yield (178 mg, 0.487 mmol). 
The general procedure C was followed using 2-phenyloxazol-5(4H)-
one (100 mg, 0.621mmol), 3-chloro-2,4,5,6 tetrafluoropyridine 
(118.0mg, 0.636 mmol), tetramethylguanidine (145 mg, 1.27 mmol), 
trifluoroacetic acid (141 mg, 1.24 mmol)/methanol (1.24 mL) and 0.621 
mL of MeCN was used  to afford 2e. FT-IR (neat) cm-1 1731, 1640, 1680, 1085. 1H NMR (400 
MHz, Chloroform-d) δ 7.83 (d, J = 7.6 Hz, 2H), 7.58 (t, J = 7.2 Hz, 1H), 7.48 (m, J = 17.0, 9.2 
Hz, 3H), 6.37 (d, J = 5.7 Hz, 1H), 3.88 (s, 3H). 19F NMR (376 MHz, Chloroform-d) δ -72.87 (dd, 
J = 27.8, 12.3 Hz), -87.48 (dd, J = 21.4, 12.5 Hz), -143.98 – -144.42 (m). 13C NMR (101 MHz, 
Chloroform-d) δ 168.2, 167.1, 151.6 (dq, J = 244.4, 12.0, 3.0 Hz), 147.6 (ddd, J = 248.6, 17.4, 
13.5 Hz), 142.1 (ddd, J = 260.7, 27.2, 6.4 Hz), 139.8 (d, J = 12.3 Hz), 132.9, 132.9, 129.3, 127.7, 
113.6 (d, J = 41.9 Hz), 54.5, 50.40. HRMS (ESI) C15H10ClF3N2O3 calcd. [M+Na]+ 381.0224 
observed 381.0203. 
 
2f ethyl 2-benzamido-2-(perfluoronaphthalen-1-yl)acetate 
Yellow oil, 82% yield (69.2 mg, 0.254 mmol). 
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The general procedure D was followed using 2-phenyloxazol-
5(4H)-one (50 mg, 0.310 mmol), octafluoronapalene (86.5 mg, 0.318 
mmol), 1,8-diazabicyclo(5.4.0)undec-7-ene (96.7 mg, 0.636 mmol), 
trifluoroacetic acid (141 mg, 1.24 mmol)/ethanol (0.620 mL) and 
0.310 mL of MeCN was used  to afford 2f. FT-IR (neat) cm-1 2943, 
2849, 1760, 1677, 1085. 1H NMR (400 MHz, Chloroform-d) δ 7.74 (d, J = 7.2 Hz, 2H), 7.46 (t, J 
= 7.4 Hz, 1H), 7.37 (m, J = 7.5 Hz, 3H), 6.25 (d, J = 6.5 Hz, 1H), 4.23 (dq, J = 10.8, 7.1 Hz, 2H), 
1.18 (t, J = 7.1 Hz, 3H). 19F NMR (376 MHz, Chloroform-d) δ -120.69 (dd, J = 68.3, 18.5 Hz), -
138.91 (d, J = 16.6 Hz), -143.22 (dt, J = 68.3, 16.8 Hz), -145.79 (dt, J = 61.8, 17.5 Hz), -148.06 
(dt, J = 57.6, 18.0 Hz), -152.40 (t, J = 18.5 Hz), -154.99 (t, J = 20.3 Hz).  13C NMR (101 MHz, 
Chloroform-d) δ 168.8, 167.1, 151.3 (d, J = 266.9 Hz), 148.1 – 145.1 (m), 147.8 – 144.9 (m), 
143.1 (d, J = 54.7 Hz), 142.5 – 139.5 (m), 142.0 – 140.2 (m), 138.6 (dd, J = 118.3 Hz), 133.3, 
132.7, 129.2, 127.6, 115.8 (t, J = 18.0 Hz), 111.9 (t, J = 13.0 Hz), 108.7 – 108.1 (m), 63.7, 47.7, 
14.4. HRMS (ESI) C21H12F7NO3 calcd. [M+K]+ 498.0337 observed 498.0309. 
 
2g methyl 2-benzamido-2-(perfluoro-[1,1'-biphenyl]-4-yl)acetate 
Colorless oil, 82% yield (265 mg, 0.508 mmol). 
The general procedure D was followed using 2-phenyloxazol-5(4H)-
one (100 mg, 0.621mmol), decafluorobiphenyl (212.7 mg, 0.637 mmol), 
1,8-diazabicyclo(5.4.0)undec-7-ene (193 mg, 1.27 
mmol),trifluoroacetic acid (141 mg, 1.24 mmol)/methanol (1.24 mL) 
and 0.621 mL of MeCN was used  to afford 2g. FT-IR (neat) cm-1 2950, 
1744, 1634, 1085. 1H NMR (400 MHz, Chloroform-d) δ 7.85 (d, J = 7.1 
Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.48 (t, J = 7.5 Hz, 2H), 7.38 (d, J = 6.8 Hz, 1H), 6.31 (d, J = 
6.8 Hz, 1H), 3.88 (s, 3H). 19F NMR (376 MHz, Chloroform-d) δ -136.95 (dtt, J = 14.0, 6.0, 2.7 
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Hz), -137.40 (h, J = 10.4 Hz), -141.84 (q, J = 11.4 Hz), -149.85 (t, J = 21.0 Hz), -160.38 (tt, J = 
21.2, 5.4 Hz). 13C NMR (101 MHz, Chloroform-d) δ 169.1, 167.1, 147.1 – 145.5 (m), 146.4 – 
143.5 (m), 143.3 (dt, J = 14.4, 3.9 Hz), 139.6 (d, J = 8.5 Hz), 137.2 (dd, J = 14.0, 5.8 Hz), 133.2, 
132.9, 129.3, 127.7, 119.1 (t, J = 15.6 Hz), 107.1 (t, J = 16.2 Hz), 102.4 (t, J = 16.8 Hz), 54.4, 
47.5. HRMS (ESI) C23H12F9NO3 calcd. [M+H]+ 508.0590 observed 508.0545. 
 
2h ethyl 2-benzamido-2-(4-(benzo[d]oxazol-2-yl)-2,3,5,6-tetrafluorophenyl)acetate 
Pale white solid, 82% yield (120 mg, 0.254 mmol). 
The general procedure D was followed using 2-phenyloxazol-
5(4H)-one (50 mg, 0.310 mmol), 2-
(perfluorophenyl)benzo[d]oxazole (90.6 mg, 0.318 mmol), 1,8-
diazabicyclo(5.4.0)undec-7-ene (96.7 mg, 0.636 mmol), 
trifluoroacetic acid (70.7 mg, 0.620 mmol)/ethanol (0.620 mL) and 
0.310 mL of MeCN was used  to afford 2h. FT-IR (neat) cm-1 2950, 
1749, 1634, 1140, 1085, 1052. 1H NMR (400 MHz, Chloroform-d) δ 7.89 (d, J = 8.8 Hz, 1H), 
7.84 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 8.4 Hz, 1H), 7.55 (t, J = 7.4 Hz, 1H), 7.51 – 7.37 (m, 5H), 
6.26 (d, J = 6.6 Hz, 1H), 4.33 (dq, J = 7.7, 3.6 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H). 19F NMR (376 
MHz, Chloroform-d) δ -139.98 – -140.48 (m), -142.52 – -143.05 (m). 
13C NMR (101 MHz, Chloroform-d) δ 168.5, 167.1, 153.3, 150.9, 145.8 (ddt, J = 250.1, 14.3, 5.3 
Hz), 145.5 (ddt, J = 260.3, 15.6, 4.1 Hz), 141.6, 133.3, 132.8, 129.2, 127.7, 127.0, 125.6, 121.4, 
119.9 (t, J = 15.8 Hz), 111.5, 108.9 (t, J = 13.5 Hz), 63.8, 47.8, 14.4. HRMS (ESI) C24H16F4N2O4 
calcd. [M+Na]+ 495.0938 observed 495.0911. 
 
2i ethyl 2-benzamido-2-(4-cyano-2,3,5,6-tetrafluorophenyl)acetic acid 
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Yellow oil,79% yield (93.1 mg, 0.245 mmol). 
The general procedure A was followed using 2-phenyloxazol-
5(4H)-one (50 mg, 0.310 mmol), 2,3,4,5,6 pentaflurobenzonitrile 
(61.4 mg, 0.318 mmol), tetramethylguanidine (73.2 mg, 0.636 
mmol), trifluoroacetic acid (72.5 mg, 0.636 mmol)/ethanol (0.620 
mL) and 0.310 mL of MeCN was used  to afford 2i. FT-IR (neat) cm-
1 2933, 2250, 1714, 1083. 1H NMR (400 MHz, Chloroform-d) δ 7.72 (d, J = 7.4 Hz, 2H), 7.47 (t, 
J = 7.4 Hz, 1H), 7.43 – 7.29 (m, 3H), 6.08 (d, J = 5.9 Hz, 1H), 4.24 (qd, J = 10.7, 5.4 Hz, 2H), 
1.20 (t, J = 7.1 Hz, 3H). 19F NMR (376 MHz, Chloroform-d) δ -131.74 (td, J = 16.4, 6.7 Hz), -
139.49 (td, J = 16.3, 6.6 Hz). 
13C NMR (101 MHz, Chloroform-d) δ 167.3, 166.7, 148.5 – 146.1 (m), 148.6 – 145.7 (m), 145.9 
– 143.4 (m), 132.5, 132.4, 128.8, 127.2, 123.4 (t), 107.1, 63.6, 47.5, 13.9. HRMS (ESI) 
C18H12F4N2O3 calcd. [M+Na]+ 403.0676 observed 403.0654. 
 
3a 2-benzamido-2-(perfluoropyridin-4-yl)acetic acid 
White solid,85% yield (1.73 g, 5.27 mmol). 
The general procedure E was followed using 2-phenyloxazol-5(4H)-
one (1.00 g, 6.20 mmol), pentafluoropyridine (1.08 g, 6.36 mmol), 
tetramethylguanidine (1.46 g, 12.71 mmol), and 6.20 mL of MeCN was 
used  to afford 3a. FT-IR (neat) cm-1 3643, 2250, 1715, 1106. 1H NMR 
(400 MHz, Acetonitrile-d3) δ 7.95 – 7.73 (m, 3H), 7.60 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.6 Hz, 
2H), 6.26 (d, J = 6.9 Hz, 1H). 19F NMR (376 MHz, CD3CN) δ -93.07, -144.38. 13C NMR (101 
MHz, Acetonitrile-d3) δ 168.3, 167.7, 151.9 (dd, J = 240.4, 9.7 Hz), 148.1 (dq, J = 244.4, 17.6, 
13.9 Hz), 142.8 (ddd, J = 258.2, 27.4, 6.2 Hz), 141.1 (d, J = 12.7 Hz), 133.8, 133.2, 129.6, 128.4, 
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114.4 (dd, J = 35.3, 6.5 Hz), 50.8. HRMS (ESI) C14H8F4N2O3 calcd. [M+K]+ 367.0103 observed 
367.0083. 
 
3b 2-benzamido-2-(3-chloro-2,5,6-trifluoropyridin-4-yl)acetic acid 
Pale white solid, 86% yield (1.84 g, 5.33 mmol). 
The general procedure E was followed using 2-phenyloxazol-5(4H)-
one (1.00 g, 6.20 mmol), 3-chloro-2,4,5,6 tetrafluoropyridine (1.18 g, 
6.36 mmol), tetramethylguanidine (1.46 g, 12.71 mmol), and 6.20 mL of 
MeCN was used  to afford 3b. FT-IR (neat) cm-1 3604, 1722, 1664, 1085. 
1H NMR (400 MHz, Acetonitrile-d3) δ 7.82 (d, J = 7.4 Hz, 2H), 7.74 (d, J = 5.9 Hz, 1H), 7.57 (t, 
J = 7.4 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 6.34 (d, J = 6.6 Hz, 1H). 19F NMR (376 MHz, Acetonitrile-
d3) δ -76.02 (dd, J = 27.3, 12.5 Hz), -91.08 (dd, J = 21.1, 13.2 Hz), -144.77 (t, J = 24.3 Hz). 13C 
NMR (101 MHz, Acetonitrile-d3) δ 168.3, 167.7, 151.9 (dd, J = 240.4, 9.7 Hz), 148.1 (dq, J = 
244.4, 17.6, 13.9 Hz), 142.8 (ddd, J = 258.2, 27.4, 6.2 Hz), 141.1 (d, J = 12.7 Hz), 133.8, 133.2, 
129.6, 128.4, 114.4 (dd, J = 35.3, 6.5 Hz), 50.8. HRMS (ESI) C14H8ClF3N2O3 calcd. [M+Na]+ 
367.0068 observed 367.0047. 
 
3c 2-benzamido-2-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)acetic acid 
White solid, 82% yield (2.00 g, 5.06 mmol). 
The general procedure E was followed using 2-phenyloxazol-5(4H)-
one (1.00 g, 6.20 mmol), octafluorotoluene (1.50 g, 6.36 mmol), 
tetramethylguanidine (1.46 g, 12.71 mmol), and 0.620 mL of MeCN was 
used  to afford 3c. FT-IR (neat) cm-1 3590, 1743, 1653, 1076.  1H NMR 
(400 MHz, Acetonitrile-d3) δ 7.82 (d, J = 7.1 Hz, 2H), 7.74 (d, J = 6.5 
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Hz, 1H), 7.62 – 7.53 (m, 1H), 7.47 (t, J = 7.6 Hz, 2H), 6.22 (d, J = 7.0 Hz, 1H). 19F NMR (376 
MHz, Acetonitrile-d3) δ -57.30 (t, J = 21.8 Hz), -141.58 (td, J = 15.6, 6.2 Hz), -142.47 – -142.84 
(m). 13C NMR (101 MHz, Acetonitrile-d3) δ 168.5, 133.5, 167.3, 147.5 – 144.4 (m), 144.7 (dd, J 
= 256.6, 17.1 Hz), 132.7, 129.1, 127.9, 122.1 (t, J = 16.2 Hz), 47.3, 121.5 (d, J = 273.6 Hz), 110.5 
– 108.3 (m). HRMS (ESI) C8H11NOS calcd. [M+Na]+ 418.0285 observed 418.0276. 
 
3d 2-(4-acetyl-2,3,5,6-tetrafluorophenyl)-2-benzamidoacetic acid 
Colorless oil, 87% yield (99.6 mg, 0.270 mmol). 
The general procedure E was followed using 2-phenyloxazol-5(4H)-
one (50 mg, 0.310 mmol), 2’,3’,4’,5’,6’ pentafluoroacetophenone (66.8 
mg, 0.318 mmol), tetramethylguanidine (118.0mg, 0.636 mmol), and 
0.310 mL of MeCN was used  to afford 3d. FT-IR (neat) cm-1 3640, 1721, 
1630, 1006. 1H NMR (400 MHz, Acetonitrile-d3) δ 7.84 (d, J = 7.3 Hz, 
2H), 7.77 (d, J = 6.5 Hz, 1H), 7.58 (t, J = 7.4 Hz, 1H), 7.49 (t, J = 7.6 Hz, 2H), 6.14 (d, J = 6.7 
Hz, 1H), 2.60 (s, 3H). 19F NMR (376 MHz, Acetonitrile-d3) δ -143.02 (dd, J = 21.5, 12.8 Hz), -
143.63 (dd, J = 21.5, 12.9 Hz). 13C NMR (101 MHz, Acetonitrile-d3) δ 193.2, 169.6, 167.6, 147.5 
– 144.4 (m), 143.4 (dt, J = 14.8, 5.4 Hz), 134.1, 132.9, 129.5, 128.3, 120.7 (t, J = 16.4 Hz), 120.3 
(t, J = 17.1 Hz), 47.9, 32.6. 
 HRMS (ESI) C17H11F4NO4 calcd. [M+]+ 369.0624 observed 369.0601. 
 
3e 2-benzamido-2-(4-cyano-2,3,5,6-tetrafluorophenyl)acetic acid 
Yellow oil, 78% yield (85.1 mg, 0.241 mmol). 
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The general procedure E was followed using 2-phenyloxazol-5(4H)-one (50 mg, 0.310 mmol), 
2,3,4,5,6 pentaflurobenzonitrile (63.4 mg, 0.318 mmol), 
tetramethylguanidine (118.0 mg, 0.636 mmol), and 0.310 mL of MeCN 
was used  to afford 3e. FT-IR (neat) cm-1 3590, 2255, 1707, 1674. 1H 
NMR (400 MHz, Acetonitrile-d3) δ 7.82 (d, J = 7.3 Hz, 2H), 7.75 (d, J = 
6.2 Hz, 1H), 7.57 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 6.23 (d, J = 6.9 Hz, 1H). 19F NMR 
(376 MHz, Acetonitrile-d3) δ -134.83 (td, J = 15.8, 6.5 Hz), -140.78 (td, J = 15.8, 6.5 Hz). 13C 
NMR (101 MHz, Acetonitrile-d3) δ 168.6 , 167.7 , 148.1 (ddt, J = 259.1, 16.5, 3.9 Hz), 147.5 – 
144.4 (m), 147.4 – 144.2 (m), 133.8 , 133.1 , 129.5 , 128.4 , 124.3 (t, J = 16.2 Hz), 108.5 , 47.8. 
HRMS (ESI) C16H8F4N2O3 calcd. [M+Na]+ 403.0676 observed 403.0701. 
 
6a methyl 2-benzamido-2-(perfluoropyridin-4-yl)propanoate 
Colorless oil, 80% yield (81.2 mg, 0.228 mmol). 
The general procedure F was followed using 4-methyl-2-
phenyloxazol-5(4H)-one (50.0 mg, 0.285 mmol), pentafluoropyridine 
(49.5 mg, 0.293 mmol), N,N-diisopropylethylamine (368 mg, 2.85 
mmol), trifluoroacetic acid (650 mg, 5.7 mmol)/methanol (0.230 mL) 
and 0.285 mL of MeCN was used  to afford 6a. FT-IR (neat) cm-1 2833, 1740, 1634, 1095. 1H 
NMR (400 MHz, Chloroform-d) δ 7.81 (s, 1H), 7.77 (d, J = 7.2 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 
7.46 (t, J = 7.5 Hz, 2H), 3.89 (s, 3H), 2.22 (t, J = 3.3 Hz, 3H). 19F NMR (376 MHz, Chloroform-
d) δ -90.86 – -91.11 (m), -140.47 – -140.85 (m). 13C NMR (101 MHz, Chloroform-d) δ 172.4, 
166.2, 146.4 (dt, J = 180.2 Hz), 141.6 (dd, J = 261.0 Hz), 133.5, 132.8, 132.1 (t, J = 3.3 Hz), 129.2, 




6b methyl 2-benzamido-4-methyl-2-(perfluoropyridin-4-yl)pentanoate 
Colorless oil, 74% yield (136 mg, 0.340 mmol). 
The general procedure F was followed using 4 4-isobutyl-2-
phenyloxazol-5(4H)-one (100 mg, 0.460 mmol), pentafluoropyridine 
(79.7 mg, 0.472 mmol), N,N-diisopropylethylamine (595 mg, 4.6 
mmol), trifluoroacetic acid (1040 mg, 9.2 mmol)/methanol (0.372 mL) 
and 0.460 mL of MeCN was used  to afford 6b. FT-IR (neat) cm-1 2893, 
1711, 1637, 1105. 1H NMR (400 MHz, Chloroform-d) δ 7.80 (s, 1H), 7.76 (d, J = 8.3 Hz, 2H), 
7.54 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.8 Hz, 2H), 3.87 (s, 2H), 3.40 – 2.14 (m, 2H), 1.74 – 1.50 
(m, 1H), 0.96 (d, J = 6.6 Hz, 2H), 0.93 (d, J = 6.7 Hz, 2H). 
19F NMR (376 MHz, Chloroform-d) δ -90.47 – -91.21 (m), -138.40 – -140.05 (m). 13C NMR (101 
MHz, Chloroform-d) δ 170.6, 165.4, 145.4 – 142.3 (m), 140.6 (ddd, J = 261.1, 27.0, 5.2 Hz), 
132.9, 132.4 (t, J = 10.4 Hz), 128.7, 126.8, 62.9, 53.9, 40.9, 24.4, 23.9, 23.7. HRMS (ESI) 
C19H18F4N2O3 calcd. [M+H]+ 399.1326 observed 399.1299. 
 
6c methyl 2-benzamido-4-(methylthio)-2-(perfluoropyridin-4-yl)butanoate 
Colorless oil, in 79% yield (69.7 mg, 0.167 mmol). 
The general procedure F was followed using 4-(2-(methylthio)ethyl)-
2-phenyloxazol-5(4H)-one (50.0 mg, 0.212 mmol), pentafluoropyridine 
(36.8 mg, 0.218 mmol), N,N-diisopropylethylamine (274 mg, 2.12 
mmol), trifluoroacetic acid (483 mg, 4.24 mmol)/methanol (0.171 mL) 
and 0.212 mL of MeCN was used  to afford 6c. FT-IR (neat) cm-1 2799, 
1739, 1655, 1005. 1H NMR (400 MHz, Chloroform-d) δ 7.81 (s, 1H), 7.77 (d, J = 8.5 Hz, 2H), 
7.56 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 3.89 (s, 3H), 3.65 – 3.52 (m, 1H), 2.67 (dt, J = 
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14.2, 5.8 Hz, 1H), 2.61 – 2.50 (m, 1H), 2.39 – 2.27 (m, 1H), 2.09 (s, 3H). 19F NMR (376 MHz, 
Chloroform-d) δ -90.31 – -90.85 (m), -139.48 (t, J = 19.6 Hz). 13C NMR (101 MHz, Chloroform-
d) δ 170.5, 166.2, 145.9 – 142.9 (m), 141.4 (dd, J = 261.5, 35.0 Hz), 133.3, 132.9, 132.0 (t, J = 
10.4 Hz), 129.3, 127.5, 63.1, 54.9, 33.4, 28.8, 16.2. HRMS (ESI) C18H16F4N2O3S calcd. [M+H]+ 




Colorless oil, 71% yield (61.1 mg, 0.141 mmol). 
The general procedure F was followed using 4-benzyl-2-
phenyloxazol-5(4H)-one (50.0 mg, 0.199 mmol), pentafluoropyridine 
(34.5 mg, 0.204 mmol), N,N-diisopropylethylamine (257 mg, 1.99 
mmol), trifluoroacetic acid (453 mg, 3.98 mmol)/methanol (0.161 mL) 
and 0.199 mL of MeCN was used  to afford 6d. FT-IR (neat) cm-1 3080, 
1715, 1674, 1040. 1H NMR (400 MHz, Chloroform-d) δ 7.65 (d, J = 8.1 
Hz, 2H), 7.48 (dd, J = 13.9, 6.5 Hz, 2H), 7.39 (t, J = 7.6 Hz, 2H), 7.20 (d, J = 7.1 Hz, 3H), 6.94 
(d, J = 7.5 Hz, 2H), 4.57 (d, J = 13.5 Hz, 1H), 3.76 (s, 3H), 3.51 (d, J = 13.5 Hz, 1H). 19F NMR 
(376 MHz, Chloroform-d) δ -93.05 (ddd, J = 23.2, 14.8, 7.7 Hz), -144.30 – -144.54 (m). 13C NMR 
(101 MHz, Chloroform-d) δ 169.76, 166.49, 144.47 (dt, J = 244.2, 17.1 Hz), 141.44 (dd, J = 260.8, 
23.6 Hz), 134.4, 133.6, 132.9, 132.4 (t, J = 10.8 Hz), 130.5, 129.3, 129.0, 128.3, 127.5, 64.4, 54.5, 




General procedure G for the deprotection of perfluoroaryl-N-benzoyl amino acids 
 
The N-benzoyl amnio acid (1.0 equiv) and 12 M HCl (0.01 M) was added to a round bottom flask 
and heated to 60 0C.  The reaction was monitored by 19F NMR and after consumption of the starting 
material the mixture was diluted with a half volume of H2O and washed with equal volumes of 
toluene x3. The aqueous layer was concentrated in vacuo to give the product.  
4a carboxy(perfluoropyridin-4-yl)methanaminium chloride 
White solid, 99% yield (59 mg, 0.228 mmol). 
The general procedure G was followed using 2-benzamido-2-
(perfluoropyridin-4-yl)acetic acid (75 mg, 0.228 mmol) and 23.4 mL of 12 M 
HCl to afford 4a. FT-IR (neat) cm-1 3670, 3300, 1724, 1065. 1H NMR (400 
MHz, Deuterium Oxide) δ 5.52 (s, 1H). 19F NMR (376 MHz, Deuterium Oxide) 
δ -89.95 – -90.40 (m), -141.50 – -142.06 (m). 13C NMR (101 MHz, Deuterium Oxide) δ 167.55, 
143.47 (dt, J = 245.5, 16.5 Hz), 140.43 (dd, J = 260.6, 35.0 Hz), 125.36 (t, J = 16.6 Hz), 46.42. 
HRMS (ESI) C7H5F4N2O2Cl calcd. [M+]+ 259.9976 observed 259.9964. 
 
4b carboxy(3-chloro-2,5,6-trifluoropyridin-4-yl)methanaminium chloride 
White solid, in 99% yield (119 mg, 0.431 mmol). 
286 
 
The general procedure G was followed using 2-benzamido-2-(3-chloro-2,5,6-
trifluoropyridin-4-yl)acetic acid (150 mg, 0.435 mmol) and 43.5 mL of 12 M 
HCl to afford 4b. FT-IR (neat) cm-1 3683, 3300, 1715, 1034. 1H NMR (400 
MHz, Deuterium Oxide) δ 5.43 (s, 1H). 19F NMR (376 MHz, Deuterium Oxide) 
δ -72.70 – -141.42 (m), -84.21 – -93.07 (m), -141.39 . 13C NMR (101 MHz, Deuterium Oxide) δ 
167.2, 151.0 (dd, J = 243.5, 10.3 Hz), 147.0 (dt, J = 246.8, 14.6 Hz), 141.5 (dd, J = 260.3, 31.8 
Hz), 134.5 (d, J = 12.7 Hz), 114.1 (dd, J = 35.1, 4.9 Hz), 48.9. HRMS (ESI) C7H5F3N2O2Cl2 
calcd.[M+]+ 275.9680 observed 275.9672. 
 
4c carboxy(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)methanaminium chloride 
White solid, 99% yield (41.1 mg, 0.125 mmol). 
The general procedure G was followed using 2-benzamido-2-(2,3,5,6-
tetrafluoro-4-(trifluoromethyl)phenyl)acetic acid (50 mg, 0.127 mmol) and 12.7 
mL of 12 M HCl to afford 4c. FT-IR (neat) cm-1 3677, 3309, 1725, 1101. 1H 
NMR (400 MHz, Acetonitrile-d3) δ 3.63 (s, 1H). 19F NMR (376 MHz, 
Acetonitrile-d3) δ -57.28 , -136.68 – -138.28 (m), -140.91 . 13C NMR (101 MHz, 
Acetonitrile-d3) δ 165.4, 146.8 – 144.9 (m), 144.3 – 142.2 (m), 128.8 – 126.4 (m), 121.7, 115.5 – 
114.6 (m), 47.6. HRMS (ESI) C9H5F7NO2Cl calcd.[M+]+ 326.9897 observed 326.9888. 
 






The amino acid (1.0 equiv) and acetone 1 M was added to a round bottom flask with a magnetic 
stir bar was left to stir for 1 hour. The reaction was monitored by 19F NMR and after consumption 
of the starting material; the mixture was concentrated in vacuo to give the product. 
 
5a (perfluoropyridin-4-yl)methanaminium chloride 
White solid, 99% yield (12.4 mg, 0.0572 mmol) 
The general procedure H was followed using carboxy(perfluoropyridin-4-
yl)methanaminium chloride (15mg, 0.0576 mmol) and 57.6 uL of acetone to 
afford 5a. FT-IR (neat) cm-1 3603, 3287, 3044, 1015. 1H NMR (400 MHz, 
Deuterium Oxide) δ 4.36 (s, 1H). 19F NMR (376 MHz, Deuterium Oxide) δ -91.12 
(dq, J = 28.3, 13.1 Hz), -142.50 – -142.83 (m). 13C NMR (101 MHz, Deuterium Oxide) δ 13C 
NMR (101 MHz, Deuterium Oxide) δ 144.8 – 141.6 (m), 140.7 (dd, J = 259.7, 34.7 Hz), 125.4 (t, 
J = 15.9 Hz), 31.1. HRMS (ESI) C6H5F4N2Cl calcd. [M+]+ 216.0077 observed 216.0054. 
 
5b (3-chloro-2,5,6-trifluoropyridin-4-yl)methanaminium chloride 
White solid, 99% yield (16.9 mg, 0.0725 mmol). 
The general procedure H was followed using carboxy(3-chloro-2,5,6-
trifluoropyridin-4-yl)methanaminium chloride (25.0 mg, 0.0725 mmol) and 72.5 
uL of acetone to afford 5b. FT-IR (neat) cm-1 3632, 3250, 3033, 1055. 1H NMR 
(400 MHz, Deuterium Oxide) δ 4.51 (s, 1H). 19F NMR (376 MHz, Deuterium 
Oxide) δ -74.14 (dd, J = 27.7, 12.4 Hz), -88.82 (dd, J = 21.4, 12.4 Hz), -140.28 – -147.60 (m). 13C 
NMR (101 MHz, Deuterium Oxide) δ 151.0 (ddd, J = 242.5, 11.9, 2.9 Hz), 147.1 (ddd, J = 246.8, 
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17.6, 13.2 Hz), 141.9 (ddd, J = 259.0, 27.0, 6.4 Hz), 135.3 (d, J = 14.2 Hz), 114.1 (dd, J = 34.7, 
6.8 Hz), 34.1. HRMS (ESI) C6H5ClF3N2Cl calcd. [M+]+ 231.9782 observed 231.9799. 
 
5c (2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)methanaminium chloride 
White solid, 99% yield (10.7 mg, 0.027 mmol). 
The general procedure H was followed using carboxy(2,3,5,6-tetrafluoro-4-
(trifluoromethyl)phenyl)methanaminium chloride (15 mg, 0.038 mmol) and 38 uL 
of acetone to afford 5c. FT-IR (neat) cm-1 3609, 3277, 3064, 1077. 1H NMR (400 
MHz, DMSO-d6) δ 4.24 (s, 1H). 19F NMR (376 MHz, Deuterium Oxide) δ -57.69 
(t, J = 21.5 Hz), -139.33 (dt, J = 17.2, 9.5 Hz), -139.69 – -140.09 (m). 
13C NMR (101 MHz, DMSO-d6) δ 145.8 (d, J = 251.7 Hz), 143.6 (dt, J = 259.4, 18.4 Hz), 121.0 
(d, J = 276.2 Hz), 118.7 (d, J = 35.9 Hz), 108.9, 30.6. 
 HRMS (ESI) C8H5F7NCl calcd. [M+]+ 282.9999 observed 283.0023. 
 
Synthesis of 2-aminohydantoins 
General procedure I for synthesis of 2-aminohydantoins  
 
Under an argon atmosphere, oxazolone (1 equiv), ArF–F (1.025 equiv), CH3CN (1 M) were added 
to small test tube, which was fitted with a septum and cooled to -20 ºC.  Then a steady stream of 
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tetramethylguanidine (1.025 equiv) was added to mixture down the side of the test tube glass 
which facilitated cooling of the TMG solution.  The reaction was left to react for 30 min and then 
the cooling bath was removed.  After, the reaction had warmed to room temperature, then a 
solution of 12 M aqueous hydrochloric acid (0.1 M) was added and refluxed for 24-48 h. The 
solution was diluted with a half volume of water and made neutral with NaHCO3. The aqueous 
layer was extracted with EtOAc x 3 and the organic layer was dried with MgSO4 and concentrated 




White solid, 95% yield (314 mg, 1.08 mmol). 
The general procedure I was followed using 4-methyl-2-phenyloxazol-
5(4H)-one (200 mg, 1.14 mmol), pentafluoropyridine (66.8 mg, 1.17 mmol), 
tetramethylguanidine (135 mg, 1.17 mmol), 11.4 mL HCl, and 1.14 mL of 
MeCN was used  to afford 7a. FT-IR (neat) cm-1 3203, 2967, 1730, 1035. 1H 
NMR (400 MHz, DMSO-d6) δ 8.99 (s, 1H), 3.11 (s, 3H), 2.98 (s, 3H), 1.75 (s, 
3H). 
19F NMR (376 MHz, CD3CN) δ -143.03, -143.64. 19F NMR (376 MHz, DMSO-d6) δ -92.57 – -
93.01 (m), -140.20 – -140.83 (m). 13C NMR (101 MHz, DMSO-d6) δ 185.8, 169.9, 145.0 – 141.5 
(m), 142.6 – 138.8 (m), 133.1 (t, J = 10.6 Hz), 64.5, 38.1, 36.2, 23.9. HRMS (ESI) C11H10F4N4O 
calcd. [M+K]+ 329.0422 observed 329.0456. 
 
7b 5-benzoyl-2-(dimethylamino)-5-(perfluoropyridin-4-yl)-1,5-dihydro-4H-imidazol-4-one 
Yellow oil, in 49% yield (37.1 mg, 0.0975 mmol). 
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The general procedure I was followed using 4-benzyl-2-phenyloxazol-
5(4H)-one (50 mg, 0.199 mmol), pentafluoropyridine (34.5 mg, 0.204 mmol), 
tetramethylguanidine (23.5 mg, 0.204 mmol), 1.99 mL HCl, and 0.199 mL of 
MeCN was used  to afford 7b. FT-IR (neat) cm-1 3222, 2957,  1710, 1005. 1H 
NMR (400 MHz, DMSO-d6) δ 8.69 (s, 1H), 7.23 (s, 5H), 3.51 (q, J = 13.0 Hz, 
2H), 2.86 (s, 3H), 2.72 (s, 3H). 19F NMR (376 MHz, DMSO-d6) δ -92.27 – -92.81 (m), -138.65 – 
-138.98 (m). 13C NMR (101 MHz, DMSO-d6) δ 183.2, 169.7, 145.23 – 142.16 (m), 142.13 – 
138.90 (m), 133.76, 132.87 (t, J = 10.9 Hz), 130.5, 127.6, 126.9, 78.6, 69.3, 37.7, 35.9. HRMS 




Yellow solid, 60% yield (45.6 mg, 0.127 mmol). 
The general procedure was followed using 4-(2-(methylthio)ethyl)-2-
phenyloxazol-5(4H)-one (50 mg, 0.212 mmol), pentafluoropyridine (36.8 
mg, 0.218 mmol), tetramethylguanidine (25.1 mg,0.218 mmol), 2.12 mL 
HCl, and 0.212 mL of MeCN was used  to afford 7c. FT-IR (neat) cm-1 
2897, 2860, 1734, 1091. 1H NMR (400 MHz, DMSO-d6) δ 8.71 (s, 1H), 
3.11 (s, 3H), 3.01 (s, 3H), 2.56 (d, J = 2.7 Hz, 1H), 2.46 – 2.26 (m, 2H). 
19F NMR (376 MHz, DMSO-d6) δ -92.35 – -92.61 (m), -139.85 – -140.08 (m). 13C NMR (101 
MHz, DMSO-d6) δ 183.7, 170.3, 145.5 – 142.6 (m), 142.4 – 138.9 (m), 132.5 (t, J = 11.0 Hz), 






NMR spectra  
Figure 4.4 Chapter IV NMR Spectrum Graphs 
























































































































































































































































































































































































































































































































































































FACILE FORMATION OF NON-NATURAL α,α-DISUBSTITUTED AMINO 
ESTERS VIA CATALYTIC MICHAEL ADDITION 
 
 
5.1 Historical background  
With their immense importance to the human condition, it is not surprising that 
methodology aimed. Not surprisingly, methodology aimed at derivatizing α-amino acids has 
received much attention.131-135  To perform selective carbon framework modifications of amino 
acids, one must contend with the presence of N–H units that are more acidic than the latent C–H. 
The use of a Schiff base is one strategy to alkylate an amino ester (Scheme 5.1A)136 this removes 
the acidic N–H proton and acidifies the C–H, facilitating formation of the requisite enolate.137-143 
Nature accesses the requisite enolate via the cyclized/dehydrated aromatic oxazolone, using it to 
epimerize α-stereocenters.144  Indeed, the oxazolone enolate will react with a number of 
electrophiles, including Michael acceptors107, 118, 128, 145-148 and is a common strategy for amino acid 




whether the enolate could be directly utilized without the need for an enolate surrogate (Scheme 
5.1C).While Michael addition to an amino ester enolate has not been explored (Scheme 5.1E), the 
C-alkylation with alkyl halides (Scheme 5.1C-D) has been extensively utilized.150-154  However, 
despite its use in the literature, key mechanistic questions remain unanswered especially 
concerning the degree of deprotonation of the requisite enolate involved in the alkylation.150-152, 
155-157 
In 1976, Krapcho proposed that under basic conditions N-acyl or carbamate protected 
amino esters must react through a dianion intermediate158 (Scheme 5.1C).  This logically stems 
from the fact that alkylation occurs at the less acidic α-carbon rather than at the more acidic N–H, 
and therefore must take place through the dianion in which the less stable carbanion reacts first.  
In 1985, Hoye159 proposed an alternative mechanism in which the substrate first undergoes a 
kinetic deprotonation of the N–H with stoichiometric base, followed by a proton transfer from the 
C–H to generate the reactive monoanionic enolate (Scheme 5.1D). We reasoned if Hoye’s 
hypothesis were true, then addition of an amino ester to a Michael acceptor could regenerate the 




Scheme 5.1. The use of enolates and equivalents to access α,α-disubstituted amino acids 
 
5.2 Optimization studies 
We initiated our investigation using the conveniently synthesized N-benzoyl 
perfluoropyridinyl glycine (A, Table 5.1).160 We anticipated that the perfluoroaryl unit would 
acidify the αC–H and tilt the equilibrium towards the enolate.  To A we added Hünigs base 
(DIPEA, 3 equiv) and methyl vinyl ketone (MVK, 3 equiv) in acetonitrile (0.5 M) (entry 1).  
Within 36 h we observed complete conversion of the starting material to a product alkylated at the 
carbon rather than at the nitrogen, and were able to isolate it in near quantitative yield. 
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1. 3 DIPEA 300        22 36 100 >99 
2. 3 TMG 105       -20 1 100 >99 
3.   3 DBU 105 -20 1 71 64 
 4. 3 NaOH 105 -20 1 100 92 
5. 1.05 TMG 105 -20 1 100 >99 
6. 1.05 TMG 10 -20 1 100 >99 
7. 1.05 TMG 1.0 -20 1 100 >99 
8. 1.05 TMG 0.1 45 48 <3 <3 
9. 1.05 MTBD 0.1 -20 1 100 >99 
10. 1.05 MTBD 0.1 22 1 100 >99 
a. Conversion determined by 19F NMR.  b. Yields determined by 19F NMR relative to 
trifluoroacetic acid as internal standard.   
 
While full conversion was achieved, the rate was rather modest. Switching to a stronger base 
such as tetramethylguanidine (TMG) (TMG-H+, pKa in MeCN = 23.3 vs. ~18.8 for DIPEA-H+)114 
or NaOH, substantially increased the rates, and the reaction completed within 1 h (Table 5.1, 
entries 2-4).  Despite its enhanced basicity, DBU (pKa in MeCN = 24.3)161 failed to give 
comparable rates and over time led to unidentified by-products in 19F NMR spectra. Using TMG, 
we next attempted to lower the base loading and run the reaction catalytically.  We observed 
complete conversion using catalyst loadings of both 10 and 1 mol% (entries 6 and 7). However, 
upon dropping the loading to 0.1 mol% TMG, no product was observed (entry 8).  This lack of 
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reactivity could potentially be due to trace acidic impurities in the reaction mixture.  However, we 
have previously observed TMG undergoing N–substitution of aromatic fluorides when subjected 
to highly electrophilic perfluoroaryl derivatives and could also explain the observation.162-163 Upon 
switching to the bulky bicyclic superbase, MTBD (7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene, 
pKa 25.4 in MeCN),164 the catalytic activity was completely restored using just 0.1 mol% both at 
room temperature and -20 oC (entries 9-10). 
 
5.3 Substrate scope 
Satisfied, we next investigated the substrate scope of the Michael acceptor (Scheme 5.2A). The 
reaction is quite general and, in addition to MVK (2a), will abide many commercially available 
mono-substituted Michael acceptors.  Both ethyl and t-butyl acrylates (2b and 2c) gave excellent 
yields, though a subtle difference was observed, potentially due to the greater steric demand of the 
t-butyl acrylate.  Acrylonitrile gave nearly quantitative yield (2d), as did unsaturated sulfones (2e 
and 2f). Diactivated fumaronitrile also underwent addition, giving a diastereomeric ratio of 1.5/1 
(2g). Resubjecting the product to the catalyst and solvent resulted in the erosion of the dr to 1.2/1, 
suggesting that selectivity may be challenging to maintain. Additionally, N-phenylmaleimide (2h) 
worked under these conditions, albeit at a noticeably diminished rate compared to the mono-
substituted alkenes, but nonetheless resulted in high yield of a mixture of diastereomers, which 
could be partially resolved upon isolation. It is worth noting that reaction with nitroalkenes failed 
to give the product and instead appeared to react with the base.  Additionally, many α-substituted 






Scheme 5.2. Exploration of the Michael acceptor, α-substituent, and the amino protecting 
group 
 




Next, we explored the scope of the aryl side chain (Scheme 5.2B). More acidic substrates (3a and 
3b) underwent smooth addition. It is noteworthy that Touzin136 observed that N,N-dimethyl-α-
amino ester enolates readily undergo 1,2-addition to ketones, whereas we exclusively observed 
1,4-addition to α,β-unsaturated ketones (2a, and 3a-3h).  In fact, not even in the case of activated 
perfluoroaryl ketones (3c), did we observe 1,2-addition.  Perfluoroarylesters (3d) and less 
stabilized enolates like perfluorobiphenyl, perfluoronapthalene amino esters (3e and 3f), and even 
trifluorophenyl glycine (3g), 4-Cl-phenyl glycine (3h), and phenylglycine (3i) worked well and 
gave excellent yields.  However, attempts to use benzoyl protected glycine (3j) failed to produce 
any product, even with elevated temperatures and higher catalyst loading. 
Next, to make the reaction more broadly useful, we investigated the nitrogen protecting groups 
standard to peptide coupling for the phenyl glycine methyl ester (Scheme 5.2C). We found that 
both N-Boc (4a) and N-Cbz (4b) protecting groups facilitated smooth addition, giving similar 
yields to the N-benzoyl group. Not surprisingly, when we attempted to use the base-labile N-Fmoc 
protected phenyl glycine the substrate underwent decomposition (4c).  
5.4 DFT calculations 
Next, we turned our attention to the reaction mechanism.  While Hoye’s mono-
anion/proton shift mechanism seemed consistent (Scheme 5.1D), with certain substrates we 
qualitatively observed a rate dependence on the loading of the electrophile which appeared to be 
greater than first order.  We wondered if the first step of the reaction might be an aza-Michael 
addition (Scheme 5.3)., which effectively removes the more acidic N–H, allowing the base to 
deprotonate the αC–H. This would generate the requisite enolate, which would then undergo 





Scheme 5.3 Retro-aza-Michael reaction 
 
In order to probe the idea of temporarily masking the acidic proton, we minimized the 
geometries and calculated energies (Table 5.4) using DFT (B3LYP/6-311+G(2d,p)).  The N-
alkylated species (comp-B, Table 5.4) was endothermic by 1.7 kcal/mol when compared to the 
starting materials, but +9.5 kcal/mol when compared to the C-alkylated final product (comp-C).  
The endothermic nature of the N-alkylation is reasonable, considering that there are no examples 
in the literature of the product of an aza-Michael addition to an α-amino acid derivative, perhaps 




Table 5.3 DFT calculations: B3LYP/6-311+G(2d,p) optimized geometries for starting 
materials and products.  
 
Below are various searches (Search 1-3) conveying reactions of aza-michael type 
observed in literature and SciFinder searches were performed on the latest online version. After 
conducting a search on SciFiner consisting of a amide and a Michael accepotr, it was found that 
indeed an Aza-Micheal type of reaction is known and well explored (Search 1). The first search 
(Search 1) clearly shows the aza-Micheal to form a tertiary nitrogen is possible. However, looking 
at the subset of products that consisted of an alpha-amino carbonyl motif that (similar to our 
products), no products were found (Search 2). Moreover, when starting with an alpha-amino 
carbonyl (Search 3) 71 hits were observed. Most of these examples were either irrelevant or 
unique multistep cases. These searches give support to the endothermic nature of N-alkylation 




Thus, our calculations explained why the N-alkylated product was never observed, but 
suggested comp-A and comp-B were energetically close enough to allow for transient N-
alkylation.  To probe this scenario, we subjected unreactive N-Bz glycine methyl ester (Scheme 
5.2B, 3j) to modified conditions, allowing us to study the proposed first step, reversible N-






5.5 (retro)aza-Michael reaction study 
Upon exposure of the protected glycine (Scheme 5.3, A) to MTBD and CD3OD, rapid deuterium 
incorporation was observed at N (int-1).  Then, protio-MVK was added to the reaction mixture.  
As expected, no N- (int-2) or C-alkylation (3j) was observed.  Decisively, we did not observe 
deuterium scrambling into the MVK (D-MVK), which would support transient and reversible N-
alkylation. Thus, we concluded that the Aza-Micheal/C-Micheal/retro-aza-Micheal mechanism 
was not operative, and that Hoye’s mechanism was likely operative in our system. 
Scheme 5.4 (retro)aza-Michael reaction study 
 
5.6 Michael reaction of natural amino esters 
The implication was that substrates that underwent C–C bond formation were doing so because 
the lowered pKa of the αC–H allowed sufficient quantities of the reactive enolate to form.  
However, substrates devoid of acidifying functional groups, such as simple glycine and other α-
alkyl amino esters were not sufficiently acidic to form the requisite enolate.  To test this, we 
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examined commercially available Boc-protected trifluoroalanine methyl ester, which indeed gave 
4d (eqn 2) in 83% isolated yield. 
 
We postulated that we could selectively acidify the αC–H over the N–H by making the ester 
component more electron withdrawing.  The N-Bz trifluoroethyl esters of several natural amino 
acids, which were otherwise, unreactive (Scheme 5.4), provided the necessary acidification of the 
C–H to turn on reactivity.  Admittedly, the reactions are more sluggish than previous substrates, 
and required both higher catalyst loadings and higher temperatures, but nonetheless reached full 
conversion at room temperature.  Attempted reaction of the methyl ester indicated the essential 
nature of the trifluoroethyl ester component (5a vs 5b).  The trifluoroethyl esters facilitated both 
the desired reaction, but were also found to be prone to hydrolysis (from adventitious H2O). We 














Scheme 5.5 Michael reaction of natural amino esters 
 
Scheme 5.6 Failed experiments 
 
The N-Bz trifluoroethyl esters of several natural amino acids provided the necessary 
acidification of the C–H to turn on reactivity but when N-Boc-Phe trifluoroethyl ester was 
attempted the reaction gave no conversion (Scheme 5.5A). We are unsure of the reason why this 
reaction failed and it is even more puzzeling since previously N-Boc protected amino acids did 
convert to product.  Further investigation of this reaction would be worthwile.  
Probing if the NH of the reaction was important we applied the reaction conditions to 
proline which displays no NH. We were surprised to find out that the N-Bz-pro trifluoroethyl ester 
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failed to react (Scheme 5.5B). We speculated this could be due to stabilization of the carbonyl 
with the adjacent NH, but again this is a question we have yet to probe.  
5.7 Late-stage modification of peptides 
Having established the importance of the α-substituent in facilitating the reaction, we speculated 
we could use the difference in reactivity between α-aryl and α-alkyl amino acids to perform 
selective modification of peptides possessing such units.  We synthesized dipeptide Boc-Ala-Phg-
OMe to test our hypothesis and after subjecting the dipeptide to our reaction conditions (Scheme 
5.6, eqn 3), we were pleased to observe a single regioisomer in which C-alkylation occurred 
exclusively at the phenyl glycine subunit in good yield (6a, 73% yield, 92% BRSM).  The reaction 
took place with little stereoinduction (dr 1.2/1), leaving open the possibility of external control.  
Intrigued by this result we thought it would be worthwhile to apply our reaction conditions to the 
dipeptide Boc-Phe-Phg-OMe (Scheme 5, eq 4), where the amino acid subunits are reversed, and 
the phenyl glycine contains an amide instead of a methyl ester. We were pleased to observe the 
product where C-alkylation occurred exclusively at the phenyl glycine subunit but the rate was 
sluggish and the yield was significantly lower (6b, 38% yield dr 1.6/1, 69% BRSM). Earlier 
attempts to try to selectively alkylate peptides through multianion approaches were often fraught 
with solubility issues when dealing with polylithiated peptides at low temperatures.165-166  The 
monoanion approach circumvents this issue altogether.165, 167  We next examined the dipeptide 
DAPT which is a γ-secretase inhibitor168 and has been shown in vivo to selectively inhibit the 
formation α-amyloid168 involved in Alzheimer’s disease.168 More generally, it is thought to 
indirectly inhibit NOTCH, an important α-secretase substrate169 involved in autoimmune and 
proliferative diseases.169  Exposing DAPT to just 1.05 equivalents of MVK and 50 mol% MTBD 
led to full conversion to give 6c in 90% yield.  Similarly, the reaction was sluggish compared to 
the simple phenylglycine derivative.  One potential reason for this is the addition of H-bond 
donors, which could stabilize, and therefore, retard the attack of the requisite carbanion on the 
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electrophile.  Additionally, it is expected that there will be greater populations of unproductive 
aza-anions that must funnel to the reactive enolate.   
 
Scheme 5.7 Late-stage modification of peptides 
A deuterium labeling study indicated that both N–Hs exchanged, as did the αC–H of the 
phenylglycine unit.  No scrambling was observed at the corresponding alanine αC–H. The phenyl 
glycine methine integrations decreased displaying evidence of deuterium incorporation at the α-
carbon of the phenyl glycine subunit. Integrations observed: 0.51, 1.05, 3.00 (Phg-H, Ala-H, Phg-










Figure 5.1 Deuterium labeling study Phg vs. Ala 
 
In conclusion, we have investigated the direct activation of useful amino acid derivatives.  
In contrast to current alkylation strategies, we have demonstrated the ability to access the enolate 
through a strategy that involves funneling of a monoanion to the reactive carbanion.  The 
operational simplicity, high chemo-selectivity, and the fast rate of the reaction make it particularly 
attractive for further development.  This reaction significantly expands access to non-natural 
amino acids derivatives, as we have demonstrated strategies to elaborate both natural, non-natural 
amino esters, and the ability to selectively functionalize the more acidic residues within small 
peptides. 







All reagents were obtained from commercial suppliers (Aldrich, VWR, TCI Chemicals, and 
Oakwood Chemicals) and used without further purification unless otherwise noted.  Reactions 
were monitored by thin layer chromatography (TLC), (obtained from sorbent technology Silica 
XHL TLC Plates, w/UV254, glass backed, 250 µm, 20 x 20 cm) and were visualized with 
ultraviolet light, potassium permanganate stain, GC-MS (QP 2010S, Shimadzu equipped with auto 
sampler) and 19F and 1H NMR. 
Isolations were carried out using Teledyne Isco Combiflash Rf 200i flash chromatograph with 
Sorbtech normal phase silica (4 g, 12 g, 24 g, 40 g) with product detection at 254 and 288 nm and 
evaporative light scattering detection.  NMR spectra were obtained on a 400 MHz Bruker Avance 
III spectrometer and 400 MHz Varian spectrometer.  1H, 19F and 13C NMR chemical shifts are 
reported in ppm relative to the residual protio solvent peak or TMS signal.  IR spectra were 
recorded on Varian 800 FT-IR.   Mass spectra (HRMS) analysis was performed on LTQ-
OrbitrapXL by Thermo Scientific ltd using a Heated-electrospray ionization (H-ESI) source.  
 
Synthesis of N-acyl/carbamate amino esters  
II.i Procedures for the esterification of amino acids170 
 
S-1: 1-(4-Chlorophenyl)-2-methoxy-2-oxoethanaminium chloride. p-
Chlorophenylglycine (1 g, 5.39 mmol) was dissolved in MeOH (5 mL). 
The solution was cooled to 0 ◦C and thionyl chloride (0.78 mL, 10.8 mmol) 
was added dropwise. The reaction mixture was heated under reflux for 3 h. 
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Cooling to rt followed by concentration in vacuo afforded the title compound as a white solid (1.27 
g, quant.). Spectral data matched the literature values.170 
S-2: 1-(3,4,5-trifluoropheny)-2-methoxy-2-oxoethanaminium chloride. 
3,4,5-trifluorophenyglycine (2.0 g, 9.7 mmol) was dissolved in MeOH (30 
mL). The solution was cooled to 0 ◦C and thionyl chloride (1.4 mL, 19.5 
mmol) was added dropwise. The reaction mixture was heated under reflux 
for 3 h. Cooling to rt followed by concentration in vacuo afforded the title compound as a crude 
semi-white solid (2.3 g, 93%). The crude compound was moved to next step without further 
purification.  
 
 N-Acylation/protection of amino acids/esters 
  -General procedure A for the preparation of N-benzoyl-α-amino acids160 
 
 
Benzoyl chloride (1.2 equiv) was added in 4 portions over 30 minutes to a 0 ºC solution of the 
amino acid (1 equiv) and 10 % NaOH (3.8 equiv) in distilled water (open to air). After the addition 
was complete, the ice bath was removed, and the reaction was quenched by the dropwise addition 
of concentrated aqueous hydrochloric acid until pH 1 was reached, which resulted in the 
precipitation of the product. The solid was isolated by filtration and then recrystallized from water. 
The resulting crystals were air dried to give the desired N-benzoyl amino acid, which showed no 
trace of benzoic acid by 1H NMR. If benzoic acid was detected, the compound was stirred in cool 




N-benzoyl glycine: The general procedure A was followed using 
glycine (5.00 g, 66.6 mmol), benzoyl chloride (9.30 mL, 79.2 mmol), 10 
% NaOH (100 mL, 251 mmol) to afford the title compound in 93% yield after isolation (10.86 g, 
60.9 mmol) as a white solid. 1H-NMR matched previous literature.126 
 
N-benzoyl phenyl alanine: The general procedure A was followed 
using phenyl alanine (2.50 g, 15.1mmol), benzoyl chloride (2.11 mL, 
18.1 mmol), 10 % NaOH (23.0 mL, 57.4 mmol) to afford the title 
compound in 79% yield after isolation (3.2 g, 11.9 mmol) as a white solid. 1H-NMR matched 
previous literature.128 
 
N-benzoyl methionine: The general procedure A was followed using 
methionine (2.50 g, 16.8 mmol), benzoyl chloride (2.34 mL, 20.1 mmol), 
10 % NaOH (25.5 ml, 63.8 mmol) to afford the title compound in 79% 
yield after isolation (3.2 g, 11.9 mmol) as a white solid.  
1H-NMR matched previous literature.129 
 
N-benzoyl leucine: The general procedure A was followed using 
leucine (2.00 g, 15.2 mmol), benzoyl chloride (2.12 mL, 18.3 mmol), 10 
% NaOH (23.1 ml, 57.8 mmol) to afford the title compound in 67% yield 




N-benzoyl L-isoleucine: The general procedure A was followed using 
L-isoleucine (300 mg, 2.3 mmol), benzoyl chloride (0.32 mL, 2.7 mmol), 
10 % NaOH (23.1 mL, 8.7 mmol) to afford the title compound in 43% 
yield after isolation (247 mg, 0.99 mmol) as a white solid. 1H-NMR matched previous literature.171 
 
N-benzoyl Valine: The general procedure A was followed using leucine 
(1 g, 8.5 mmol), benzoyl chloride (1.2 mL, 10 mmol), 10 % NaOH (10 
mL, 25.5 mmol) to afford the title compound in 88% yield after isolation 
(1.64 g, 7.5 mmol) as a white solid. 1H-NMR matched previous literature.128 
 
-General procedure B for the preparation of N-benzoyl-α-amino esters172 
 
A solution of benzoyl chloride (1 equiv) in CH2Cl2 (2 M) was added dropwise to a suspension of 
the glycine methyl ester hydrochloride (1 equiv) and triethylamine (2.2 equiv) in CH2Cl2 (0.5 M) 
at 0 oC. The reaction mixture was stirred at room temperature for 18 h, it was washed with equal 
volumes of aq. HCl (3 x 1 M), saturated aq. NaHCO3 (3x) and saturated aq. NaCl, successively. 
Next the organic extract was dried (over MgSO4) and concentrated under reduced pressure. Then, 
the crude amide was purified via column chromatography. 
 
- General procedure C for the preparation of N-benzoyl-α-amino esters173 
N-Benzoyl amino acid (1 equiv), alcohol (3 equiv), EDC (1.5 equiv), DMAP (1 equiv) were 
dissolved in anhydrous DCM (0.2 M) and the reaction was stirred for 16 h at room temperature 
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under an argon atmosphere. The workup consisted of diluting solution with DCM and quenching 
with equal amount of water. The organic layer was separated and washed with equal amount of 
sat. NaHCO3 (3x), 0.01 M HCl (2x) (this step was omitted when synthesizing trifluoroethyl esters), 
and water twice.  The organic layer was separated, and the solution was concentrated under 
vacuum. Flash column chromatography was used to purify the desired compound. 
Methyl 2-benzamido-2-phenylacetate. The general procedure B was 
followed using the glycine methyl ester hydrochloride (1.00 g, 4.81 
mmol), benzoyl chloride (0.560 mL, 4.81 mmol), triethylamine (1.48 mL, 
10.6 mmol) to afford the title compound in 90% yield after isolation (1.17 
g, 4.34 mmol) as a white solid. 1H-NMR matched previous literature.174 
methyl 2-benzamido-2-(4-chlorophenyl)acetate. The general 
procedure B was followed using the 1-(4-Chlorophenyl)-2-methoxy-2-
oxoethanaminium chloride (1.5 g, 6.35 mmol), benzoyl chloride (0.740 
mL, 6.35 mmol), triethylamine (1.97 mL, 13.97 mmol) to afford the title 
compoound in 83% yield after isolation (1.6 g, 5.37 mmol) as a white solid. 1H NMR (400 MHz, 
Chloroform-d) δ 7.84 (d, J = 7.1 Hz, 2H), 7.55 (t, J = 8.0 Hz, 1H), 7.46 (t, J = 7.9 Hz, 2H), 7.43 – 
7.33 (m, 4H), 7.29 (d, J = 6.3 Hz, 1H), 5.77 (d, J = 6.7 Hz, 1H), 3.79 (s, 3H).13C NMR (101 MHz, 
Chloroform-d) δ 171.3, 166.6, 135.3, 134.6, 133.4, 132.1, 129.2, 128.8, 128.7, 127.3, 56.31, 53.2. 
 
methyl 2-benzamido-2-(3,4,5-trifluorophenyl)acetate. The general 
procedure B was followed using the 1-(3,4,5-trifluoropheny)-2-
methoxy-2-oxoethanaminium chloride. (0.700 mg, 2.74 mmol), benzoyl 
chloride (0.318 mL, 2.74 mmol), triethylamine (0.841 mL, 6.03 mmol) 
to afford the title compound in 71% yield after isolation (628 mg, 1.95 
mmol) as a white solid. 1H-NMR matched previous literature. 19F NMR (376 MHz, Chloroform-
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d) δ -131.81 – -134.40 (m), -160.07 (tt, J = 20.4, 6.4 Hz). 1H NMR (400 MHz, Chloroform-d) δ 
7.85 (d, J = 7.1 Hz, 2H), 7.57 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.5 Hz, 2H), 7.41 (d, J = 6.2 Hz, 1H), 
7.12 (dd, J = 7.9, 6.4 Hz, 2H), 5.72 (d, J = 6.4 Hz, 1H), 3.82 (s, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 13C NMR (101 MHz, Chloroform-d) δ 170.5, 166.7, 151.5 (ddd, J = 251.4, 10.2, 
3.9 Hz), 139.9 (dt, J = 253.0, 15.3 Hz), 133.1, 132.4, 128.9, 128.5, 127.8 – 126.4 (m), 113.3 – 
110.1 (m), 55.9 (d, J = 1.8 Hz), 53.6. 
methyl benzoylglycinate. The general procedure C was followed 
using the N-benzoyl glycine (250 mg, 1.40 mmol), methanol (0.170 mL, 
4.19 mmol), EDC (401 mg, 2.09 mmol), DMAP (170 mg, 1.40 mmol), 
and 7 mL of CH2Cl2 to afford the title compound in 73% yield after isolation (197 mg, 1.02 mmol) 
as a white solid. 1H-NMR matched previous literature.175  
methyl benzoylalaninate. The general procedure C was followed 
using the N-benzoyl alanine (300 mg, 1.55 mmol), methanol (0.188 mL, 
4.66 mmol), EDC (447 mg, 2.33 mmol), DMAP (190 mg, 1.55 mmol), 
and 7.8 mL of CH2Cl2 to afford the title compound in 82% yield after isolation (264 mg, 1.27 
mmol) as a white solid. 1H-NMR matched previous literature.176  
2,2,2-trifluoroethyl benzoylalaninate. The general procedure C 
was followed using the N-benzoyl alanine (500 mg, 2.59 mmol), 
trifluroethanol (0.586 mL, 7.76 mmol), EDC (744 mg, 3.88 mmol), 
DMAP (316 mg, 2.59 mmol), and 13 mL of CH2Cl2 to afford the title compound in 54% yield 
after isolation (290 m g, 1.40 mmol) as a white solid. 19F NMR (376 MHz, Chloroform-d) δ -73.85 
(t, J = 8.3 Hz). 1H NMR (400 MHz, Chloroform-d) δ 7.80 (d, J = 7.0 Hz, 2H), 7.53 (t, J = 7.4 Hz, 
1H), 7.46 (t, J = 7.4 Hz, 2H), 6.58 (d, J = 6.9 Hz, 1H), 4.90 (p, J = 7.2 Hz, 1H), 4.67 (dq, J = 12.6, 
8.3 Hz, 1H), 4.48 (dq, J = 12.6, 8.3 Hz, 1H), 1.58 (d, J = 7.3 Hz, 3H).13C NMR (101 MHz, 
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Chloroform-d) δ 172.2, 167.6, 133.9, 132.3, 129.0, 127.9 – 127.3 (m), 123.1 (q, J = 277.3 Hz), 
61.3 (q, J = 36.9 Hz), 48.8, 18.4. 
 
2,2,2-trifluoroethyl benzoylvalinate. The general procedure C 
was followed using the N-benzoyl valine (600 mg, 2.71 mmol), 
trifluroethanol (0.614 mL, 8.13 mmol), EDC (780 mg, 4.07 
mmol), DMAP (331 mg, 2.71 mmol), and 14 mL of CH2Cl2 to afford the title compound in 67% 
yield after isolation (551 mg, 1.82 mmol) as a white solid. 19F NMR (376 MHz, Methylene 
Chloride-d2) δ -74.05 (t, J = 8.5 Hz). 1H NMR (400 MHz, Methylene Chloride-d2) δ 7.79 (d, J = 
8.0 Hz, 2H), 7.54 (d, J = 7.5 Hz, 1H), 7.47 (t, J = 7.4 Hz, 2H), 6.52 (d, J = 8.5 Hz, 1H), 4.79 (dd, 
J = 8.5, 5.1 Hz, 1H), 4.59 4.76 – 4.40 (m, 2H), 2.31 (hept, J = 6.9, 5.1 Hz, 1H), 1.03 (dd, J = 9.5, 
6.9 Hz, 6H). 13C NMR (101 MHz, Methylene Chloride-d2) δ 171.2, 167.8, 134.6, 132.4, 129.2, 
127.6, 123.5 (q, J = 277.2 Hz), 61.2 (d, J = 36.7 Hz), 58.1, 31.8, 19.3, 18.2. 
 
2,2,2-trifluoroethyl benzoylphenylalaninate. The general 
procedure C was followed using the N-benzoyl phenylalanine 
(1000 mg, 3.71 mmol), trifluroethanol (0.841 mL, 11.1 mmol), 
EDC (1068 mg, 5.57 mmol), DMAP (454 mg, 3.71 mmol), and 14 mL of CH2Cl2 to afford the title 
compound in 61% yield after isolation (796 m g, 2.27 mmol) as a white solid. 19F NMR (376 MHz, 
Chloroform-d) δ -73.48 (t, J = 8.3 Hz). 1H NMR (400 MHz, Chloroform-d) δ 7.71 (d, J = 7.1 Hz, 
2H), 7.52 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 7.9 Hz, 2H), 7.36 – 7.27 (m, 3H), 7.16 (d, J = 6.5 Hz, 





2,2,2-trifluoroethyl benzoyl-iso-leucinate. The general 
procedure C was followed using the N-benzoyl iso-leucine (250 
mg, 1.06 mmol) as one diastereomer, trifluroethanol (0.319 mL, 
3.19 mmol), EDC (306 mg, 1.59 mmol), DMAP (130 mg, 1.06 mmol), and 5.3 mL of CH2Cl2 to 
afford the title compound in 78% yield after isolation (263 mg, 0.83 mmol) as a white solid. 19F 
NMR (376 MHz, Methylene Chloride-d2) δ -74.03 (t, J = 8.3 Hz), -74.09 (d, J = 8.4 Hz). 1H NMR 
(400 MHz, Methylene Chloride-d2) δ 7.78 (dt, J = 8.3, 1.2 Hz, 4H), 7.58 – 7.52 (m, 2H), 7.47 (tt, 
J = 8.3, 0.9 Hz, 4H), 6.54 (d, J = 7.9 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 4.96 (dd, J = 8.7, 4.2 Hz, 
1H), 4.83 (dd, J = 8.4, 5.2 Hz, 1H), 4.68 (dqd, J = 12.7, 8.5, 1.4 Hz, 2H), 4.49 (dqd, J = 12.7, 8.5, 
2.0 Hz, 2H), 2.17 – 1.98 (m, 2H), 1.61 – 1.44 (m, 5H), 1.38 – 1.23 (m, 2H), 1.06 – 0.93 (m, 12H). 
13C NMR (101 MHz, Methylene Chloride-d2) δ 171.57, 171.18, 167.83, 167.65, 134.65, 134.59, 
132.36, 129.18, 127.59 – 127.53 (m), 124.89, 122.14, 119.38, 61.16 (qd, J = 36.7, 6.0 Hz), 57.40, 
56.23, 38.38, 38.16, 26.83, 25.84, 15.83, 15.00, 12.01, 11.82. d.r.-1.6/1. 
 
2,2,2-trifluoroethyl benzoylleucinate. The general procedure C was followed using the N-
benzoyl leucine (1000 mg, 4.250 mmol), trifluroethanol (1.275 mL, 
12.75 mmol), EDC (1222 mg, 6.37 mmol), DMAP (519 mg, 4.25 
mmol), and 21 mL of CH2Cl2 to afford the title compound in 88% yield 
after isolation (1187 mg, 3.74 mmol) as a white solid. 19F NMR (376 MHz, Methylene Chloride-
d2) δ -74.15 (t, J = 8.5 Hz). 1H NMR (400 MHz, Methylene Chloride-d2) δ 7.79 (d, J = 7.1 Hz, 
2H), 7.54 (t, J = 7.4 Hz, 1H), 7.47 (d, J = 7.7 Hz, 2H), 6.57 (d, J = 8.1 Hz, 1H), 4 4.92 – 4.77 (m, 
1H), 4.64 (dq, J = 12.7, 8.5 Hz, 1H), 2.00 – 1.53 (m, 3H), 1.06 – 0.94 (m, 6H). 13C NMR (101 
MHz, Methylene Chloride-d2) δ 172.2, 167.7, 134.4, 132.4, 129.2, 127.6, 125.4 – 119.1 (m), 61.3 




2,2,2-trifluoroethyl benzoylmethioninate. The general procedure C 
was followed using the N-benzoyl leucine (1000 mg, 3.95 mmol), 
trifluroethanol (0.894 mL, 11.84 mmol), EDC (1135 mg, 5.92 mmol), 
DMAP (482 mg, 3.95 mmol), and 20 mL of CH2Cl2 to afford the title compound in 61% yield 
after isolation (807 mg, 2.41 mmol) as a white solid. 19F NMR (376 MHz, Chloroform-d) δ -73.65 
(t, J = 8.4 Hz). 1H NMR (400 MHz, Chloroform-d) δ 7.82 (d, J = 7.1 Hz, 2H), 7.54 (t, J = 7.4 Hz, 
1H), 7.46 (t, J = 7.4 Hz, 2H), 6.98 (d, J = 7.4 Hz, 1H), 5.03 (td, J = 7.4, 5.0 Hz, 1H), 4.49 (dq, J = 
12.6, 8.3 Hz, 1H), 4.49 (dq, J = 12.6, 8.3 Hz, 1H), 2.69 – 2.56 (m, 2H), 2.32 (ddd, J = 14.5, 7.3, 
5.0 Hz, 1H), 2.20 (dt, J = 14.4, 7.0 Hz, 1H), 2.13 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 
170.7, 167.3, 133.4, 132.0, 128.7, 127.1, 122.7 (q, J = 277.4 Hz), 61.0 (q, J = 36.9 Hz), 52.1, 30.9, 
30.0, 15.5. 
 
methyl 2-((tert-butoxycarbonyl)amino)-2-phenylacetate. To a solution 
of glycine methyl ester hydrochloride (500 mg, 2.48 mmol), triethylamine 
(0.864 mL, 6.20 mmol, 2.5 equiv), and a mixture of THF and H2O (2.5/2.5 
mL), Boc2O (650 mg, 2.98 mmol, 1.2 equviv) was gradually added at 0 °C. After strirring for 15 
h at rt, the mixture was concentrated in vacuo to a rid the mixture of THF. After extractions of 
ethyl acetate (3 x 50 mL), the combined organic layer was washed with aqueous HCl (0.1 M, 40 
mL), water (40 mL), and saturated aqueous NaCl solution (20 mL), dried over MgSO4, filtered 
and concentrated in vacuo to afford the title compound as a white solid (631 mg, 96%). The 
procedure and spectral data corresponds to that reported in the literature.177-178 
methyl 2-(((benzyloxy)carbonyl)amino)-2-phenylacetate A solution 
of glycine methyl ester hydrochloride (500 mg, 2.48 mmol) and Et3N 
(0.864 mL, 6.20 mmol, 2.5 equiv) in CH2Cl2 (5 mL) was added 
dropwise to a solution of benzyl chloroformate (0.425 mL, 2.98 mmol, 1.2 equiv) in CH2Cl2 (20 
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mL) at 0 °C. The solution was warmed to room temperature and stirred over night. Then, the 
reaction was quenched by the addition of water (20 mL). The organic layer was seperated and then 
dried over anhydrous MgSO4. Evaporation and column chromatography on silica gel afforded 
corresponding the title compound as white solid  (623 mg, 84%). The procedure and spectral data 
corresponds to that reported in the literature.179-180 
Methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-
phenylacetate. A solution of glycine methyl ester hydrochloride (300 
mg, 1.49 mmol) and Et3N (0.518 mL, 3.72 mmol, 2.5 equiv) in CH2Cl2 
(5 mL) was added dropwise to a solution of fluorenyl chloroformate 
(0.463 mL, 1.79 mmol, 1.2 equiv) in CH2Cl2 (20 mL) at 0 °C. The solution was warmed to room 
temperature and stirred overnight. Then, the reaction was quenched by the addition of water (20 
mL). The organic layer was seperated and then dried over anhydrous MgSO4. Evaporation and 
column chromatography on silica gel afforded corresponding the title compound as white solid 
(340 mg, 59%). The procedure and spectral data corresponds to that reported in the literature.181 
 
Synthesis of perfluoro-N-benzoyl amino esters 
(see our previous work for more details in regards to synthesizing fluorinated non-natural amino 









To a suspension of N-benzoyl glycine (2.50 g, 14.0 mmol) in dry CH2Cl2 (200 mL) under argon 
at 0 ºC was added EDC HCl (2.38 g, 15.3 mmol). The materials were stirred at 0 ºC for 1 hour. 
The reaction mixture was diluted with an equal volume of CH2Cl2, and washed successively with 
water, saturated aqueous NaHCO3, and water (each 1/2 the volume of the organic phase), then 
dried over MgSO4 and concentrated under reduced pressure to afford the title compound in 80 % 
yield after isolation (1.80 g, 11.1 mmol) as a pale white solid. 1H-NMR spectrum matched that 











Under an inert atmosphere oxazolone (1 equiv), ArFn (1.025 equiv), CH3CN (1 M) was added to 
small test tube and cooled to -20 ºC.  Then a steady stream of tetramethylguandine (2.05 equiv) 
was added to mixture down the side of the test tube glass. The reaction was left to react for 30 
min. After the reaction was complete, the cooling bath was removed, and the reaction was left to 
warm to room temperature, then quenched by the addition of a trifluoroacetic acid/alcohol solution 
(2 equiv and double the volume of the MeCN). The solution was concentrated and brought into 
CHCl3 then the organic layer was washed with half volumes of a 1 M HCl brine solution (3x). The 
organic layer was dried with MgSO4 and concentrated to give the crude product. The crude product 
was purified by column chromatography.  
 





Under an inert atmosphere oxazolone (1 equiv), ArF (1.025 equiv), CH3CN (1 M) was added to 
small test tube at room temperature.  Then a steady stream of 1,8-Diazabicyclo(5.4.0)undec-7-ene 
(2.05 equiv) was added to mixture down the side of the test tube glass. The reaction was left to 
react for 30 min. After the reaction was complete, the cooling bath was removed, and the reaction 
was left to warm to room temperature, then quenched by the addition of a trifluoroacetic 
acid/alcohol solution (2 equiv and double the volume of the MeCN). The solution was 
400 
 
concentrated and brought into CHCl3 then the organic layer was washed with half volumes of a 1 
M HCl brine solution (3x). The organic layer was dried with MgSO4 and concentrated giving 
crude product. The crude product was purified by column chromatography.    
 
2a methyl 4-(1-benzamido-2-ethoxy-2-oxoethyl)-2,3,5,6-tetrafluorobenzoate 
The general procedure D was followed using 2-phenyloxazol-5(4H)-
one (300 mg, 1.86 mmol), 2,3,4,5,6 pentafluorobenzoate (431 mg, 1.91 
mmol), tetramethylguanidine (0.487 ml, 3.81 mmol), 1.86 mL of MeCN 
and trifluoroacetic acid (0.284 mL, 3.72 mmol) in methanol (3.72 mL) 
was used  to afford the titled compound in 90% yield (668 mg, 1.67 
mmol). NMR data matched previous literature value.160 
 
2b methyl 2-(4-acetyl-2,3,5,6-tetrafluorophenyl)-2-benzamidoacetate 
The general procedure D was followed using 2-phenyloxazol-5(4H)-
one (150 mg, 0.931 mmol), 2’,3’,4’,5’,6’ pentafluoroacetophenone (200 
mg, 0.954 mmol), tetramethylguanidine (239 µL, 1.91 mmol), 
trifluoroacetic acid (142 µL, 1.86 mmol) in methanol (1.86 mL) and 
0.931 mL of MeCN was used  to afford the titled compound in 71 % 
yield (253 mg, 0.661 mmol). 19F NMR (376 MHz, Chloroform-d) δ -141.06 – -141.36 (m), -141.59 
– -141.77 (m). 1H NMR (400 MHz, Chloroform-d) δ 7.81 (d, J = 7.1 Hz, 2H), 7.55 (t, J = 7.4 Hz, 
1H), 7.46 (t, J = 7.5 Hz, 2H), 7.36 (d, J = 6.4 Hz, 1H), 6.21 (d, J = 6.5 Hz, 1H), 3.84 (s, 3H), 2.61 
(t, J = 1.6 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 191.9, 168.6, 166.8, 146.8 – 144.8 (m), 
143.9 (dt, J = 13.6, 4.7 Hz), 142.8 – 142.4 (m), 132.8, 132.5, 128.9, 127.3, 120.3 – 118.7 (m), 




2d methyl 2-benzamido-2-(perfluoropyridin-4-yl)acetate 
The general procedure D was followed using 2-phenyloxazol-5(4H)-
one (300 mg, 1.86 mmol), pentafluoropyridine (323 mg, 1.91 mmol), 
tetramethylguanidine (0.487 µL, 3.81 mmol), trifluoroacetic acid (0.284 
mL, 3.72 mmol) in methanol (3.72 mL) was used  to afford the titled 
compound in 69% yield (439 mg, 1.28 mmol). 19F NMR (376 MHz, Chloroform-d) δ -88.79 – -
90.87 (m), -142.46 – -145.85 (m). 1H NMR (400 MHz, Chloroform-d) δ 7.80 (d, J = 7.1 Hz, 2H), 
7.57 – 7.48 (m, 2H), 7.44 (t, J = 7.6 Hz, 2H), 6.22 (d, J = 6.3 Hz, 1H), 3.85 (s, 3H). 13C NMR (101 
MHz, Chloroform-d) δ 167.7, 166.8, 143.4 (dddd, J = 246.3, 16.0, 12.6, 2.8 Hz), 141.9 – 138.9 
(m), 132.5 (d, J = 11.1 Hz), 129.9 (tt, J = 14.1, 2.4 Hz), 128.8, 127.3, 54.7, 47.4. 
 
2e methyl 2-benzamido-2-(3-chloro-2,5,6-trifluoropyridin-4-yl)acetate 
The general procedure D was followed using 2-phenyloxazol-5(4H)-
one (100 mg, 0.621 mmol), 3-chloro-2,4,5,6 tetrafluoropyridine (118.0 
mg, 0.636 mmol), tetramethylguanidine (145 mg, 1.27 mmol), 
trifluoroacetic acid (95 µL, 1.24 mmol) in methanol (1.24 mL) and 0.621 
mL of MeCN was used to afford 2e in 85% yield (178 mg, 0.487 mmol). NMR data matched 
previous literature values.160 
 
2f methyl 2-benzamido-2-(perfluoronaphthalen-1-yl)acetate 
The general procedure E was followed using 2-phenyloxazol-
5(4H)-one (50 mg, 0.310 mmol), octafluoronapalene (86 mg, 0.318 
mmol), 1,8-diazabicyclo(5.4.0)undec-7-ene (96.7 mg, 0.636 mmol), 
trifluoroacetic acid (95 µL, 1.24 mmol) in ethanol (0.620 mL) and 
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0.310 mL of MeCN was used  to afford 2f in 82% yield (69.2 mg, 0.254 mmol). 19F NMR (376 
MHz, Chloroform-d) δ -120.66 (dd, J = 68.1, 18.4 Hz), -138.68 – -139.91 (m), -142.74 – -143.82 
(m), -145.84 (dtd, J = 57.6, 16.7, 4.6 Hz), -148.02 (dtt, J = 57.7, 18.1, 4.7 Hz), -152.03 – -153.02 
(m), -154.60 – -155.85 (m). 1H NMR (400 MHz, Chloroform-d) δ 7.80 (d, J = 7.1 Hz, 2H), 7.55 
– 7.47 (m, 1H), 7.43 (t, J = 7.5 Hz, 2H), 6.36 (d, J = 6.6 Hz, 1H), 3.84 (s, 3H). 13C NMR (101 
MHz, Chloroform-d) δ 168.9, 166.8, 150.9 (d, J = 260.5 Hz), 146.1 (d, J = 252.4 Hz), 142.8 (d, J 
= 41.3 Hz), 141.9, 141.4 (t, J = 15.1 Hz), 140.9 – 139.7 (m), 138.3 (dt, J = 118.8, 15.2 Hz), 132.8, 
132.4, 128.8, 127.3, 115.2 (t, J = 17.7 Hz), 111.6, 108.0 (t, J = 13.7 Hz), 53.9, 47.2 (dt, J = 3.9, 
2.1 Hz). 
 
2g methyl 2-benzamido-2-(perfluoro-[1,1'-biphenyl]-4-yl)acetate 
The general procedure E was followed using 2-phenyloxazol-5(4H)-
one (100 mg, 0.621 mmol), decafluorobiphenyl (212.7 mg, 0.637 
mmol), 1,8-diazabicyclo(5.4.0)undec-7-ene (193 mg, 1.27 mmol), 
trifluoroacetic acid (95 µL, 1.24 mmol) in methanol (1.24 mL) and 0.621 
mL of MeCN was used  to afford 2g in 82% yield (265 mg, 0.508 mmol). 
NMR data matched previous literature values.160 
 
2i methyl 2-benzamido-2-(4-cyano-2,3,5,6-tetrafluorophenyl)acetic acid 
The general procedure D was followed using 2-phenyloxazol-5(4H)-
one (300 mg, 1.86 mmol), 2,3,4,5,6 pentaflurobenzonitrile (240 µL, 1.91 
mmol), tetramethylguanidine (0.487 ml, 3.81 mmol), 1.86 mL of MeCN 
and trifluoroacetic acid (0.284 mL, 3.72 mmol) in methanol (3.72 mL) 
was used  to afford the titled compound in 66% yield (668 mg, 1.67 
mmol). 19F NMR (376 MHz, Chloroform-d) δ -128.70 – -134.21 (m), -139.47 (td, J = 16.5, 6.8 
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Hz). 1H NMR (400 MHz, Chloroform-d) δ 7.79 (d, J = 8.1 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.45 
(t, J = 7.6 Hz, 2H), 7.41 (d, J = 6.0 Hz, 1H), 6.18 (d, J = 6.1 Hz, 1H), 3.85 (s, 3H). 13C NMR (101 
MHz, Chloroform-d) δ 167.9, 166.8, 148.8 – 145.4 (m), 146.6 – 143.2 (m), 132.6, 132.4, 128.9, 
127.3, 123.2 (t, J = 15.3 Hz), 107.19 (t, J = 3.7 Hz), 94.65 (tt, J = 17.0, 2.8 Hz), 54.18, 47.46 (p, 
J = 2.1 Hz).  
 
Michael reaction: synthesis of α,α-disubstituted amino acid derivatives 
 




Under an inert atmosphere the methyl 2-benzamido-2-(perfluoropyridin-4-yl)acetate (1 equiv), 
Michael acceptor (1.05 equiv), CH3CN (0.5 M) was added to a small test tube.  Then MTBD 
(0.001 equiv made from a stock solution) was added to mixture and stirred vigorously. The 
reaction was monitored by 19F NMR until the starting material was consumed. After the reaction 
was complete, the reaction was quenched with acetic acid (1 equiv). The solution was then 
concentrated and a half volume of brine solution was added. The salty water was extracted with 
CH2Cl2 (3x) and the combined organic extracts were washed with half volumes of a 1 M HCl brine 
solution (3x), and a final wash with tap water. The organic layer was dried with MgSO4 and 









Under an inert atmosphere the amino ester substrate (1 equiv), methylvinyl ketone (1.05 equiv), 
CH3CN (0.5 M) was added to a small test tube.  Then MTBD (0.001-0.01 equiv made from a 
stock solution) was added to mixture and stirred vigorously. The reaction was monitored by 19F 
NMR/1H NMR until the starting material was consumed. After the reaction was complete, the 
reaction was quenched with acetic acid (1 equiv). The solution was then concentrated and a half 
volume of brine solution was added. The salty water was extracted with CH2Cl2 (3x) and the 
combined organic extracts were washed with half volumes of a 1 M HCl brine solution (3x) and 
a final wash with tap water. The organic layer was dried with MgSO4 and concentrated giving 
crude/pure product. The crude product was purified further by column chromatography. 
 




Under an inert atmosphere the protected phenyl glycine substrate (1 equiv), methylvinyl ketone 
(1.05 equiv), CH3CN (0.5 M) was added to a small test tube.  Then MTBD (0.001 equiv made 
from a stock solution) was added to mixture and stirred vigorously. The reaction was monitored 
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by 19F NMR/1H NMR until the starting material was consumed. After the reaction was complete, 
the reaction was quenched with acetic acid (1 equiv). The solution was then concentrated and a 
half volume of brine solution was added. The salty water was extracted with CH2Cl2 (3x) and the 
combined organic extracts were washed with half volumes of a 1 M HCl brine solution (3x) and 
a final wash with tap water. The organic layer was dried with MgSO4 and concentrated giving 
crude/pure product. The crude product was purified further by column chromatography. 
 
General procedure I for synthesis of N-benzoyl Michael adducts (natural amino esters) 
 
Under a dry inert atmosphere, the amino ester substrate (1 equiv), methylvinyl ketone (1.05 
equiv), dry DCM (0.5 M) was added to a small test tube.  Then MTBD (0.10-0.40 equiv) was 
added to mixture and stirred vigorously. The reaction was monitored by 19F NMR/1H NMR until 
the starting material was consumed. The organic solution was then dried with MgSO4 and 




The general procedure F was followed using methyl 2-benzamido-2-
(perfluoropyridin-4-yl)acetate (150 mg, 0.438 mmol), methyl vinyl ketone 
(38.4 µL, 0.460 mmol), 0.880 mL of a 0.0005 M MTBD/CH3CN solution 
(0.0004383 mmol of MTBD) to afford the title compound in 99% yield (179 
mg, 0.430 mmol). 19F NMR (376 MHz, Chloroform-d) δ -90.52 – -90.94 (m), -137.70 – -142.09 
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(m). 1H NMR (400 MHz, Chloroform-d) δ 7.81 – 7.72 (m, 3H), 7.56 (t, J = 7.4 Hz, 1H), 7.47 (t, J 
= 7.5 Hz, 2H), 3.84 (s, 3H), 3.43 (dddt, J = 14.1, 6.9, 4.8, 2.1 Hz, 1H), 2.82 (dddt, J = 14.2, 6.9, 
4.3, 2.2 Hz, 1H), 2.59 (dt, J = 18.2, 6.7 Hz, 1H), 2.47 (dt, J = 18.3, 7.0 Hz, 1H), 2.14 (s, 3H).  13C 
NMR (101 MHz, Chloroform-d) δ 206.7, 170.8, 166.1, 144.4 (dt, J = 244.7, 18.2 Hz), 141.4 (dd, 
J = 261.2, 34.6 Hz), 133.2, 132.9, 132.4 – 131.9 (m), 129.3, 127.5, 54.9, 38.4, 30.4, 27.7, 2.4. FT-
IR (neat) cm-1 1743, 1754, 1680, 1085. HRMS (ESI) C19H16F4N2O4 calcd. [M+Na]+ 435.0938 
observed 435.0908. 
 
2b 5-ethyl 1-methyl-2-benzamido-2-(perfluoropyridin-4-yl)pentanedioate 
The general procedure F was followed using methyl 2-benzamido-2-(perfluoropyridin-4-
yl)acetate (50 mg, 0.146 mmol), ethyl acrylate (18.0. µL, 0.153 mmol), 
0.293 mL of a 0.0005 M MTBD/CH3CN solution (0.0001463 mmol of 
MTBD) to afford the title compound in 97% yield (63 mg, 0.140 mmol). 
19F NMR (376 MHz, Chloroform-d) δ -88.61 – -92.72 (m), -136.58 – -141.53 (m). 1H NMR (400 
MHz, Chloroform-d) δ 7.80 – 7.73 (m, 3H), 7.55 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.5 Hz, 2H), 4.08 
(q, J = 7.1 Hz, 2H), 3.86 (s, 3H), 3.56 (dddd, J = 14.7, 8.6, 6.6, 2.1 Hz, 1H), 2.79 (dddd, J = 16.7, 
8.6, 4.5, 2.2 Hz, 1H), 2.44 (ddd, J = 16.8, 7.9, 6.6 Hz, 1H), 2.29 (ddd, J = 16.7, 8.3, 6.7 Hz, 1H), 
1.22 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 172.4, 170.6, 166.1, 146.0 – 142.9 
(m), 142.9 – 139.5 (m), 133.2, 132.9, 132.0 (t, J = 10.4 Hz), 129.3, 127.5, 62.9, 61.4, 54.9, 29.5, 
29.1, 14.5.  FT-IR (neat) cm-1 3412, 1748, 1730, 1508, 1270. HRMS (ESI) C20H18F4N2O5 calcd. 
[M+Na]+ 465.1044 observed 465.1027. 
 
2c 5-(tert-butyl) 1-methyl-2-benzamido-2-(perfluoropyridin-4-yl)pentanedioate 
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The general procedure F was followed using methyl 2-benzamido-2-
(perfluoropyridin-4-yl)acetate (50 mg, 0.146 mmol), methyl vinyl 
ketone (22.5 µL, 0.153 mmol), 0.293 mL of a 0.0005 M MTBD/CH3CN 
solution (0.000146  mmol of MTBD)  to afford the title compound in 
92% yield (63 mg, 0.130 mmol). 19F NMR (376 MHz, Chloroform-d) δ -88.33 – -93.28 (m), -
139.54 (h, J = 13.8 Hz). 1H NMR (400 MHz, Chloroform-d) δ 7.83 (s, 1H), 7.76 (d, J = 8.0 Hz, 
2H), 7.52 (t, J = 7.4 Hz, 1H), 7.43 (tt, J = 8.1, 1.4 Hz, 2H), 3.84 (s, 3H), 3.45 (dt, J = 14.7, 7.5 Hz, 
1H), 2.75 (dt, J = 14.4, 7.1 Hz, 1H), 2.45 – 2.31 (m, 1H), 2.21 (dt, J = 16.9, 7.5 Hz, 1H), 1.40 (s, 
9H). 13C NMR (101 MHz, Chloroform-d) δ 171.7, 170.5, 166.1, 144.3 (dt, J = 243.6, 15.7 Hz), 
142.8 – 139.1 (m), 133.2, 132.8, 132.2 (t, J = 10.4 Hz), 129.2, 127.5, 81.6, 62.9, 54.8, 30.4, 28.9, 
28.4. FT-IR (neat) cm-1 3430, 1727, 1702, 1595, 1310. HRMS (ESI) C22H22F4N2O5 calcd. [M+H]+ 
471.1538 observed 471.1530. 
 
2d methyl-2-benzamido-4-cyano-2-(perfluoropyridin-4-yl)butanoate 
The general procedure F was followed using methyl 2-benzamido-2-
(perfluoropyridin-4-yl)acetate (100 mg, 0.292 mmol), acrylonitrile (20.1 
µL, 0.307 mmol), 0.584 mL of a 0.0005 M MTBD/CH3CN solution 
(0.000292 mmol of MTBD) to afford the title compound in 99% yield (114 
mg, 0.29 mmol). 19F NMR (376 MHz, Chloroform-d) δ -87.49 – -92.37 (m), -137.14 – -143.28 
(m). 1H NMR (400 MHz, Chloroform-d) δ 7.76 (d, J = 1.3 Hz, 3H), 7.57 (t, J = 7.4 Hz, 1H), 7.48 
(t, J = 7.6 Hz, 2H), 3.95 (s, 3H), 3.72 (dtt, J = 14.2, 7.0, 2.0 Hz, 1H), 2.79 (dtd, J = 14.2, 8.3, 2.2 
Hz, 1H), 2.50 (dt, J = 17.4, 6.7 Hz, 1H), 2.38 (dt, J = 17.4, 7.2 Hz, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 169.6, 166.1, 145.7 – 142.6 (m), 140.9 (dd, J = 261.4, 35.1 Hz), 132.9, 132.4, 
130.9 (t, J = 11.2 Hz), 129.1, 127.2, 118.2, 62.1, 55.1, 29.5, 12.4. FT-IR (neat) cm-1 3270, 2248, 





The general procedure F was followed using methyl 2-benzamido-2-
(perfluoropyridin-4-yl)acetate (75 mg, 0.219 mmol), methyl vinyl sulfone 
(24 mg, 0.230 mmol), 0.438 mL of a 0.0005 M MTBD/CH3CN solution 
(0.000219 mmol of MTBD)   to afford the title compound in 99% yield (97 
mg, 0.22 mmol). 19F NMR (376 MHz, Chloroform-d) δ -86.03 – -92.09 (m), -138.05 – -142.09 
(m). 1H NMR (400 MHz, Chloroform-d) δ 7.79 – 7.72 (m, 3H), 7.59 (t, J = 7.4 Hz, 1H), 7.49 (t, J 
= 7.6 Hz, 2H), 3.93 (s, 3H), 3.81 (td, J = 14.2, 13.0, 4.9 Hz, 1H), 3.16 (ddd, J = 14.0, 10.8, 5.1 Hz, 
1H), 3.04 – 2.77 (m, 5H). 13C NMR (101 MHz, Chloroform-d) δ 169.7, 166.1, 154.1 – 145.0 (m), 
143.7 – 139.1 (m), 133.0, 132.3, 131.6 (t, J = 10.2 Hz), 129.2, 127.2, 62.0, 55.2, 49.9, 40.6, 27.3. 
FT-IR (neat) cm-1 3208, 1761, 1517, 1328, 1282. HRMS (ESI) C18H16F4N2O5S calcd. [M+Na]+ 
471.0608 observed 471.0597. 
 
2f methyl-2-benzamido-2-(perfluoropyridin-4-yl)-4-(phenylsulfonyl)butanoate 
The general procedure F was followed using methyl 2-benzamido-2-
(perfluoropyridin-4-yl)acetate (50 mg, 0.146 mmol), phenyl vinyl sulfone 
(26 mg, 0.153 mmol), 0.29 mL of a 0.0005 M MTBD/CH3CN solution 
(0.0001461 mmol of MTBD)   to afford the title compound in 99% yield 
(72 mg, 0.14 mmol). 19F NMR (376 MHz, Chloroform-d) δ -86.31 – -93.00 (m), -136.30 – -142.65 
(m). 1H NMR (400 MHz, Chloroform-d) δ 7.88 (d, J = 7.3 Hz, 2H), 7.70 – 7.61 (m, 4H), 7.59 – 
7.51 (m, 3H), 7.45 (t, J = 7.6 Hz, 2H), 3.87 (s, 3H), 3.66 – 3.57 (m, 1H), 3.20 (ddd, J = 14.2, 10.8, 
5.1 Hz, 1H), 3.03 – 2.90 (m, 1H), 2.81 (ddd, J = 15.5, 12.7, 3.5 Hz, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 169.9, 165.9, 150.0 – 145.2 (m), 143.7 – 139.6 (m), 138.8, 134.7, 133.1, 133.0, 
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132.0 – 130.9 (m), 130.0, 129.3, 128.1, 127.6, 60.9, 32.2, 23.2, 14.4. FT-IR (neat) cm-1 3409, 
1750, 1506, 1308, 1145.  HRMS (ESI) C23H18F4N2O5S calcd. [M+H]+ 511.0945 observed 
511.0949. 
 
2g methyl 2-benzamido-3,4-dicyano-2-(perfluoropyridin-4-yl)butanoate 
 The general procedure F was followed using methyl 2-benzamido-2-
(perfluoropyridin-4-yl)acetate (50 mg, 0.146 mmol), fumanitrile (12 mg, 
0.153 mmol), 0.29 mL of a 0.0005 M MTBD/CH3CN solution (0.0001461 
mmol of MTBD)   to afford the title compound (d.r. 1.5:1) in 87% yield (53 
mg, 0.130 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.94 (s, 1H), 7.81 – 7.72 (m, 8H), 7.64 – 
7.57 (m, 3H), 7.49 (ddd, J = 8.1, 6.7, 1.2 Hz, 6H), 5.39 (t, J = 5.8 Hz, 1H), 5.23 (t, J = 6.4 Hz, 
2H), 4.08 (s, 6H), 4.06 (s, 3H), 3.16 – 2.67 (m, 6H).  13C NMR (101 MHz, Chloroform-d) δ 167.2, 
166.9, 166.6, 166.2, 145.9 – 142.5 (m), 142.4 – 138.8 (m), 133.6, 133.4, 131.7, 131.4, 129.3, 
129.2, 128.1 – 127.5 (m), 127.4, 127.4, 115.2, 114.8, 114.6, 114.5, 62.5, 62.2, 55.9, 55.8, 34.1 (t, 
J = 4.7 Hz), 31.5 (t, J = 4.4 Hz), 18.8 (t, J = 3.5 Hz), 17.4. FT-IR (neat) cm-1 3376, 2999, 1752, 
1505, 1316.  HRMS (ESI) C19H12F4N4O3 calcd. [M+H]+ 421.0918 observed 421.0910. 
 
2h methyl 2-benzamido-2-(2,5-dioxo-1-phenylpyrrolidin-3-yl)-2-(perfluoropyridin-4-yl)acetate 
 The general procedure F was followed using methyl 2-benzamido-2-
(perfluoropyridin-4-yl)acetate (50 mg, 0.146 mmol), N-
Phenylmaleimide (27 mg , 0.153 mmol), 0.29 mL of a 0.0005 M 
MTBD/CH3CN solution (0.0001461 mmol of MTBD)   to afford the title 
compound (d.r. 1.9:1 based on crude 19F NMR) in 87% yield (66 mg, 0.130 mmol) when 
considering both diastermers, however we were able to separate one diastermer for 
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characterization. 19F NMR (376 MHz, Chloroform-d) δ -86.86 – -93.28 (m), -139.58 (dt, J = 35.9, 
17.9 Hz). 1H NMR (400 MHz, Chloroform-d) δ 7.86 (s, 1H), 7.79 (d, J = 7.2 Hz, 2H), 7.61 (d, J 
= 7.4 Hz, 1H), 7.54 – 7.37 (m, 5H), 7.20 (d, J = 7.1 Hz, 2H), 4.97 (dd, J = 9.8, 5.0 Hz, 1H), 3.97 
(s, 3H), 3.62 (dd, J = 19.0, 5.0 Hz, 1H), 3.20 (dd, J = 19.0, 9.7 Hz, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 174.4, 174.1, 168.6, 167.6, 146.4 – 143.1 (m), 142.8 – 139.0 (m), 133.4, 132.7, 
131.7, 129.7, 129.5, 129.4, 128.9 (d, J = 10.0 Hz), 127.6, 126.6, 63.4, 55.7, 46.9, 32.5. FT-IR 




The general procedure G was followed using substrate (75 mg, 0.209 
mmol), methyl vinyl ketone (18.3 µL, 0.220 mmol), 0.42 mL of a 0.005 M 
MTBD/CH3CN solution (0.002094 mmol of MTBD)   to afford the title 
compound in 94% yield (84 mg, 0.20 mmol). 19F NMR (376 MHz, 
Chloroform-d) δ -73.82 (dd, J = 26.5, 13.0 Hz), -87.39 (dd, J = 22.4, 13.0 Hz), -136.78 (ddt, J = 
27.3, 22.2, 5.5 Hz). 1H NMR (400 MHz, Chloroform-d) δ 7.80 – 7.74 (m, 2H), 7.70 (s, 1H), 7.56 
(t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.5 Hz, 2H), 3.80 (s, 3H), 3.47 (ddd, J = 12.0, 6.8, 5.1 Hz, 1H), 
2.87 (ddd, J = 14.2, 12.7, 6.6 Hz, 1H), 2.55 (q, J = 6.9, 1.3 Hz, 2H), 2.13 (s, 3H). 13C NMR (101 
MHz, Chloroform-d) δ 206.5, 171.3, 165.7, 147.2 (d, J = 15.3 Hz), 145.4 (d, J = 16.5 Hz), 143.8 
(dd, J = 183.2, 14.8 Hz), 133.3, 128.9, 127.2, 121.4 (t, J = 12.0 Hz), 119.4 – 119.0 (m), 62.6, 54.4, 
38.3, 32.6, 30.1, 27.7. FT-IR (neat) cm-1 1754, 1739, 1676, 1100.  HRMS (ESI) C19H16ClF3N2O4 





The procedure G was followed using substrate (75 mg, 0.205 mmol), 
methyl vinyl ketone (18.0 µL, 0.215 mmol), 0.41 mL of a 0.0005 M 
MTBD/CH3CN solution (0.0002048 mmol of MTBD) to afford the title 
compound in 93% yield (83 mg, 0.20 mmol). 19F NMR (376 MHz, 
Chloroform-d) δ -132.44 (td, J = 15.1, 7.0 Hz), -135.22 (dq, J = 15.9, 6.9 Hz).1H NMR (400 MHz, 
Chloroform-d) δ 7.74 – 7.64 (m, 3H), 7.49 (t, J = 7.4 Hz, 1H), 7.40 (t, J = 7.5 Hz, 2H), 3.76 (s, 
3H), 3.34 (dtt, J = 14.0, 6.7, 2.1 Hz, 1H), 2.73 (dtt, J = 14.1, 6.9, 4.5, 2.2 Hz, 1H), 2.39 (dt, J = 
18.3, 7.0 Hz, 1H), 2.39 (dt, J = 18.2, 7.0 Hz, 1H)2.07 (s, 3H). 13C NMR (101 MHz, Chloroform-
d) δ 206.6, 171.0, 166.1, 148.9 (dt, J = 18.1, 3.8 Hz), 147.7 – 144.5 (m), 133.2, 132.9, 129.3, 
127.5, 125.7 (t, J = 11.7 Hz), 107.6 (t, J = 3.6 Hz), 94.5, 63.1 (d, J = 2.4 Hz), 54.9, 38.4 (t, J = 1.8 
Hz), 30.4, 27.9 (t, J = 6.6 Hz). FT-IR (neat) cm-1 3412, 2246, 1747, 1718, 1581, 1303. HRMS 
(ESI) C21H16F4N2O4 calcd. [M+H]+ 437.1119 observed 437.1123. 
 
3c methyl-2-(4-acetyl-2,3,5,6-tetrafluorophenyl)-2-benzamido-5-oxohexanoate 
The procedure G was followed using substrate (90 mg, 0.235 mmol), 
methyl vinyl ketone (20.5 µL, 0.247 mmol), 0.47 mL of a 0.0005 M 
MTBD/CH3CN solution (0.0002348 mmol of MTBD) to afford the title 
compound in 98% yield (104 mg, 0.230 mmol). 19F NMR (376 MHz, 
Chloroform-d) δ -137.37 (dd, J = 21.1, 11.4 Hz), -141.87 (dd, J = 21.2, 11.2 Hz). 1H NMR (400 
MHz, Chloroform-d) δ 7.84 – 7.73 (m, 3H), 7.55 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.5 Hz, 2H), 3.81 
(s, 3H), 3.53 – 3.36 (m, 1H), 2.81 (dtt, J = 14.3, 7.0, 2.3 Hz, 1H), 2.60 (t, J = 1.7 Hz, 3H), 2.55 
(m, 1H), 2.48 – 2.39 (m, 1H), 2.13 (s, 3H). 13C NMR (101 MHz, Methylene Chloride-d2) δ 206.8, 
192.4, 171.6, 165.9, 148.3 – 145.5 (m), 145.4 – 143.1 (m), 134.1, 132.6, 129.2 (d, J = 4.1 Hz), 
127.6 (d, J = 4.2 Hz), 122.5 – 121.6 (m), 119.9 (d, J = 31.1 Hz), 63.1, 54.7, 38.6, 32.8, 30.3, 28.2. 
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FT-IR (neat) cm-1 3306, 1762, 1715, 1533, 1184. HRMS (ESI) C22H19F4NO5 calcd. [M+H]+ 
454.1272 observed 454.1269. 
 
3d methyl-4-(2-benzamido-1-methoxy-1,5-dioxohexan-2-yl)-2,3,5,6-tetrafluorobenzoate 
The procedure G was followed using substrate (50 mg, 0.125 mmol), 
methyl vinyl ketone (11.0 µL, 0.131 mmol), 0.25 mL of a 0.0005 M 
MTBD/CH3CN solution (0.0001252 mmol of MTBD) to afford the title 
compound in 99% yield (58 mg, 0.124 mmol). 19F NMR (376 MHz, 
Chloroform-d) δ -137.55 (dt, J = 16.2, 8.2 Hz), -139.33 – -139.83 (m). 1H NMR (400 MHz, 
Chloroform-d) δ 7.80 – 7.73 (m, 3H), 7.53 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.5 Hz, 2H), 3.95 (s, 
3H), 3.80 (s, 3H), 3.43 (dddd, J = 16.3, 8.6, 6.1, 2.1 Hz, 1H), 2.88 – 2.72 (m, 1H), 2.57 (dt, J = 
18.1, 6.8 Hz, 1H), 2.57 (dt, J = 18.1, 6.8 Hz, 1H), 2.12 (s, 3H). 13C NMR (101 MHz, Chloroform-
d) δ 206.5, 171.2, 165.7, 160.0, 146.6 (ddt, J = 98.8, 16.4, 5.2 Hz), 144.1 (ddt, J = 103.8, 16.7, 5.2 
Hz), 133.3, 132.4, 128.9, 127.1, 121.8 (t, J = 12.0 Hz), 112.3 (t, J = 16.0 Hz), 62.6, 54.3, 53.4, 
38.2, 30.0, 27.7 (t, J = 6.4 Hz).FT-IR (neat) cm-1 2933, 2848, 1434, 1085. FT-IR (neat) cm-1 3240, 






The procedure G was followed using substrate (62 mg, 0.122 mmol), methyl 
vinyl ketone (10.7 µL, 0.128 mmol), 0.24 mL of a 0.0005 M MTBD/CH3CN 
solution (0.0001222 mmol of MTBD) to afford the title compound in 98% 
yield (69 mg, 0.120 mmol). 19F NMR (376 MHz, Chloroform-d) δ -136.42 – 
-136.89 (m), -137.52 (dt, J = 14.3, 7.6 Hz), -138.31 (dt, J = 19.3, 9.3 Hz), -
150.13 (tt, J = 20.9, 3.2 Hz), -159.19 – -162.48 (m). 1H NMR (400 MHz, 
Chloroform-d) δ 7.89 – 7.75 (m, 3H), 7.55 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.5 Hz, 2H), 3.85 (s, 
3H), 3.51 (dt, J = 14.2, 6.9 Hz, 1H), 2.85 (dddd, J = 16.3, 7.0, 4.4, 2.0 Hz, 1H), 2.46 (dt, J = 18.0, 
7.1 Hz, 1H), 2.46 (dt, J = 18.0, 7.1 Hz, 1H), 2.15 (s, 3H).13C NMR (101 MHz, Chloroform-d) δ 
206.6, 171.4, 165.7, 145.9 (d, J = 9.1 Hz), 145.6 – 144.5 (m), 145.3 – 142.8 (m), 141.3, 138.0 (d, 
J = 255.6 Hz), 133.4, 132.4, 128.9, 127.2, 120.9 (t, J = 12.0 Hz), 106.3 (t, J = 18.1 Hz), 102.3, 
64.5 – 59.8 (m), 54.4, 38.3 (d, J = 1.8 Hz), 30.1, 27.7 (t, J = 6.4 Hz). FT-IR (neat) cm-1 3417, 
1745, 1719, 1530, 1276. HRMS (ESI) C26H16F9NO4 calcd. [M+H]+ 578.1008 observed 578.1000. 
 
3f methyl-2-benzamido-5-oxo-2-(perfluoronaphthalen-1-yl)hexanoate 
The procedure G was followed using substrate (69 mg, 0.155 mmol), 
methyl vinyl ketone (13.6 µL, 0.163 mmol), 0.31 mL of a 0.0005 M 
MTBD/CH3CN solution (0.0001550 mmol of MTBD) to afford the title 
compound in 98% yield (78 mg, 0.152 mmol). 19F NMR (376 MHz, 
Chloroform-d) δ -115.07 (dd, J = 78.1, 17.1 Hz), -134.52 (d, J = 15.4 Hz), -142.70 (dtt, J = 77.8, 
16.5, 4.3 Hz), -146.41 (dtd, J = 56.5, 16.9, 4.7 Hz), -148.46 (dtt, J = 56.5, 16.9, 4.7 Hz), -151.37 
– -153.74 (m),153.74 – -158.34 (m). 1H NMR (400 MHz, Chloroform-d) δ 7.85 (s, 1H), 7.77 (d, J 
= 7.1 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.5 Hz, 2H), 3.82 (s, 3H), 3.54 (dt, J = 12.0, 
7.0 Hz, 1H), 2.90 (dddd, J = 16.3, 6.7, 4.5, 2.2 Hz, 1H), 2.69 – 2.41 (m, 2H), 2.15 (s, 3H). 13C 
NMR (101 MHz, Chloroform-d) δ 206.6, 171.7, 165.7, 152.7, 150.2, 148.5, 146.1, 143.3, 142.4, 
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141.3, 140.6, 140.2, 138.8, 137.8, 133.4, 132.4, 128.9, 127.2, 118.1 – 116.5 (m), 62.8, 54.3, 38.4, 
30.1, 27.9.  FT-IR (neat) cm-1 3270, 1765, 1712, 1512, 1246. HRMS (ESI) C24H16F7NO4 calcd. 
[M+H]+ 516.1040 observed 516.1031. 
 
3g methyl-2-benzamido-5-oxo-2-(3,4,5-trifluorophenyl)hexanoate 
The procedure G was followed using substrate (100 mg, 0.309 mmol), 
methyl vinyl ketone (27.1 µL, 0.325 mmol), 0.62 mL of a 0.005 M 
MTBD/CH3CN solution (0.003093 mmol of MTBD) to afford the title 
compound in 85% yield (103 mg, 0.263 mmol). 19F NMR (376 MHz, 
Chloroform-d) δ -130.73 – -135.68 (m), -160.84 (tt, J = 20.6, 6.3 Hz). 1H NMR (400 MHz, 
Chloroform-d) δ 8.01 (s, 1H), 7.86 (d, J = 7.2 Hz, 2H), 7.57 (t, J = 7.3 Hz, 1H), 7.50 (t, J = 7.5 
Hz, 2H), 7.14 (dd, J = 8.9, 6.4 Hz, 2H), 3.77 (s, 3H), 3.05 – 2.95 (m, 1H), 2.79 (ddd, J = 14.1, 8.1, 
6.3 Hz, 1H), 2.62 (ddd, J = 17.9, 8.1, 6.0 Hz, 1H), 2.29 (ddd, J = 17.9, 8.5, 6.3 Hz, 1H), 2.14 (s, 
3H).13C NMR (101 MHz, Chloroform-d) δ 207.5, 172.4, 165.8, 151.2 (ddd, J = 249.9, 10.0, 4.0 
Hz), 139.4 (dt, J = 252.7, 15.3 Hz), 136.0 (td, J = 6.8, 4.4 Hz), 133.4, 132.4, 128.9, 127.2, 111.4 
– 110.6 (m), 64.4, 54.1, 38.8, 30.1, 28.6. FT-IR (neat) cm-1 3405, 1739, 1717, 1530, 1239. HRMS 
(ESI) C20H18F3NO4 calcd. [M+H]+ 394.1261 observed 394.1254. 
 
3h methyl-2-benzamido-2-(4-chlorophenyl)-5-oxohexanoate 
The procedure G was followed using substrate (100 mg, 0.329 mmol), 
methyl vinyl ketone (28.8 µL, 0.346 mmol), 0.66 mL of a 0.0005 M 
MTBD/CH3CN solution (0.0003293 mmol of MTBD) to afford the title 
compound in 99% yield (122 mg, 0.326 mmol). 1H NMR (400 MHz, 
Chloroform-d) δ 7.96 (s, 1H), 7.86 (d, J = 7.3 Hz, 2H), 7.54 (t, J = 7.3 Hz, 1H), 7.45 (dd, J = 21.0, 
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8.2 Hz, 4H), 7.30 (d, J = 8.7 Hz, 2H), 3.73 (s, 3H), 3.10 (ddd, J = 14.5, 9.2, 5.7 Hz, 1H), 3.10 
(ddd, J = 14.5, 9.2, 5.7 Hz, 1H), 2.60 (ddd, J = 17.6, 8.8, 5.7 Hz, 1H), 2.28 (ddd, J = 17.6, 9.2, 5.9 
Hz, 1H), 2.12 (s, 3H).13C NMR (101 MHz, Chloroform-d) δ 207.7, 173.1, 165.7, 137.9, 133.9, 
133.8, 132.1, 128.8, 128.8, 127.6, 127.1, 64.8, 53.8, 38.9, 30.1, 28.3. FT-IR (neat) cm-1 3315, 
1737, 1702, 1525, 695. HRMS (ESI) C20H20ClNO4 calcd. [M+H]+ 374.1154 observed 374.1151. 
 
3i methyl-2-benzamido-5-oxo-2-phenylhexanoate 
The procedure G was followed using substrate (25 mg, 0.093 mmol), methyl 
vinyl ketone (8.1 µL, 0.097 mmol), 0.19 mL of a 0.0005 M MTBD/CH3CN 
solution (0.0000928 mmol of MTBD) to afford the title compound in 94% yield 
(30 mg, 0.087 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.89 – 7.81 (m, 
3H), 7.53 (t, J = 7.3 Hz, 1H), 7.50 – 7.42 (m, 4H), 7.34 (t, J = 7.5 Hz, 2H), 7.28 (t, J = 7.2 Hz, 
1H), 3.72 (s, 3H), 3.18 (ddd, J = 14.9, 9.7, 5.5 Hz, 1H), 2.92 (ddd, J = 14.5, 9.4, 5.7 Hz, 1H), 2.60 
(ddd, J = 17.4, 9.3, 5.5 Hz, 1H), 2.27 (ddd, J = 17.4, 9.7, 5.7 Hz, 1H), 2.11 (s, 3H). 13C NMR (101 
MHz, Chloroform-d) δ 207.9, 173.5, 165.7, 139.2, 134.2, 132.0, 128.8, 128.8, 128.1, 127.2, 126.1, 
65.3, 53.7, 39.1, 30.0, 28.2. FT-IR (neat) cm-1 3356, 1744, 1709, 1561.  HRMS (ESI) C20H21NO4 
calcd. [M+H]+ 340.1543 observed 340.1549. 
 
4a methyl-2-((tert-butoxycarbonyl)amino)-5-oxo-2-phenylhexanoate 
The procedure G was followed using substrate (150 mg, 0.565 mmol), methyl 
vinyl ketone (50.0 µL, 0.594 mmol), 1.13 mL of a 0.0005 M MTBD/CH3CN 
solution (0.0005654 mmol of MTBD) to afford the title compound in 92% 
yield (174 mg, 0.520 mmol). 1H NMR (400 MHz, Methylene Chloride-d2) δ 
7.43 (d, J = 7.6 Hz, 2H), 7.35 (t, J = 7.4 Hz, 2H), 7.28 (t, J = 7.2 Hz, 1H), 6.06 
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(s, 1H), 3.64 (s, 3H), 2.75 (m, 2H), 2.51 (ddd, J = 17.2, 9.7, 5.4 Hz, 1H), 2.26 (ddd, J = 17.2, 10.2, 
5.6 Hz, 1H), 2.10 (s, 3H), 1.33 (s, 9H).13C NMR (101 MHz, Methylene Chloride-d2) δ 207.8, 
173.4, 154.3, 140.9, 128.9, 128.3, 126.5, 80.2, 65.0, 53.7, 39.1, 30.2, 29.1, 28.5. FT-IR (neat) cm-
1 3424, 2976, 1709. HRMS (ESI) C18H25NO5 calcd. [M+H]+ 336.1802 observed 336.1805. 
4b methyl-2-(((benzyloxy)carbonyl)amino)-5-oxo-2-phenylhexanoate 
The procedure G was followed using substrate (25 mg, 0.084 mmol), 
methyl vinyl ketone (7.3 µL, 0.088 mmol), 0.17 mL of a 0.0005 M 
MTBD/CH3CN solution (0.0000835 mmol of MTBD) to afford the title 
compound in 89% yield (27 mg, 0.074 mmol). 1H NMR (400 MHz, 
Chloroform-d) δ 7.46 – 7.40 (m, 2H), 7.37 – 7.28 (m, 8H), 6.37 (s, 1H), 
5.02 (q, J = 12.3 Hz, 2H), 3.66 (s, 3H), 2.96 (s, 1H), 2.82 (td, J = 9.5, 9.0, 5.0 Hz, 1H), 2.38 (m, 
2H), 2.11 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 207.5, 172.9, 154.1, 139.6, 136.5, 128.8, 
128.6, 128.3, 128.2, 128.2, 125.9, 66.8, 64.7, 53.6, 38.8, 30.0, 28.1. FT-IR (neat) cm-1 3361, 3060, 
3030, 1740, 1716. HRMS (ESI) C21H23NO5 calcd. [M+Na]+ 392.1468 observed 392.1462. 
 
4d methyl-2-((tert-butoxycarbonyl)amino)-5-oxo-2-(trifluoromethyl)hexanoate 
The procedure G was followed using substrate (100 mg, 0.389 mmol), methyl vinyl ketone (34.0 
µL, 0.408 mmol), 0.78 mL of a 0.0005 M MTBD/CH3CN solution 
(0.0003888 mmol of MTBD) to afford the title compound in 83% yield (106 
mg, 0.323 mmol). 19F NMR (376 MHz, Methylene Chloride-d2) δ -74.70. 1H 
NMR (400 MHz, Methylene Chloride-d2) δ 5.61 (s, 1H), 3.80 (s, 3H), 2.72 – 2.52 (m, 2H), 2.49 – 
2.38 (m, 1H), 2.31 (ddd, J = 14.9, 8.7, 6.2 Hz, 1H), 2.12 (s, 3H), 1.41 (s, 9H). 13C NMR (101 MHz, 
Methylene Chloride-d2) δ 207.2, 167.6, 153.9, 124.9 (q, J = 287.5 Hz), 81.3, 65.2 (q, J = 28.1 Hz), 
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54.1, 37.9, 30.2, 28.4, 24.8. FT-IR (neat) cm-1 3425, 1740, 1723, 1537. HRMS (ESI) 
C13H20F3NO5calcd. [M+H]+ 328.1366 observed 328.1366. 
 
5b 2,2,2-trifluoroethyl-2-benzamido-2-methyl-5-oxohexanoate 
The procedure H was followed using substrate (40 mg, 0.145 mmol), 
methyl vinyl ketone (12.7 µL, 0.153 mmol), 0.290 mL of CH2Cl2, and 
MTBD (12.7 µL, 0.153 mmol, 20 mol %) to afford the title compound in 
72% yield (36 mg, 0.100 mmol). 19F NMR (376 MHz, Chloroform-d) δ -
73.69 (t, J = 8.4 Hz). 1H NMR (400 MHz, Chloroform-d) δ 7.81 (d, J = 7.1 Hz, 2H), 7.60 (s, 1H), 
7.51 (d, J = 6.0 Hz, 1H), 7.45 (t, J = 7.3 Hz, 2H), 4.81 – 4.29 (m, 2H), 2.69 (qdd, J = 18.9, 7.6, 
5.2 Hz, 2H), 2.36 (ddd, J = 14.8, 7.8, 5.2 Hz, 1H), 2.19 (s, 3H), 2.18 – 2.11 (m, 1H), 1.71 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ 209.8, 172.2, 166.8, 133.8, 131.9, 128.8, 127.2, 123.0 (q, J 
= 277.4, 277.3 Hz), 61.2 (q, J = 36.6 Hz), 59.3, 38.7, 31.5, 30.1, 23.2. FT-IR (neat) cm-1 3445, 
1733, 1718, 1598. HRMS (ESI) C16H18F3NO4 calcd. [M+H]+ 346.1261 observed 346.1254. 
 
5c 2,2,2-trifluoroethyl-2-benzamido-2-isopropyl-5-oxohexanoate 
The procedure H was followed using substrate (150 mg, 0.495mmol), 
methyl vinyl ketone (43.3 µL, 0.519 mmol), 1.00 mL of CH2Cl2, and MTBD 
(21.3 µL, 0.148 mmol,30 mol %) to afford the title compound in 76% yield 
(140 mg, 0.376mmol). 19F NMR (376 MHz, Methylene Chloride-d2) δ -
73.76 (t, J = 8.5 Hz). 1H NMR (400 MHz, Methylene Chloride-d2) δ 7.76 (d, J = 7.2 Hz, 2H), 7.53 
(t, J = 6.7 Hz, 1H), 7.45 (t, J = 7.4 Hz, 2H), 6.97 (s, 1H), 4.60 (qq, J = 8.6, 4.2 Hz, 2H), 2.79 – 
2.58 (m, 2H), 2.57 – 2.45 (m, 1H), 2.45 – 2.27 (m, 2H), 2.05 (s, 3H), 1.07 (d, J = 7.0 Hz, 3H), 
0.98 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, Methylene Chloride-d2) δ 208.2, 172.2, 166.8, 
135.2, 132.2, 129.2, 127.4, 120.8 (q, J =277.3, 277.3 Hz), 67.4, 61.6 (q, J = 36.7 Hz), 39.2, 34.4, 
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30.2, 26.9, 18.2, 17.8. FT-IR (neat) cm-1 3423, 1741, 1720, 1560. HRMS (ESI) C18H22F3NO4 
calcd. [M+H]+ 374.1574 observed 374.1581. 
 
5d 2,2,2-trifluoroethyl-2-benzamido-2-benzyl-5-oxohexanoate 
The procedure H was followed using substrate (120 mg, 0.342 mmol), 
methyl vinyl ketone (30.0 µL, 0.359 mmol), 1.00 mL of CH2Cl2, and MTBD 
(9.8 µL, 0.0684 mmol,20 mol %) to afford the title compound in 76% yield 
(115 mg, 0.273 mmol). 19F NMR (376 MHz, Chloroform-d) δ -73.27 (t, J = 
8.5 Hz). 1H NMR (400 MHz, Chloroform-d) δ 7.82 (d, J = 7.0 Hz, 2H), 7.64 (t, J = 7.4 Hz, 1H), 
7.55 (t, J = 7.5 Hz, 2H), 7.34 – 7.29 (m, 3H), 7.17 – 7.13 (m, 2H), 7.12 (s, 1H), 4.68 (q, J = 8.4 
Hz, 2H), 3.77 (d, J = 13.8 Hz, 1H), 3.58 (d, J = 13.8 Hz, 1H), 2.86 (dt, J = 14.2, 7.0 Hz, 1H), 2.64 
(m, 2H), 2.36 (dt, J = 14.4, 6.7 Hz, 1H), 2.21 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 208.2, 
171.9, 167.0, 135.7, 134.3, 132.0, 130.2, 128.9, 128.5, 127.3, 127.1, 122.9 (q, J =277.2, 277.3 
Hz), 64.5, 61.7 (q, J = 36.8 Hz), 40.2, 38.5, 29.9, 29.6. FT-IR (neat) cm-1 3451, 1743, 1725, 1527. 
HRMS (ESI) C22H22F3NO4 calcd. [M+H]+ 422.1574 observed 422.1570. 
 
5e 2,2,2-trifluoroethyl-2-benzamido-2-isobutyl-5-oxohexanoate 
 The procedure H was followed using substrate (100 mg, 0.315 mmol), 
methyl vinyl ketone (27.6 µL, 0.313 mmol), 0.600 mL of CH2Cl2, and 
MTBD (10.0 µL, 0.0894 mmol, 20 mol %) to afford the title compound (d.r. 
1.5:1) in 52% yield (63 mg, 0.164 mmol). 1H NMR (400 MHz, Methylene 
Chloride-d2) δ 7.68 (dt, J = 6.9, 1.3 Hz, 4H), 7.50 – 7.42 (m, 2H), 7.44 – 7.34 (m, 5H), 7.33 – 7.27 
(m, 1H), 6.91 (s, 1H), 6.85 (s, 1H), 4.51 (qd, J = 8.5, 1.9 Hz, 4H), 2.77 – 2.61 (m, 3H), 2.57 – 2.37 
(m, 3H), 2.37 – 2.15 (m, 6H), 1.98 (s, 6H), 0.98 (d, J = 6.9 Hz, 3H), 0.94 – 0.67 (m, 12H). 13C 
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NMR (101 MHz, Methylene Chloride-d2) δ 208.2, 208.2, 172.4, 172.3, 166.7, 166.6, 135.2, 132.2, 
129.5, 129.5, 129.2, 129.1, 127.4, 126.6 (d, J = 10.3 Hz), 125.7 (d, J = 162.6 Hz), 67.6, 67.4, 61.6 
(qd, J = 36.8, 1.4 Hz, two carb ons), 46.8, 41.7, 41.3, 40.4, 39.3, 39.2, 30.2, 26.99, ,26.95, 26.3, 




The procedure H was followed using substrate (150 mg, 0..473 mmol), 
methyl vinyl ketone (41.4 µL, 0.496 mmol), 1.00 mL of CH2Cl2, and MTBD 
(27.2  µL, 0.189 mmol,20 mol %) to afford the title compound in 68% yield 
(125 mg, 0.321 mmol). 19F NMR (376 MHz, Chloroform-d) δ -73.27 (t, J = 
8.5 Hz). 1H NMR (400 MHz, Methylene Chloride-d2) δ 7.77 (d, J = 7.2 Hz, 2H), 7.53 (t, J = 7.3 
Hz, 1H), 7.45 (t, J = 7.4 Hz, 2H), 7.14 (s, 1H), 4.58 (q, J = 8.4 Hz, 2H), 2.74 (ddd, J = 14.5, 8.7, 
6.0 Hz, 1H), 2.53 – 2.39 (m, 2H), 2.31 (ddd, J = 17.8, 8.7, 6.1 Hz, 1H), 2.17 (ddd, J = 14.5, 8.5, 
6.1 Hz, 1H), 2.05 (s, 3H), 1.93 (dd, J = 14.4, 6.9 Hz, 1H), 1.72 – 1.55 (m, 1H), 0.90 (d, J = 6.7 
Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H). 13C NMR (101 MHz, Methylene Chloride-d2) δ 208.0, 173.8, 
166.6, 135.1, 132.2, 129.2, 127.4, 123.5(q, J =277.2, 277.3 Hz), 63.9, 61.9 (q, J = 36.8 Hz), 43.7, 







The procedure H was followed using substrate (100 mg, 0.298 mmol), 
methyl vinyl ketone (26.1 µL, 0.313 mmol), 0.600 mL of CH2Cl2, and 
MTBD (12.8 µL, 0.0894 mmol,30 mol %) to afford the title compound in 
79% yield (96 mg, 0.235 mmol). 19F NMR (376 MHz, Methylene Chloride-
d2) δ -73.85 (t, J = 8.5 Hz). 1H NMR (400 MHz, Methylene Chloride-d2) δ 7.71 (d, J = 7.3 Hz, 
2H), 7.47 (t, J = 7.3 Hz, 1H), 7.39 (t, J = 7.5 Hz, 2H), 7.24 (s, 1H), 4.52 (q, J = 8.4 Hz, 2H), 2.59 
(ddd, J = 14.5, 10.1, 6.9 Hz, 2H), 2.52 – 2.23 (m, 5H), 2.15 – 2.06 (m, 1H), 2.01 (s, 3H), 1.97 (s, 
3H). 13C NMR (101 MHz, Methylene Chloride-d2) δ 208.4, 172.6, 166.8, 134.6, 132.4, 129.2, 
127.5, 123.0 (q, J =277.2, 277.3 Hz), 63.5, 61.9 (q, J = 36.7 Hz), 38.6, 34.9, 30.2, 29.8, 29.1, 15.8. 
FT-IR (neat) cm-1 3421, 1752, 1726, 1608. HRMS (ESI) C18H22F3NO4S calcd. [M+H]+ 406.1294 
observed 406.1303. 





N-Boc phenyl alanine (500 mg, 1.89 mmol), phenyl glycine methyl ester HCl (380 mg,1.89 
mmol), EDC (432 mg, 2.26 mmol), HOBt (346 mg , 2.26 mmol) and NaHCO3 (380 mg, 2.88 
mmol) were dissolved in anhydrous DMF/DCM (9.43 mL 20/80 v/v) at 0 oC and the reaction was 
stirred for 16 h at room temperature under inert atmosphere. The workup consisted of 
concentrating the solution, diluting with EtOAc 20 mL, and adding with an equal amount of water. 
The organic layer was separated and then washed with equal amount of sat. NaHCO3 (x3), 1 M 
HCl (x2), and water.  The organic layer was again separated and the solution was concentrated 
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under vacuum. Flash column chromatography was used to purify the desired compound giving a 
yeild 60% (467 mg, 1.13 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.33 – 7.29 (m, 3H), 7.24 
– 7.18 (m, 5H), 7.11 (dd, J = 7.3, 2.1 Hz, 2H), 6.88 – 6.71 (m, 1H), 5.50 (d, J = 7.1 Hz, 1H), 5.04 
(s, 1H), 4.40 (s, 1H), 3.70 (s, 3H), 3.04 (d, J = 7.0 Hz, 2H), 1.40 (s, 9H). 
 
DAPT, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester  
 
Synthesis of  (3,5-difluorophenyl)acetyl chloride- 2-(3,5-difluorophenyl)acetic acid (3.00 g, 17.4 
mmol) was added to 35 mL of DCM and 6 mL of SOCl2 and left to react until by 19F the starting 
material was consumed. Then the solution was concentrated and used without further 
purification.182 Synthesis of (2-(3,5-difluorophenyl)acetyl)-L-alanine-2-(3,5-
difluorophenyl)acetyl chloride (1.49 g, 16.8 mmol) was added alternately in 4 portions over 30 
minutes to a solution of alanine (3.18 g, 16.8 mmol) in 20 mL of a 10 % NaHCO3. After the 
addition was complete the reaction was left to react for 2 h. After 2 h, the reaction was quenched 
by the dropwise addition of concentrated aqueous hydrochloric acid until pH 1, which resulted in 
the formation of a precipitate. The solid was isolated by filtration and then trituration from 
DCM/Hexanes. The resulting crystals were filtered and air dried to give the desired acid in 62% 
(2.5 g, 10.3 mmol). Synthesis of DAPT, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester- 2-(3,5-difluorophenyl)acetyl)-L-alanine (300 mg, 1.23 mmol) from 
the above procedure, phenyl glycine tert-butyl ester HCl (331 mg,1.36 mmol), EDC (259 mg, 1.36 
mmol), HOBt (208 mg , 1.36 mmol) and NaHCO3 (155 mg, 1.85 mmol) were dissolved in 
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anhydrous DMF/DCM (9.43 mL 20/80 v/v) at 0 oC and the reaction was stirred for 16 hr at room 
temperature under inert atmosphere. The workup consisted of concentrating solution, diluting with 
EtOAc  20 mL, and an equal amount of water. The organic layer was separated and washed with 
equal amount of sat. NaHCO3 (x3), 1 M HCl (x2), and water.  The organic layer was again 
separated and the solution was concentrated under vacuum. Flash column chromatography was 
used to purify the desired compound at 79% (421 mg, 0.973 mmol).Characterization data matched 
that was seen in literature.182 
 
-Late stage functionliaztion of peptides Boc-Phe-Phg-OMe and DAPT 
 
General Procedure A: Under an dry inert atmosphere the peptide (1 equiv), methylvinyl ketone 
(1.05 equiv), MeCN (0.5 M) was added to a small test tube.  Then MTBD (0.10-0.50 equiv) was 
added to mixture and stirred vigorously. The reaction was monitored by 19F NMR/1H NMR until 
the starting material was consumed. The organic solution was then dried with MgSO4 and 






The procedure A was followed using substrate (25 mg, 0.0601  
mmol), methyl vinyl ketone (5.3 µL, 0.0640 mmol), 0.120 mL of ACN, 
and MTBD (0.87 µL, 0.0060608 mmol, 20 mol %) to afford the title 
compound in 73% yield (21 mg, 0.044 mmol).  1H NMR (400 MHz, 
Chloroform-d) δ 7.40 (s, 1H), 7.29 – 7.15 (m, 19H), 7.14 – 7.10 (m, 3H), 4.88 (dd, J = 16.1, 7.1 
Hz, 2H), 4.32 (p, J = 7.5 Hz, 2H), 3.58 (s, 3H), 3.56 (s, 3H), 3.07 – 2.85 (m, 6H), 2.65 (ddd, J = 
423 
 
14.5, 10.3, 5.2 Hz, 2H), 2.32 (ddd, J = 16.1, 10.4, 5.1 Hz, 1H), 2.15 (ddd, J = 15.7, 10.2, 5.1 Hz, 
1H), 2.09 – 2.04 (m, 1H), 2.02 (s, 2H), 1.99 (s, 3H), 1.94 (ddd, J = 16.9, 10.6, 5.3 Hz, 1H), 1.39 
(s, 9H), 1.38 (s, 9H). 13C NMR (101 MHz, Chloroform-d) δ 207.6, 207.6, 172.9, 172.8, 169.9, 
169.7, 139.1, 138.8, 136.7, 136.6, 129.6, 129.6, 128.9, 128.7, 128.7, 128.1, 128.1, 127.1, 125.9, 
65.0, 64.9, 56.2, 53.5, 53.5, 38.7, 38.5, 37.6, 37.5, 30.1, 29.9, 28.4, 27.6, 27.3. FT-IR (neat) cm-
1: 3327, 3061, 1760, 1635. HRMS (ESI) C27H34N2O6 calcd. [M+H]+ 483.2490 observed 483.2499. 
6b Boc-Phg-Phe-OMe derivative, methyl 2-((tert-butoxycarbonyl)amino)-5-oxo-2-
phenylhexanoyl)-D-phenylalaninate 
The procedure A was followed using substrate (135 mg, 0.328  
mmol), methyl vinyl ketone (28.7 µL, 0.344 mmol), 0.655 mL of ACN, 
and MTBD (10.1 µL, 0.0655 mmol, 20 mol %) to afford the title 
compound in 33% yield (58 mg, 0.120 mmol).  1H NMR (400 MHz, 
Methylene Chloride-d2) δ 7.42 – 7.27 (m, 10H), 7.21 (dq, J = 8.6, 2.9, 2.1 Hz, 2H), 7.17 – 7.12 
(m, 1H), 7.08 (t, J = 7.4 Hz, 2H), 7.03 – 6.94 (m, 2H), 6.63 (s, 2H), 6.46 (s, 1H), 6.28 (s, 1H), 6.15 
(s, 1H), 4.70 (ddd, J = 13.0, 7.8, 5.3 Hz, 2H), 3.85 – 3.67 (m, 1H), 3.66 (s, 3H), 3.57 (s, 2H), 3.17 
– 3.01 (m, 1H), 2.89 (dd, J = 6.0, 3.5 Hz, 3H), 2.86 – 2.65 (m, 3H), 2.43 – 2.30 (m, 2H), 2.10 (s, 
4H), 2.04 (s, 2H), 1.37 – 1.28 (m, 32H). 13C NMR (101 MHz, Methylene Chloride-d2) δ 208.4, 
208.1, 172.3, 171.9, 171.7, 171.7, 154.4, 154.4, 142.1, 136.7, 135.9, 131.3, 129.7, 129.6, 129.4, 
129.4, 129.2, 129.1, 128.3, 128.3, 127.5, 127.4, 126.4, 126.4, 80.2, 80.0, 64.7, 64.6, 52.8, 52.7, 
38.8, 38.6, 38.2, 37.9, 30.4, 30.4, 30.3, 29.9, 29.9, 29.5, 28.8, 28.6, 28.6, 28.5. FT-IR (neat) cm-




6c DAPT deravative, tert-butyl-2-2-(2-(3,5-difluorophenyl)acetamido)propanamido)-5-oxo-2-
phenylhexanoate 
The procedure A was followed using substrate (100 mg, 
0.231  mmol), methyl vinyl ketone (20.2 µL, 0.243 mmol), 
0.120 mL of ACN, and MTBD (16.60 µL, 0.116 mmol, 50 
mol %) to afford the title compound in 90% yield (105 mg, 0.208 mmol). 19F NMR (376 MHz, 
Methylene Chloride-d2) δ -110.39 – -110.46 (m), -110.47 – -110.53 (m). 1H NMR (400 MHz, 
Methylene Chloride-d2) δ 7.52 (s, 1H), 7.46 (s, 1H), 7.40 – 7.18 (m, 9H), 6.84 (ddt, J = 6.7, 4.3, 
2.1 Hz, 3H), 6.73 (tdd, J = 9.1, 5.2, 2.5 Hz, 2H), 6.34 (dd, J = 12.6, 7.0 Hz, 2H), 4.45 (td, J = 7.0, 
3.6 Hz, 2H), 3.49 (s, 3H), 3.48 (s, 1H), 2.90 (dddd, J = 14.1, 10.8, 5.1, 3.3 Hz, 2H), 2.67 (ddd, J 
= 13.8, 10.5, 5.0 Hz, 2H), 2.43 (dddd, J = 17.5, 10.6, 5.1, 2.0 Hz, 2H), 2.23 – 2.11 (m, 3H), 2.08 
(s, 1H), 2.06 (s, 1H), 1.32 (dd, J = 7.0, 4.8 Hz, 5H), 1.29 (d, J = 1.0 Hz, 16H). 13C NMR (101 
MHz, Methylene Chloride-d2) δ 207.9, 207.7, 171.5, 171.5, 170.9, 170.9, 169.9, 169.8, 140.3, 
140.3, 139.4 (td, J = 9.7, 5.5 Hz), 128.9, 128.1 (d, J = 1.3 Hz), 126.3, 113.6 – 112.1 (m), 103.0 
(td, J = 25.3, 4.1 Hz), 83.8 (d, J = 3.3 Hz), 65.5 (d, J = 2.6 Hz), 50.1, 49.9, 43.2, 43.15, 4.99, 38.9, 
30.2, 30.2, 27.9, 27.8, 27.7, 18.4 (d, J = 2.3 Hz). FT-IR (neat) cm-1 3431, 1502, 1254. HRMS 











Phenyl glycine methyl ester substrate (10 mg, 0.0518 mmol,1 equiv) was added to a NMR tube 
fitted with a C6D6 capillary (for NMR locking purposes) and a 1H NMR experiment was conducted 
as a baseline (Figure 5.2). Then MTBD (7.9 mg, 0.0518 mmol, 1 equiv) was added to mixture 
and 1H NMR experiment was conducted observing the N-H of the ester has been completely 
deprotonated (Figure 5.3). Then MeOD (100 µL, 0.518 mmol,100 equiv) was added and the 
mixture was left to react for 1 h, then the solution was concentrated removing the excess MeOD.  
1H NMR indicated that the glycine ester nitrogen was either deutrerated, more likely bonded to 
MTBD-D which is indicated by the broadening of MTBD signal (Figure 5.4). Next, methylvinyl 
ketone (4.3 µL, 0.0518 mmol, 1 equiv) was added and left to react for 6 h, and a final 1HNMR 
was performed, which showed no incorporation of deuterium in the methylvinyl ketone nor a 
return of the ester’s N-H (Figure 5.5), indicating the lack of a transient N-alkylation event. 
 
 
Figure 5.2 Initial 1H NMR 
experiment containing only 





Figure 5.3 1H NMR experiment 
after adding MTBD to phenyl 





Figure 5.4 1H NMR experiment 










To a dry NMR tube, MTBD (7.8 mg, 0.051 mmol) was added to a solution of the peptide (20 mg, 
0.051 mmol) in acetonitrile (0.3 mL). Then D2O (9.25 µL, 0.51 mmol) was added and the 
experiment was left to react for 24 h and monitored by 1H NMR.  
 
Figure 5.5 1H NMR experiment 
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NMR spectra  
Figure 5.6 Chapter V NMR Spectrum Graphs 
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